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Abstract 
With the discovery of next generation sequencing techniques the landscape of 
pathogenic gene discovery has shifted drastically over the last ten years. For the 
purpose of this thesis, focus was applied on finding genetic causes of inherited 
neuropathies, mainly Charcot-Marie-Tooth disease, by using both old and new 
genetic techniques and the accompanying functional investigations to prove the 
pathogenicity of these variants. Mutations in ATPase 6, the first mitochondrially 
encoded gene responsible for an isolated neuropathy, were found in five families 
with CMT2 by a traditional Sanger sequencing approach. The same approach was 
used to expand the phenotype associated with FIG4 mutations, known as CMT4J. 
Compound heterozygous mutations were found in a patient with a proximal and 
asymmetric weakness and rapid deterioration of strength in a single limb, mimicking 
CIDP.  
 
Several appropriate cohorts were screened for mutations in candidate genes with the 
traditional Sanger sequencing approach; however, no new pathogenic genes were 
found. In the case of the HINT1 gene, the originally stated frequency of 11% could 
not be replicated and a founder effect was suggested, underlying the importance of 
considering the ethnic background of a patient when screening for mutations in 
neuropathy-related genes. After the incorporation of exome sequencing, five CMT 
families were provided with a genetic diagnosis due to mutations in three novel 
genes and two previously known pathogenic genes. Many more families are 
currently under investigation and candidate genes have been found in some.  
 
Lastly, a series of divergent functional techniques was used to investigate the 
pathogenicity of IGHMBP2 mutations in 11 families with CMT2. IGHMBP2 
mutations normally lead to SMARD1 and fibroblast and lymphoblast studies 
indicate that the IGHMBP2 protein levels are significantly higher in CMT2 than 
SMARD1, but lower than controls, suggesting that the clinical phenotype differences 
correlate to the IGHMBP2 protein levels.  
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HEK293  Human embryonic kidney 293 
HEPES  4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid 
HGK   Hepatocyte progenitor kinase-like 
HIV   Human immunodeficiency virus 
HMSN   Hereditary motor and sensory neuropathy 
HRP   Horseradish peroxidase 
HSAN   Hereditary sensory and autonomic neuropathy 
HSP   Hereditary spastic paraplegia 
IEM   Inherited erythromelalgia 
IGF1   Insulin-like growth factor 1  
ION   Institute of Neurology 
IP   Immunoprecipitation 
IPS (cell)  Induced pluripotent stem (cell) 
KDa   Kilodalton 
LB   Luria broth  
LDS   Lithium dodecyl sulfate 
LOD   Logarithm (base 10) of odds 
LS   Leigh syndrome 
MAF   Minor allele frequency 
MAPS   Motor action potentials 
MELAS Mitochondrial encephalomyopathy, lactic acidosis, and stroke-
like episodes 
MERFF  Myoclonic epilepsy with ragged-red fibers  
MES   2-(N-morpholino) ethanesulfonic acid 
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MILS   Maternally inherited Leigh syndrome 
MLPA   Multiplex ligation-dependent probe amplification 
MNCV  Motor nerve conduction velocity 
MND   Motor neurone disease 
MRC   Mitochondrial respiratory chain 
MRC (Centre)  Medical Research Council (Centre) 
MRI   Magnetic resonance imaging 
mRNA   Messenger ribonucleic acid 
MT   Mitochondrial transcript 
mTOR   Mammalian target of rapamycin 
NA   Not applicable 
NAD
+ 
  Nicotinamide adenine dinucleotide (oxidised) 
NADH   Nicotinamide adenine dinucleotide (reduced) 
NARP   Neurogenic muscle weakness, ataxia, and retinitis pigmentosa 
NCBI   National centre for biotechnology information 
NCS   Nerve conduction study 
NCV   Nerve conduction velocity 
NF   Neurofilament 
NGS   Next-generation sequencing 
NH2-terminus  NH2-terminus 
NHNN   National hospital for neurology and neurosurgery 
NMD   Nonsense-mediated decay 
NP40
+
   Nonyl phenoxypolyethoxylethanol 
NSC   Neuronal stem cell 
OMIM   Online mendelian inheritance in man 
OXPHOS  Oxidative phosphorylation 
PBMC   Peripheral blood mononuclear cell 
PBS   Phosphate buffered saline 
PCR   Polymerase chain reaction 
PD   Parkinson disease 
PDC   Pyruvate dehydrogenase complex 
PEI   Polyethulenimine 
PEPD   Paroxysmal extreme pain disorder 
PET   Positron emission tomography 
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PFA   Paraformaldehyde 
PI   Phosphatidylinositol 
PNS    Peripheral nervous system 
POLG   Polymerase (DNA directed), gamma 
PTC   Premature termination codons 
qPCR   Quantitative polymerase chain reaction 
RAN   Repeat-associated non-ATG  
RC-DC  Reducing agent and detergent compatible 
RNA   Ribonucleic acid 
ROS   Reactive oxygen species 
RPMI   Roswell park memorial institute 
RT   Reverse transcription 
RT-qPCR  Real-time reverse transcription polymerase chain reaction 
RTT    Rett syndrome 
SCA   Spinocerebellar ataxias 
SDS   Sodium dodecyl sulphate 
shRNA  Short hairpin ribonucleic acid 
SIFT   Sorting intolerated from tolerated 
siRNA   Small interfering RNA  
SMA   Spinal muscular atrophy 
SMA-LED  Spinal muscular atrophy with lower extremity predominance 
SMARD1   Spinal muscular atrophy with respiratory distress type 1 
SNP   Single nucleotide polymorphism 
TBE   Tris/borate/EDTA 
TCA   Tricarboxylic acid 
TLC   Thin layer chromatography 
TMRM  Tetramethylrhodamine methyl ester 
TNF   Tumour necrosis factor 
tRNA   Transfer RNAs 
TTX   Tetrodotoxin 
UCL   University College London 
UCSC   University of California, Santa Cruz 
UMN    Upper motor neurone 
UTR    Untranslated region 
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UPR   Unfolded protein response 
UV   Ultraviolet 
WES   Whole exome sequencing 
WGS   Whole genome sequencing 
WT    Wild type 
∆Ψm   Mitochondrial membrane potential 
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Chapter 1:   
Introduction  
1.1 Phenotypic spectrum of peripheral neuropathies  
1.1.1 The peripheral nervous system 
The main function of the peripheral nervous system (PNS) is to transfer information 
from the limbs to and from the central nervous system (CNS), which consists of 
brain and the spinal cord. The nerves responsible for this include the cranial nerves 
that link to the brainstem and 31 pairs of spinal nerves with their roots and rami that 
branch out between each of the vertebrae of the spine, connecting to the spinal cord. 
Considering this is a two-way system, a division is made between the afferent nerves 
that convey information from the sensory organs and limbs to the brainstem and the 
spinal cord – the sensory nerves – and the efferent nerves that transfer information 
from the brainstem and the spinal cord to the neuromuscular junctions at the muscles 
– the motor nerves. Working in conjunction with this, there is the autonomic nervous 
system that extends out of the CNS and regulates the visceral organs, which is also 
regarded as part of the PNS (Hubbard et al., 1974).  
 
Characteristic of the peripheral nerves are the long axons, extending to the 
extremities of the body. The axons can be both unmyelinated and myelinated and are 
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organised in multiple bundles or fascicles, together with their supporting elements, in 
the peripheral nerves. Unmyelinated axons are solely enveloped by a single layer of 
Schwann cell cytoplasm whilst myelinated axons are surrounded by concentric 
layers of the Schwann cell plasma membrane which form the myelin sheath. This 
myelin sheath serves as an insulating layer resulting in a higher conduction velocity 
depending on the diameter of the sheath. In the context of peripheral neuropathies, 
abnormalities can be found in both the axon and the myelin sheath, causing different 
phenotypes (Hubbard, 1974). 
1.1.2 Peripheral neuropathies   
Whether abnormalities are found in the axon or the myelin sheath or in the cell body, 
the covering term for diseases affecting the PNS is peripheral neuropathies. Causes 
for peripheral neuropathies can be multiple, such as hereditary, infectious, 
inflammatory, exposure to toxins, metabolic or traumatic. These mainly result in an 
overall phenotype of muscle weakness and/or sensory loss and sometimes pain. 
Depending on the cause of disease, peripheral neuropathies can have an acute or 
chronic progression. When only one single nerve is affected, the term 
mononeuropathy is used and localised trauma or infection is suspected to be the most 
likely cause of disease. The myelin sheath or part of the axon can be damaged due to 
long-term pressure on a nerve due to swelling or injury. Multiple mononeuropathy or 
mononeuritis multiplex is characterised by two or more nerves being affected 
simultaneously or sequentially where the pattern is asymmetric. These can be caused 
by multiple medical conditions, such as diabetes mellitus, lupus erythematosus or 
HIV, and are sometimes difficult to distinguish from the polyneuropathies when 
their progress becomes more symmetrical (Dyck, 1927).  
 
Polyneuropathies such as Charcot-Marie-Tooth (CMT) disease and Chronic 
Inflammatory Demyelinating Polyneuropathy (CIDP) are characterised by the 
involvement of multiple nerves and the effects can encompass the whole body. 
Peripheral neuropathies can be manifested as part of a more widespread neurological 
or multisystem disorder or they can be the sole part of disease (Dyck, 1927). For the 
purpose of this thesis, the main focus will be on the latter and in particular on the 
different forms of Charcot-Marie-Tooth disease (CMT).  
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1.1.3 Charcot-Marie-Tooth disease  
CMT, also known as hereditary motor and sensory neuropathy (HMSN), functions as 
a term covering a group of clinically and genetically heterogeneous inherited 
neuropathies (Skre, 1974).  Their prevalence in the general population can vary but 
has an overall estimation of 1 in 2500. Depending on the genetic defect, the severity 
and age of onset, the disease can be extensively divergent. Clinical symptoms are 
determined by the type of peripheral nerve that is affected (Harding et al., 1980). 
This results in a broad primary classification in the following three groups:  
 CMT, both motor and sensory nerves are affected  
 Hereditary Sensory and Autonomic Neuropathy (HSAN), predominantly 
sensory and autonomic features are affected  
 Distal Hereditary Motor Neuropathy (dHMN), only motor neurons are 
affected.  
A clear distinction cannot always be made between these different groups and 
especially patients presenting with dHMN on first examination can develop sensory 
symptoms later on in life and be classified as having CMT.  
 
Due to the phenotypic variability, classification of CMT is not only based on clinical 
presentation, but also on neurophysiology and/or genetic testing. An important 
concept in this classification is motor nerve conduction velocity (MNCV). 
Uniformly slow MNCV less than 38 m/s in the arms is characteristic for 
demyelinating CMT1 while MNCV above this cut-off is typical of axonal CMT2. 
The intermediate form of CMT has intermediate electrophysiological features, i.e. 
MNCV from 25 to 45 m/s (Harding et al., 1980).   
 
1.2 Genetic diversity and classification of CMT  
Next to the phenotypic variability seen in patients with CMT, there is also a very 
heterogeneous genotypic presence that characterises this disease. Mutations in more 
than 80 genes have been found so far and more are being unravelled. The genetic 
background plays an important role in the classification of the disease and will be 
crucial to find common pathways to explain the characteristic features seen in most 
patients. In this section, the different subgroups of CMT will be discussed and the 
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most important causative genes that have been involved in each of these subgroups 
will be highlighted (Braathen, 2012).  
1.2.1 Demyelinating CMT 
For the demyelinating form of CMT, genes are often associated with Schwann cells 
and the myelin sheath surrounding the axon (Table 1.1), although their function can 
be very disparate, which causes a phenotypic heterogeneity (Nave et al., 2007; 
Berger et al., 2006). Inheritance can be dominant, recessive or X-linked and the 
autosomal dominant form of demyelinating CMT is often referred to as CMT1, 
accounting for at least two thirds of all patients with CMT.  
PMP22 as the most common mutated gene in CMT1  
The most prevalent  mutation, which occurs in more than 70% of the European cases 
with autosomal dominant inheritance, is the duplication of a region containing the 
Peripheral myelin protein 22 (PMP22) gene on chromosome 17, and is classified as 
CMT1A (Raeymaekers et al., 1991). This duplication results in the presence of three 
copies of the PMP22 gene instead of two and it is believed that the higher levels of 
PMP22 result in CMT1A (Lupski et al, 1992). These altered levels of the protein 
have been shown to influence the production of cholesterol, causing reduced myelin 
thickness and shortened internodes during the development of peripheral nerves. 
This may partially explain the slowed conduction velocity observed in CMT1A (Li 
et al., 2013).  
 
Patients with autosomal dominant CMT1A present in the first two decades with a 
classical CMT phenotype, starting with foot deformities and difficulty walking. 
There is mainly distal involvement with wasting and weakness of the muscles and 
sensory loss. This occurs more prominent in the lower limbs than the upper limbs. In 
the absence of the duplication, CMT1 can also be caused by missense mutations in 
the PMP22 gene, which results in a more severe phenotype in the patients and a 
classification of CMT1E (Reilly, 2007). In contrast to the duplication, mutations in 
PMP22 result in protein aggregates in Schwann cells and are believed to exert a 
toxic gain of function (Li et al., 2013).   
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Mutations in MPZ cause CMT1B  
Another important protein involved in autosomal dominant CMT is Myelin Protein 
Zero (MPZ), which causes CMT1B. In comparison to CMT1A, patients present with 
a more severe and earlier onset of the disease or a milder late-onset form. MPZ is the 
major component of myelin, comprising up to 50% of the myelin sheath (Siskind et 
al, 2013). Mutations in this gene have been shown to disrupt the myelination process 
and the compaction of myelin, subsequently failing to be incorporated in the plasma 
membrane or disrupting its structure due to a dominant negative effect (Berger et al., 
2006). 
Rare causes of AD CMT1  
The remaining cases of autosomal dominant CMT1 can be explained by mutations in 
the Lipopolysaccharide–Induced TNF Factor (LITAF), Early Growth Response 2 
(EGR2) or Neurofilament Light Chain (NEFL) genes, each on its own being a very 
rare cause of CMT1 with only few families reported (Houlden et al., 2006). The role 
of EGR2 protein in myelination is crucial and mice harbouring mutations in this 
gene present with nerves devoid of myelin. EGR2 serves as a transcription factor 
directly working on MPZ, which explains its involvement in demyelinating CMT.  
 
Mutations in LITAF are known to affect ubiquitination, sorting and/or degrading of 
the myelin, but the exact pathway that causes the CMT1C phenotype is not known 
yet (Berger et al., 2006). This is in contrast with the NF-L protein, which was 
originally described in the context of axonal CMT2. It has an important role within 
the cytoskeleton of axons and it has been speculated that it exerts an effect on the 
myelin sheath via the axon-myelin interactions (Houlden et al., 2006).  
Autosomal Recessive CMT4  
The occurrence of autosomal recessive CMT1, also known as CMT4, is relatively 
rare in the general population, although this varies depending on the community 
(Schenone et al., 2011). The autosomal recessive neuropathies tend to have an earlier 
onset and a more severe progression than the autosomal dominant varieties. Except 
in the case of consanguinity, they appear only in sibs or as simplex cases (Espinos et 
al., 2012). So far, fifteen genes have been described that cause an autosomal 
recessive inheritance pattern and several different molecular genetic subtypes of 
demyelinating AR CMT have been identiﬁed. These molecular genetic subtypes all 
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show a demyelinating phenotype but often have distinct clinical and nerve biopsy 
features (Reilly et al., 2011). Some of the genes implicated in the autosomal 
dominant form of CMT, such as PMP22, EGR2 or MPZ, are predominantly found in 
patients with CMT1, but are known to also cause the recessive variant in rare cases. 
Others are only found to cause the recessive form but have a distinctive link to 
demyelinating features. One example of the latter is Periaxin (PRX), part of the 
complex responsible for linking Schwann cells to the basal lamina.  
 
Whilst all the above-mentioned genes appear to be involved in myelin pathways, a 
considerable number of genes play a role in the mitochondrial compartment.  One of 
these has been shown to cause autosomal recessive CMT1. Ganglioside-induced 
Differentiation Associated Protein 1 (GDAP1) is a tail-anchored protein in the outer 
mitochondrial membrane, implicated in mitochondrial fission. Mutations in this 
protein cause a range of early onset demyelinating, intermediate, and/or axonal 
forms of CMT (CMT4A, CMTRIA, CMT2K). Since mutations in the Mitofusin 2 
(MFN2) gene - involved in mitochondrial fusion - are the main cause for axonal 
CMT, it is surprising that mutations in this mitochondrial fission protein mainly lead 
to a demyelinating neuropathy. It has been established that mitochondrial dynamics 
are a very important feature in the maintenance of the nerves and have a significant 
role in the pathogenicity of axonal neuropathies. It remains a mystery so far how 
these mutations in GDAP1 correlate with a primary myelin defect in the peripheral 
nerves (Berger et al., 2006; Tazir et al., 2013).  
 
Apart from these two examples, there are many more genes responsible for 
autosomal recessive CMT (Table 1.1), for which I will not go into further detail. 
However, as mentioned before, the majority of these have specific clinical features 
that can be of guidance in finding a molecular diagnosis. For example, mutations in 
the SH3 domain and tetratricopeptides repeats 2 gene (SH3TC2) are often found in 
patients with severe scoliosis and recent reports have suggested mutations in this 
gene to be the commonest form of autosomal recessive CMT (Houlden et al., 2009).  
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CMT1 Gene/Locus Function 
Autosomal dominant 
CMT1  
  
CMT 1A Dup 17p (PMP22) Myelin structure and formation 
CMT 1B MPZ Myelin structure 
CMT 1C LITAF Vesicular transport 
CMT 1D EGR2 Transcription factor, including myelin 
proteins 
CMT 1E PMP22 (Point 
mutations) 
Myelin structure and formation 
CMT 1F NEFL Cytoskeleton component 
Autosomal recessive 
CMT1  
  
CMT4A GDAP1 Mitochondrial dynamics 
CMT4B1 MTMR2 Vesicular transport, Active phosphatase of 
PI(3,5)P2 and PI(3)P 
CMT4B2 MTMR13 Vesicular transport, Inactive phosphatase of 
PI(3,5)P2 and PI(3)P 
CMT4B3 MTMR5 Vesicular transport 
CMT4C SH3TC2 Endocytic recycling  
CMT4D NDRG1 Signalling protein 
CMT4E EGR2 Transcription factor, including myelin 
proteins 
CMT4F PRX Myelin structure 
CMT4G (HMSN 
Russe)  
HK1 Glucose metabolism 
CMT4H FGD4 Cytoskeletal remodelling  
CMT4J FIG4 PI (3,5)P2 5-phosphatase / endocytotic 
recycling 
AR CMT1 PMP22 (point 
mutations) 
Myelin structure and formation 
Other SURF1 Assembly factor of OXPHOS complex  
CCFDN CTDP1 Phosphatase in transcription 
Table 1-1 Classification of demyelinating CMT according to genotype. AR, autosomal recessive; 
Dup, duplication; PMP-22, peripheral myelin protein 22; MPZ, myelin protein zero; LITAF, 
lipopolysaccharide-induced tumour necrosis factor; EGR2, early growth response 2; NEFL, 
neurofilament, light polypeptide 68 kDa; GDAP1, ganglioside-induced differentiation-associated 
protein 1; MTMR2, myotubularin-related protein 2; MTMR13, myotubularin-related protein 13; 
MTMR13, myotubularin-related protein 5; SH3TC2, SH3 domain and tetratricopeptides repeats 2; 
NDRG1, N-myc downstream-regulated gene 1; PRX, periaxin; HK, Hexokinase 1; FGD4,  FYVE, 
RhoGEF and PH domain containing 4; FIG4, Phosphoinositide phosphatase 4; SURF1: Surfeit locus 
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protein 1; CCFDN, Congenital Cataracts, Facial Dysmorphism & Neuropathy Syndrome; CTDP1, 
carboxy-terminal domain RNA polymerase II polypeptide A phosphatase subunit 1. 
1.2.2 Axonal CMT 
Autosomal dominant CMT2  
Several genes are known to cause AD CMT2, but only a quarter of the patients 
receive a molecular diagnosis. There is no main gene responsible for the majority of 
cases in the way that PMP22 is the main gene explaining the AD CMT1 phenotype. 
From a genetic point of view, point mutations in the MFN2 gene account for 20% of 
patients and are the most common cause of CMT2 (Zuchner et al., 2004). Eleven 
additional genes have been identified to date causing the dominant variant of this 
disease, most of them ubiquitously expressed (Table 1.2). The majority of these 
genes were not specifically associated with the function of the axon before mutations 
were discovered. By discovering these mutations, important pathways were revealed 
that are necessary for maintaining the axonal integrity; for example the 
mitochondrial fusion and fission process, in which not only MFN2 but also GDAP1 
participates (Patzkó et al., 2011), alterations of the cytoskeleton, mitochondrial 
dynamics and endocytosis, have all been found to be affected by mutations that 
cause CMT2 (Niemann et al, 2006).  
Classic CMT2 phenotype 
A distinction between three different subtypes can be made according to the clinical 
presentation of the patients. Most patients present with the classical CMT phenotype, 
and differentiation between AD CMT2 and CMT1 is difficult before 
neurophysiology is performed. The presence of reduced motor action potentials 
(MAPS) with normal or near normal NCVs will confirm the diagnosis of CMT2 
(Reilly, 2007). The majority of these patients will be diagnosed with mutations in the 
MFN2 gene, which frequently results in an early-onset, more severe phenotype. 
Interestingly, up to 20% of mutations in MFN2 are de novo, making it more difficult 
to decide on the pathogenicity of a new variant. MFN2 is a GTPase located in the 
outer mitochondrial membrane and serves as a regulator for mitochondrial fusion 
and tethering to the endoplasmic reticulum. Together with MFN1, homo-oligomeric 
and hetero-oligomeric complexes are formed between opposing mitochondria to 
facilitate fusion of the outer membrane (Milone et al., 2012). Disruptions in this 
process lead to increased mitochondrial fragmentation, where part of the fragmented 
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mitochondria lose their membrane potential and show impaired mitochondrial 
transport (Chen et al., 2003). In the context of disease, it has been suggested that this 
altered physiology and/or lack of healthy mitochondria at the distal parts of the 
axons could lead to the degeneration of the axons (Niemann et al., 2009). 
 
Apart from MFN2 mutations, the classical phenotype can also be caused by 
mutations in three genes known to cause CMT1: NEFL, MPZ or GDAP1 - although 
this accounts for only a very small percentage of patients (Reilly et al., 2011).  
 
After the myelin and mitochondrial groups of genes, recent discoveries found 
mutations in a range of tRNA synthetase genes, causing CMT. One of these, the 
Alanyl tRNA synthetase (AARS) gene, can also be responsible for the typical CMT2 
phenotype. However, an accurate estimate of the prevalence of these mutations has 
not been established yet (Latour et al., 2010; Mclaughlin et al., 2012). Other tRNA 
synthetase genes have been found in different CMT phenotypes and will be 
discussed in section 1.3.6. Even though it was first only found to be involved in the 
recessive form of axonal neuropathies, mutations in the leucine rich repeat and 
sterile alpha motif containing 1 (LRSAM1) gene were reported in several families 
with a dominant inheritance, suggesting the phenotypes of these mutations might 
expand further than causing recessive CMT2 (Weterman et al., 2012; Nicolaou et al., 
2013). Lastly, a mutation in the dehydrogenase E1 and transketolase domain-
containing 1 (DHTKD1) gene was found in a large Chinese family with five affected 
generations. This gene has been implied to have a role in the degradation pathways 
of several amino acids, but no further investigations regarding to disease pathways 
have been made (Xu et al., 2012).  
CMT2 with prominent sensory features  
Patients with CMT2 can also present with more prominent sensory features. Two 
main genes have been described causing this phenotype: Ras-related protein 7 
(RAB7A) and Serine palmitoyltransferase, long chain base subunit 1 (SPTLC1). 
Characteristically, patients suffer from lack of sensation and complications of 
sensory loss leading to ulcerations, osteomyelitis, and even amputations. This is very 
similar to patients with HSAN and it can be difficult to distinguish between the two 
forms, especially since patients with mutations in SPTLC1 are frequently classified 
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as having HSAN. These patients often suffer from neuropathic pain, which is the 
main determining feature that differentiates them from patients with mutations in 
RAB7A (Houlden et al., 2006).  
CMT2 with major motor involvement  
The last phenotype associated with AD CMT2 has a large overlap with dHMN, since 
patients present with major motor involvement due to mutations in six different 
genes: Glycyl tRNA synthetase (GARS), heat shock protein beta-1 (HSPB1), heat 
shock protein beta-8 (HSPB8), Transient receptor potential cation channel subfamily 
V member 4 (TRPV4), dynein, cytoplasmic 1, heavy chain 1 (DYNC1H1) or ATPase 
6. Whilst mutations in the heat shock protein genes are a very rare cause of AD 
CMT2 and are more frequently known to cause a purely motor phenotype, mutations 
in TRPV4 not only cause CMT2C, but can lead to a spectrum of inherited 
neuropathies with varying clinical features. However, caution has to be applied 
before diagnosing these patients since asymptomatic carriers and polymorphisms in 
the gene have been reported (Zimon et al., 2010; Fawcett et al., 2012).  
 
It was not surprising when mutations in dynein were reported to cause CMT, 
considering it is the primary motor protein responsible for retrograde axonal 
transport in neurons. Mouse model studies have shown that mutations affect the 
processivity of the protein and the ability to move along the microtubule (Ori-
McKenney et al., 2010; Weedon et al., 2011).  
 
As mentioned before, a small subset of genes mutated in CMT encode mitochondrial 
proteins, the most common of which is MFN2. All of these are encoded by the 
nuclear DNA, but our research recently showed that mutations in the mitochondrially 
encoded ATPase6 gene could lead to axonal neuropathy with predominantly motor 
involvement. More detail can be found in Chapter 3.  
 
Mutations in GARS cause CMT2D, which can be distinguished by involvement of 
the small hand muscles (Reilly et al., 2011). GARS was the first aminoacyl tRNA 
synthetase identified in 2003 by Antonellis et al. to be causative for a human genetic 
disease and after its discovery, five more aminoacyl tRNA synthetase genes have 
been implicated in CMT disease, one is which is the AARS gene, mentioned before. 
35 
 
Table 1-2 Classification of axonal CMT according to genotype. KIF1Bβ: kinesin family member 1B;  
MFN 2: Mitofusin 2; RAB7: Ras-related protein 7; TRPV4: Transient receptor potential cation 
channel subfamily V member 4;  GARS: Glycyl tRNA synthetase; NEFL: neurofilament, light 
polypeptide 68 kDa; HSPB1: Heat Shock Protein 27 kDa; MPZ: myelin protein zero; GDAP1: 
ganglioside-induced differentiation-associated protein 1; HSPB8: Heat shock protein, 22 kDa; DNM2: 
Dynamin-2; AARS: Alanyl tRNA synthetase; DYNC1H1: dynein, cytoplasmic 1, heavy chain 1; 
CMT2 Gene/locus Function 
Autosomal dominant 
CMT2  
  
CMT 2A KIF1Bβ Axonal transport 
CMT 2A MFN 2 Mitochondrial dynamics 
CMT 2B RAB7 GTPase in vesicular transport 
CMT 2C TRPV4 Calcium homeostasis 
CMT 2D GARS Aminoacyl synthetase 
CMT 2E NEFL Cytoskeleton component 
CMT 2F HSPB1 Heat shock protein/cytoskeleton 
remodelling 
CMT 2G 12q12-q13.3  
CMT 2 I/J MPZ Myelin protein 
CMT 2K GDAP1 Mitochondrial dynamics 
CMT 2L HSPB8 Heat shock protein/cytoskeleton 
remodelling 
CMT 2M DNM2 Instability of microtubule and endocytosis 
CMT 2N AARS Aminoacyl synthetase 
CMT 2O DYNC1H1 Axonal transport  
CMT 2P LRSAM1 E3-Ubiquitin Protein Ligase 
CMT 2Q DHTKD1 Degradation of AA  
 MT-
ATPase6  
ATP production  
Autosomal recessive CMT 2    
CMT 2B1 LMNA Intermediate filaments protein 
CMT 2B2 MED25 Transcription regulation 
CMT 2H GDAP1 Mitochondrial dynamics 
CMT 2P  LRSAM1 E3-Ubiquitin Protein Ligase 
CMT 2R TRIM2 E3-Ubiquitin Protein Ligase 
ARAN-NM HINT1 Purine phosporamidase  
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LRSAM1: leucine rich repeat and sterile alpha motif containing 1; DHTKD1: dehydrogenase E1 and 
transketolase domain-containing 1; LMNA: Lamin A/C; MED25: mediator complex subunit 25; 
TRIM2: tripartite motif containing 2; HINT1: histidine triad nucleotide–binding protein 1 
 
It has been suggested that mutations in this gene lead to an impaired GARS enzyme 
activity and a GARS localisation defect that is predominantly present in the longest 
axons due to a higher need in localised protein synthesis (Antonellis et al., 2006).  
Autosomal recessive CMT2 
Axonal autosomal recessive neuropathies are very rare and most cases found to date 
have been restricted to specific geographical areas or families. In a recent study, 
mutations in the histidine triad nucleotide–binding protein 1 (HINT1) gene have been 
found in 11% of AR CMT patients with neuromyotonia, comprising a new disease 
identity. In patients with AR CMT2 and neuromyotonia, this percentage went up to 
76%. Most of these families were eastern European and presented with the same 
homozygous mutation, suggesting a founder effect (Zimon et al., 2012).  
 
In North Africa, multiple families were found with mutations in Lamin A/C 
(LMNA), causing CMT2B1. LMNA mutations can cause a variety of phenotypes, 
ranging from peripheral neuropathies and cardiac disorders to lipodystrophy and 
premature aging disorders. More than ten different phenotypes have been shown to 
be caused by mutations in this gene and many of them show overlapping clinical 
features (Tazir et al., 2013).  
 
Only one large consanguineous Costa Rican family was found with a mutation in the 
mediator complex subunit 25 (MED25) gene (Leal et al., 2009), classifying this as a 
very rare cause of AR CMT2. In very few cases, GDAP1, normally causing AR 
CMT1, can also be found to cause AR CMT2. One paper by Guernsey et al. 
investigating a large Canadian family suggested a missense mutation of a splice site 
acceptor in the leucine rich repeat and sterile alpha motif containing 1 (LRSAM1) 
gene as cause of the disease. This encodes for an E3-Ubiquitin protein ligase 
important for vesicle fusion. More recently, this gene has also been found to cause 
the autosomal dominant form, as mentioned above.  
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In 2013, a patient was reported with a mutation in the tripartite motif containing 2 
(TRIM2) gene, which also encodes for an E3-Ubiquitin ligase (Ylikalio et al., 2013). 
Loss of either of these proteins in mouse models leads to neurodegeneration, 
indicating an important role for these proteins. In rare cases, genes known to cause 
the dominant form of the disease are found to be the responsible gene in families 
with a recessive inheritance, such as NEFL (Abe et al., 2009), HSPB1 (Houlden et 
al., 2008) and MFN2 (Polke et al., 2011).  
 1.2.3 Intermediate CMT  
So far, five genes and one locus are known to specifically cause dominant 
intermediate CMT, whereas the recessive form can be caused by three different 
genes (Table 1.3). Intermediate CMT is characterised by patients having NCS values 
in the intermediate range (25-45 m/s). In rare cases, genes that normally cause a 
demyelinating or axonal form of disease can mimic intermediate conditions and be 
classified as intermediate CMT. Patients with mutations in MPZ normally have 
NCV< 38m/s,  however more recently several missense mutations have been shown 
to results in NCV of the motor median nerve varying from <38 m/s to normal (De 
jonghe et al., 1999; Banchs et al., 2010). 
 
Similar results have been shown for mutations in GDAP1, where NCVs were 
between 25 and 35 m/s and peripheral nerve pathology showed axonal as well as 
demyelinating changes (Senderek et al., 2003). Apart from mutations in genes 
implicated in the myelin pathway and mitochondrial dynamics, dysfunction of 
cytoskeleton can also lead to intermediate forms of CMT. Dynamin-2 (DNM2) has a 
dual role in the regulation of the dynamic instability of microtubules and in 
endocytosis. Different mutations can have their effect on either of these pathways 
and result in intermediate CMT (Tanabe et al., 2012). So do mutations in inverted 
formin-2 (INF2), a member of the diaphanous-related formin family involved in 
remodelling the microtubule cytoskeleton and actin (Rodriguez et al., 2013). Whilst 
a connection with CMT is apparent in these patients, the pathologic mechanisms that 
cause intermediate CMT in patients with mutations in the other genes such as GNB4 
and PLEKHG5 are not known yet (Azzedine et al., 2013; Soong et al., 2013).  
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Table 1-3 Classification of intermediate CMT according to genotype. DNM2: Dynamin-2; YARS: 
tyrosyl tRNA synthetase; MPZ, myelin protein zero; INF2: inverted formin, FH2 and WH2 domain 
containing; GNB4: guanine nucleotide binding protein (G protein), beta polypeptide 4; GDAP1, 
ganglioside-induced differentiation-associated protein 1; KARS: lysyl-tRNA synthetase; PLEKHG5: 
pleckstrin homology domain containing, family G. 
 
Three years after the discovery of the GARS gene, mutations in the tyrosyl tRNA 
synthetase (YARS) gene were found, making it the second aminocyl synthetase 
responsible for causing CMT. A dominant-negative effect on the normal function 
and distribution of YARS in the neuronal endings was observed when the protein 
was mutated. Even though the exact pathway leading to CMT is still a mystery, the 
specific subcellular localisation of YARS to the nerve endings – which was not 
observed in other tRNA synthetases studied – indicates an important function at the 
neuronal endings (Jordanova et al., 2006). Four years later, another tRNA synthetase 
gene was discovered to be involved in intermediate CMT - lysyl-tRNA synthetase 
(KARS). In these cases, compound heterozygous mutations resulted in a loss-of-
function effect on the protein (McLaughlin et al., 2010). The presence of a null allele 
in combination with a hypomorphic allele significantly reduces the charging activity 
Intermediate CMT Gene/locus Function 
Dominant intermediate CMT 
(CMTDI) 
  
CMTDIA 10q24.1-
q25.1. 
 
CMTDIB DNM2 Instability of microtubule and 
endocytosis  
CMTDIC YARS Aminoacyl synthetase 
CMTDID MPZ Myelin structure  
CMTDIE INF2 Cytoskeletal remodelling 
CMTDIF GNB4 Signal transduction 
Recessive intermediate CMT 
(CMTRI) 
  
CMTRIA GDAP1 Mitochondrial dynamics  
CMTRIB KARS Aminoacyl synthetase 
CMTRIC PLEKHG5 Signal transduction 
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to a level were barely any functionality remains, effects that have also been seen in 
several GARS mutations (Antonellis et al., 2008). 
1.2.4 Hereditary Sensory and Autonomic Neuropathy 
Patients presenting with mainly sensory involvement and autonomic features are 
classified as having HSAN. Sensory loss, insensitivity to pain, a variable degree of 
muscle weakness and wasting, as well as autonomic features have been observed. 
This can occur in both dominant and recessive form and can be subdivided into six 
different groups according to the age of onset, inheritance and characteristic clinical 
features (Rotthier et al., 2010; Table 1.4).  
Autosomal Dominant HSAN 
All dominant forms are classified under the HSAN1 subtype and can be caused by 
mutations in five known genes and one locus for which the gene has not been found 
yet. As mentioned above, there is a significant overlap with some of the AD axonal 
phenotypes with predominantly sensory features and mutations in SPTLC1 and 
RAB7A are known to cause phenotypes with varying degree of motor involvement. 
These two phenotypes are very similar, apart from an overall sensory loss in the 
somatosensory system in patients with RAB7A. Next to mutations in subunit 1 of the 
serine palmitoyltransferase, mutations in subunit 2 can cause the same phenotype, 
which are indistinguishable. The presence of lancinating pain can differentiate these 
patients from others (Rotthier et al., 2010).  
 
Two other genes are known to cause autosomal dominant HSAN: Atlastin-1 (ATL1), 
which has a role in ER formation, and DNA methyltransferase 1 (DNMT1), 
important in DNA methylation and gene regulation. Most of these genes act in the 
cell body, but a common pathway for these genes resulting in HSAN has not been 
established (Rotthier et al., 2012). Some families present with sensory loss, cough 
and gastroesophageal reflux, also classified as HSAN-1B, but no gene responsible 
for this phenotype has been found so far and linkage has narrowed it down to 
chromosomal location 3p22–p24 (Kok et al., 2003). 
Autosomal Recessive HSAN 
While all phenotypes of autosomal dominant HSAN are classified under the HSAN1 
subtype, there are several different sub classifications for autosomal recessive 
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HSAN. HSAN II is characterised by distal numbness and progressive loss of pain, 
temperature and touch sensation and can be caused by mutations in three different 
genes: WNK lysine deficient protein kinase 1 (WNK1), involved in sodium, chloride 
and potassium homeostasis; Family with sequence similarity 134, Member B 
(FAM134B), a component of the cis-golgi matrix, and kinesin family member 1A 
(KIF1A), which has a role in anterograde axonal transport. So far, a link between 
these different genes has not been documented, although an interaction has been 
found between KIF1A and the domain of WNK1 that is primarily mutated (Riviere 
et al., 2011).  
 
HSAN III is also known as Riley-Day syndrome or Familial Dysautonomia and is 
caused by mutations in the inhibitor of kappa light polypeptide gene enhancer in B-
cells, kinase complex-associated protein (IKBKAP). This gene encodes for the IκB 
kinase complex-associated protein (ELP1), an important subunit of the RNA 
polymerase II complex, necessary for transcriptional elongation. Disruptions in this 
gene result in prominent, widespread autonomic disturbances, as well as small-fibre 
sensory dysfunction and are almost solely seen in patients with eastern European 
Jewish ethnicity. Only three mutations have been found so far, of which one 
accounts for more than 99% of the patients, suggesting a founder effect.  
 
Patients with a more severe form of this disease, also involving prominent autonomic 
features, are classified as having HSAN VI, linking to mutations in Dystonin (DST). 
The neuronal isoform of DST has been shown to link actin filaments to the 
microtubule to maintain the neuronal cytoskeleton organisation. Interestingly, DST 
is upregulated in fibroblasts of patients with mutations in IKBKAP, suggesting a 
compensatory mechanism. The RNA polymerase II complex has been shown to 
interact with the microtubuli and microtubule disorganisation was observed in 
fibroblasts, explaining the possibility of a compensatory mechanism by DST 
(Edvardson et al., 2012).  
 
In some cases, HSAN is accompanied by insensitivity to temperature and pain and 
generalised anhidrosis, known as congenital insensitivity to pain with anhidrosis 
(CIPA) or HSAN IV. Several families of different ethnicities and more than 40 
different mutations have been found with mutations in the neurotrophic tyrosine 
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kinase, receptor, type 1 (NTKR1) gene. This encodes for the high-affinity nerve 
growth factor receptor Trk-A protein, a kinase involved in neurotrophin signalling 
supporting neurite outgrowth and survival of neurons.  
 
HSAN Gene/Locus Function 
Autosomal Dominant HSAN   
HSAN-I SPTLC1 Sphingolipid biosynthesis pathway 
HSAN-I SPTLC2 Sphingolipid biosynthesis pathway 
HSAN-I ATL1 GTPase in the Endoplasmatic 
Reticulum 
CMT2B/HSAN-I RAB7A GTPase in vesicular transport 
HSAN-I with dementia and 
hearing loss 
DNMT1 DNA methylation, gene regulation 
HSAN-IB 3p24–p22  
Autosomal recessive HSAN   
HSAN-II WNK1 Regulator of ion channels 
HSAN-II FAM134B Structural protein of the cis golgi-body 
HSAN-II KIF1A Axonal transport 
HSAN-III IKBKAP Scaffold protein for transcriptional 
elongation 
HSAN-IV NTRK1 Neurotrophin signalling  
HSAN-V NGFB Neurotrophin signalling 
HSAN-VI DST Adhesion junction protein 
HSAN with spastic paraplegia CCT5 Molecular chaperone  
Table 1-4 Classification of Hereditary sensory and autonomic neuropathy according to genotype. 
SPTLC1: Serine palmitoyltransferase, long chain base subunit 1; SPTLC2: Serine 
palmitoyltransferase, long chain base subunit 2; ATL1: Atlastin-1; RAB7A: Ras-related protein 7; 
DNMT1: DNA methyltransferase 1; WNK1: WNK lysine deficient protein kinase 1; FAM134B: 
Family with sequence similarity 134, Member B; KIF1A: kinesin family member 1A; IKBKAP: 
inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-associated protein; 
NTRK1: neurotrophic tyrosine kinase, receptor, type 1; NGFB: nerve growth factor, beta-subunit; 
DST: Dystonin; CCT5: chaperonin containing TCP1-complex subunit 5. 
 
A very similar phenotype is seen in patients with HSAN V, although patients suffer 
from hypohidrosis instead of anhidrosis. This phenotype is also caused by mutations 
in a gene important in neurotropin signalling, called nerve growth factor (NGF), 
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encoding for the β-NGF protein. β-NGF serves downstream as a ligand for Trk-A, 
which will autophosphorylate to activate downstream signalling pathways 
(Einarsdottiret al., 2004; Carvalho et al., 2011).  
 
The last phenotype associated with recessive HSAN is accompanied with spastic 
paraplegia and can be explained by mutations in the chaperonin containing TCP1-
complex subunit 5 (CCT5) gene. This protein is important for the protein folding and 
assembly of a range of proteins, and it has been suggested that disruptions in this 
process lead to protein misfolding and ER-stress, causing the phenotype (Bouhouche 
et al., 2006). Previous reports have also shown that this particular subunit is 
important for the binding of the CCT5 protein to actin and tubulin (Llorca et al., 
2000). Patients with this phenotype can also be classified as having Hereditary 
Spastic Paraplegia (HSP), when the lower extremity spastic weakness is the primary 
clinical symptom (Fink, 2013).  
1.2.5 Distal Hereditary Motor Neuropathy  
In contrast to patients with HSAN, a significant group of patients present with 
predominantly motor involvement. Distal hereditary motor neuropathy (dHMN) is 
characterised by the selective loss of motor neurons and/or their long axons in the 
peripheral nervous system. Apart from the absence of sensory abnormalities, distal 
HMN closely resembles axonal CMT2 and clinical overlap is ever-present, often 
dependent on the stage of disease and the age of the patient. Recurrently, mutations 
in the same gene may cause either dHMN or CMT2. In some cases, minor sensory 
involvement is present, comparable to the symptoms seen in other motor neuron 
diseases such as Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy 
(SMA) or Kennedy’s disease. dHMN is often referred to as distal Spinal Muscular 
Atrophy (dSMA) or Spinal CMT, since various hypotheses have suggested that the 
primary pathological process is located in the cell body of the anterior horn.  
 
Similarly to the previous subgroups, dHMN is also classified according to 
inheritance, age of onset and phenotype, even though multiple genes can cause the 
same subtype of dHMN (Table 1.5). Seven subtypes of dHMN have been described, 
which will be discussed below depending on their mode of inheritance (Rossor et al., 
2012). 
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Autosomal dominant dHMN  
Of the seven subtypes of dHMN, four have an autosomal dominant mode of 
inheritance: Types I, II, V and VII. Patients presenting with typical dHMN 
phenotype are classified as type I or II, depending on whether they have a childhood 
or adult onset respectively. Clinical features are very similar to CMT2, apart from 
the absence of sensory abnormalities.  
dHMN I and II  
The childhood onset (dHMN I) can be caused by mutations in either HSPB1, 
HSPB8, GARS or dynein, cytoplasmic 1, heavy chain 1 (DYNC1H1). As seen before, 
all these genes have already been implemented in respectively CMT 2F, CMT 2L, 
CMT 2D or CMT 2O. Depending on the development of sensory signs, these will be 
classified amongst dHMN or CMT2 and a significant amount of overlap can occur.  
Interestingly, mutations in the HSPB1 and HSPB8 genes can also cause the adult 
onset subtype of dHMN II. Both of these genes encode for small heat-shock proteins 
and are part of a group of stress-induced chaperone proteins that are ubiquitously 
expressed. When mutated, protein aggregates are formed and it has been suggested 
that mutations also influence the chaperone function (Carra et al., 2010). By using a 
candidate gene approach screening, mutations in the heat-shock protein 27-like 
protein (HSPB3) were also found to be responsible for the adult onset subtype (Kolb 
et al., 2010). 
 
Apart from faulty chaperones, dHMN II can also be caused by mutations in the 
Berardinelli–Seip Congenital Lipodystrophy type 2 gene (BSCL2), known to cause 
Congenital Generalised  Lipodystrophy type 2 in a recessive manner. BSCL2 
encodes for Seipin, a glyco-protein present in the Endoplasmatic reticulum (ER). 
Previous reports have suggested that malfunction of Seipin leads to incorrect folding 
and activation of the Unfolded Protein response (UPR) in the ER, a pathway implied 
in many neurodegenerative diseases (Ito et al., 2008; Liu et al., 2003).  
 
Lastly, a recent paper by Sumner et al. in 2013 reported mutations in F-box protein 
38 (FBXO38) to cause an adult onset of dHMN.  
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dHMN V 
In the event of more predominant upper limb symptoms, classification will lean 
towards dHMN V. This can be caused by both the GARS and BSCL2 genes. The 
latter protein has been implied in a variety of diseases, such as classical Silver 
Syndrome, severe spastic paraplegia with amyotrophy predominantly affecting the 
lower limbs, dHMN II as mentioned before and dHMN V (Irobi et al., 2006). Inter- 
and intrafamilial variability has been shown in 14 unrelated Austrian families, which 
raises the question of modifying factors (Auer-Grumbach et al., 2005). In both cases, 
families with a recessive inheritance have been found which will still be classified as 
dHMN V. More recently, a new splice site mutation was found in receptor accessory 
protein 1 (REEP1) in a family with dHMN and dHMN V. Missense mutations in this 
gene normally lead to HSP, due to a loss-of-function mechanism. Whilst the 
majority of mutations found in HSP result in nonsense-mediated decay, the 
suspected skipping of exon 5 would not result in a frameshift, which could account 
for the difference in phenotype (Beetz et al., 2012).  
dHMN VII 
The last autosomal dominant dHMN subtype is characterised by an adult onset of 
upper limb before lower limb involvement and the main distinguishing feature is the 
presence of vocal cord paralysis. Four loci have been found to be linked to the 
dHMN VII phenotype, three of which have been narrowed down to a specific gene. 
The first gene encodes for the P150Glued subunit of Dynactin (DCTN1), a 
microtubule motor protein important in the retrograde axonal transport. As seen 
before, compromised axonal transport is an important molecular pathway leading to 
disease and previous reports have shown that mutations in DCTN1 interfere with the 
binding of dynactin to the microtubule (Puls et al., 2003).  
 
The second locus overlapped with one of the genes already known for CMT2; 
TRPV4. Whilst mutations in dynactin lead to issues with axonal transport, TRPV4 
encodes for a non-selective cation channel. In normal conditions it exhibits a 
moderate permeability to calcium, which will be affected when mutations are 
present. There have been contradicting studies about the effects of mutations on the 
calcium import, but recent studies in neuronal derived cell lines have shown a toxic 
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gain of function, with a higher level of calcium import in comparison to basal levels 
(Fecto et al., 2011).  
 
The most recent gene responsible for the dHMN VII phenotype is the solute carrier 
family 5, member 7 (SLC5A7). This is a choline transporter in the cholinergic 
neurons, dependent on sodium and chloride. A dominant-negative mutation was 
found, resulting in reduced protein levels (Barwick et al., 2012).  
SMA-LED  
A separate entity of patients shows autosomal dominant inheritance with muscle 
weakness predominantly affecting the proximal lower extremities and is classified as 
SMA-LED. This can be caused by two different genes: DYNC1H1 and bicaudal D 
homolog 2 (BICD2). Dynein has already been implicated in CMT disease and is 
known to have an important role in axonal transport. The BICD2 protein was 
discovered by three groups simultaneously (Oates et al., 2013; Peeters et al., 2013; 
Neveling et al., 2013) and is known to bind to the dynactin-dynein complex to 
transport cargo such as mRNA, Golgi, and secretory vesicles. Mutations in BICD2 
affect the binding to this complex and the small GTPase RAB6 and will be more 
extensively discussed in Chapter 5.  
Autosomal recessive dHMN 
The remaining three subtypes of dHMN have a recessive pattern of inheritance and 
are classified as subtypes III, IV and VI. For both dHMN III and IV, the causative 
gene has not been found yet. Classification of these two subtypes depends on the 
severity of disease and the presence of diaphragmatic palsy (Harding et al., 1980; 
Pearn et al., 1979). Both have been linked to the same locus on chromosome 11q13, 
which encompasses the immunoglobulin μ binding protein 2 (IGHMBP2), 
responsible for dHMN VI. However, genetic studies rule out this gene as the 
causative factor for disease and further studies in multiple families managed to 
narrow down the linkage area to a region of 1Mb, telomeric to the IGHMBP2 gene. 
Ten known genes are located in this area, but none of these were shown to segregate 
with disease (Viollet et al., 2004).  
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dHMN Gene/Loci Function 
Autosomal Dominant 
dHMN 
  
dHMN I HSPB1 Heat shock protein 
HSPB8 Heat shock protein 
GARS Aminoacyl synthetase 
DYNC1H1 Axonal transport 
dHMN II HSPB1 Heat shock protein 
HSPB8 Heat shock protein 
HSPB3 Heat shock protein 
BSCL2 Glyco protein in the Endoplasmatic Reticulum 
FBXO38 Neuronal axon outgrowth and repair 
dHMN V GARS Aminoacyl synthetase 
BSCL2 Glyco protein in the Endoplasmatic Reticulum 
REEP1 Olfactory receptor binding  
dHMN VII DCTN1 Axonal transport 
TRPV4 Calcium homeostasis  
SLC5A7 Choline transporter 
2q14  
SMA-LED  DYNC1H1 Axonal transport 
BICD2 Motor adaptor protein 
Autosomal recessive 
dHMN 
  
dHMN III 11q13  
dHMN IV 11q13  
dHMN VI IGHMBP2 ATP-dependent helicase in RNA translation 
Table 1-5 Classification of Distal Hereditary Motor Neuropathy according to genotype. HSPB1: Heat 
Shock 27kDa Protein 1; HSPB8: Heat Shock 22kDa Protein 8; GARS: Glycyl tRNA synthetase; 
DYNC1H1: dynein, cytoplasmic 1, heavy chain 1; HSPB3: Heat Shock 27kDa Protein 3; BSCL2: 
Berardinelli–Seip Congenital Lipodystrophy type 2; FBXO38: F-box protein 38; REEP1: receptor 
accessory protein 1; DCTN1: P150Glued subunit of Dynactin; TRPV4: Transient receptor potential 
cation channel subfamily V member 4; SLC5A7: solute carrier family 5, member 7; BICD2: bicaudal 
D homolog 2; IGHMBP2: immunoglobulin μ binding protein 2. 
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As mentioned in the previous paragraph, dHMN VI is caused by mutations in the 
IGHMBP2 gene and results in a phenotype of Spinal Muscular Atrophy with 
Respiratory Distress 1 (SMARD1). Patients typically present in early childhood with 
a very severe neuropathy and diaphragmatic paralysis and rarely survive the first 
decade. IGHMBP2 functions as an ATP-dependent 5′–3′ helicase and unwinds RNA 
and DNA duplexes. Further detail can be found in Chapter 6 of this thesis.  
1.2.6 X-linked CMT 
Demyelinating CMTX1  
The second commonest form of CMT is characterised by an X-linked inheritance 
and mutations in the Gap Junction Protein Beta 1 (GJPB1) gene, encoding for the 
connexin 32 protein (Cx32). Consistent with an X-linked disease, males typically 
present with a more severe phenotype than females. Central nervous system 
manifestations can also occur in these cases.  
 
Connexin 32 is expressed by Schwann cells and oligodendrocytes that fail to 
assemble functional gap junctions or assemble defective gap junctions when 
mutated. Being important for myelin homeostasis, disruptions in the function of 
these gap junctions will lead to a demyelinating neuropathy (Scherer et al., 2012). 
CMTX2 and CMTX3  
One family with CMTX2 has been studied by Ionasescu et al., showing a disease 
phenotype similar to CMT1 but showing both demyelinating and axonal 
involvement in electrophysiological studies. This family showed an infantile onset, 
with two out of five affected individuals having mental retardation and carrier 
females being unaffected. Linkage analysis showed peak scores on Xp22.2 (Table 
1.6).   
 
So far, three families have been reported with CMTX3 (Ionasescu et al., 1991; 
Huttner et al., 2006; Brewer et al., 2008). All families presented with juvenile onset 
of distal muscle atrophy and weakness and electromyography data showed variable 
NCVs, both above and below 38 m/s. Again, carrier females were unaffected. In two 
of the families, the majority of patients reported pain and paraesthesia as the initial 
sensory symptom before the onset of sensory loss. Linkage analysis carefully refined 
48 
 
the locus to a 2.5-Mb region on Xq26.3-27.1, consisting of 10 genes that showed no 
variants.  
Axonal CMTX 
Three other types of CMTX are predominantly axonal: CMTX4, CMTX5 and 
CMTX6. CMTX4 - also known as Cowchock syndrome - is characterised by early 
onset polyneuropathy, sensorineural hearing loss and mental retardation, caused by 
mutations in the apoptosis- inducing factor (AIF) gene (Rinaldi et al., 2012).  
 
Rosenburg-Chutorian syndrome, CMTX5, is caused by mutations in the 
phosphoribosyl pyrophosphate synthetase 1 (PRPS1) gene. Patients present with a 
very severe neuropathy, deafness and optic atrophy and can also be referred to as 
having Rosenberg-Chutorian syndrome (Kim et al., 2007). 
 
The last X-linked axonal form has only been found in one family so far and has been 
linked to mutations in the Pyruvate dehydrogenase kinase, isoenzyme 3 (PDK3) gene 
(Kennerson et al., 2013).  
X-linked dHMN  
So far, only one gene has been found to be responsible in families with X-linked 
dHMN. ATPase, Cu++ transporting, alpha polypeptide (ATP7A) encodes for a 
copper-transporting ATPase 1 that is located to the transmembrane from the golgi in 
response to copper. When mutated, there is a significant accumulation of this protein 
at the plasma membrane, interfering with the copper metabolism (Kennerson et al., 
2010). Originally, mutations in this gene were found to cause Menke’s disease, 
characterised by an infantile onset of cerebral and cerebellar neurodegeneration, 
failure to thrive, kinky hair and connective-tissue abnormalities. The mutation 
spectrum of Menke’s disease does not include either of the mutations found in the 
dHMN families, which suggest the mutation spectrum might have an influence on 
the phenotype.  
 
 
 
 
49 
 
 
1.3 Pathogenic pathways involved in Charcot -Marie-Tooth  
1.3.1 Myelin assembly and Schwann cell dynamics  
Not surprisingly, the first genes involved in CMT were found to be part of the 
myelin pathway. In a normal situation, myelin will reduce the capacitance of the 
internodal axonal membrane and cluster ion channels at nodes to facilitate saltatory 
conduction. Demyelination increases internodal capacitance and disrupts the 
organisation of ion channels in the nodal region, resulting in conduction slowing and 
even conduction block. 
 
The majority of demyelinating neuropathies result from defects in the development 
and functioning of Schwann cells and the myelin sheath they produce by mutations 
in genes such as PMP22, MPZ, GJB1 and PRX.  Axonal loss will occur as a 
secondary outcome, displaying a higher correlation with the severity of disease than 
the initial demyelination (Fledrich et al., 2012). Demyelination can be the result of 
disrupted structure of the myelin sheath (MPZ), formation of aggresomes and 
actin/PI4-5P2 positive vacuoles (PMP22), retention of the proteins in the ER 
(PMP22), alterations of the gap junctions between compact and uncompact myelin 
(Cx32) or interruption of the Schwann cell-ECM connection (PRX, PMP22). 
Different mutations in the same gene can lead to distinct effects, as is the case for 
X-linked Gene/locus Function 
X-linked CMT   
CMTX1 GJB1 Myelin assembly/Myelin transport 
CMTX2 Xp22.2  
CMTX3 Xq26  
CMTX4 AIF Apoptotic pathway 
CMTX5 PRPS1 Purine metabolism and nucleotide biosynthesis 
CMTX6 PDK3 Regulation of glucose metabolism 
X-linked HMN  ATP7A Copper-transporting ATPase 
Table 1-6 Classification of X-linked CMT. GJB1: Gap Junction Protein Beta 1; AIF: 
apoptosis- inducing factor. PRPS1: phosphoribosyl pyrophosphate synthetase 1; PDK3: 
Pyruvate dehydrogenase kinase, isoenzyme 3; ATP7A: ATPase, Cu++ transporting, alpha 
polypeptide. 
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MPZ: depending on the location of the mutation, there is disruption of the myelin 
structure or direct axonal loss, thought to arise from aberrant Schwann cell-axon 
interactions (Berger et al., 2006). The effects do not limit themselves to the structure 
of myelin. For example, mutations in PMP22 will also result in misregulation of 
apoptosis. How and whether this will be a determining factor for the observed 
phenotype has not been established yet.  
 
As evidenced by the pathogenic results of the altered dosage of the PMP22, protein 
levels have to be tightly regulated to control myelination. An important transcription 
factor in this pathway is EGR2, which is likely to control the expression of myelin 
proteins such as MPZ (LeBlanc et al., 2006). Mice lacking this gene are devoid of 
peripheral nerve myelin, and the phenotype in humans with mutations generally 
results in severe demyelination or dysmyelination.  
1.3.2 Altered protein synthesis, sorting and/or degradation  
The internalisation and subsequent endosomal trafficking or recycling of proteins 
and membrane along the endocytic pathway is a fundamental cellular process. Cells 
can internalise components in diverse ways, such as phagocytosis, caveolea or 
clathrin-dependent endocytosis (CDE). Along the latter pathway, several genes have 
been found to result in a CMT phenotype when mutated (Fig. 1.1). At the early 
stages, DNM2 is involved as a large GTPase to constrict and deform membranes; 
including pinching off newly formed clathrin-coated vesicles. Mutations are mainly 
located in the pleckstrin-homology domain and can either cause axonal or 
intermediate versions of CMT. This results in a reduced binding of DNM2 to 
vesicles, leading to a reduction of CDE (Zuchner et al., 2005; Durieux et al., 2010).  
Few mutations will maintain the membrane localisation but instead affect the 
microtubule-dependent membrane transport (Tanabe et al., 2012).  
 
Further in the endocytic pathway at the late endosome-/lysosome state, a small 
GTPase, RAB7, regulates endosomal sorting, biogenesis of lysosomes and 
phagocytosis (Zhang et al., 2009). Mutant forms of the protein exhibited lower 
GTPase activity, with a predisposition for GTP binding leading to a more activated 
state of RAB7 (Spinosa et al., 2008).   
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Figure 1-1 Proteins of the endocytic pathway implicated in CMT. ERC = Endocytic recycling compartment.  
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As mentioned in section 1.2.2, the axonal phenotype with prominent sensory features 
that originates from mutations in RAB7A has an extensive similarity with the 
SPTLC1-phenotype, involved in sphingolipid synthesis, suggesting the pathogenic 
mechanism originates from the transport or endocytosis of sphingolipids. Another 
small GTPase, RAB11, interacts with SH3TC2 to target the intracellular recycling 
endosome, responsible for the recycling of internalised membrane and receptors 
back to the plasma membrane. Mutant forms of SH3TC2 are unable to associate with 
Rab11, resulting in a loss of recycling endosome localisation. Phenotypically, this 
will result in progressive demyelination of the peripheral nerves (Roberts et al., 
2010).  
 
Recently, one more autosomal recessive demyelinating form of CMT, linked to 
mutations in the NDRG1 gene, has also been implicated in vesicular transport. Even 
though the exact function is not known yet, evidence shows localisation to the 
recycling/sorting endosomes for E-cadherin transport and recycling (Kachhap et al., 
2007). 
 
As a whole, the endocytic pathway is subject to regulation by phosphoinositides 
(PIs), phosphorylated versions of phosphatidylinositol, a minor component on the 
cytosolic side of cell membranes. Whilst phosphatidylinositol-4,5-bisphosphate 
[PI(4,5)P2] is the main PI present, accountable for initiation of clathrin-coated pit 
(CCP) formation, generation of phosphatidylinositol-3,4-bisphosphate [PI(3,4)P2] 
and dephosphorylation of [PI(4,5)P2] later in the pathway are necessary for the 
regulation of CCP maturation and vesicle uncoating. [PI(3)P] is localised on early 
endosomes and, together with [PI(3,3)P2], can be dephosphorylated by active 
myotubularins such as MTMR2 and MTMR13. Mutant forms of these enzymes in 
demyelinating CMT show reduced phosphatase activity and indicate a necessity for a 
tight control of PI levels along the endocytic pathway (Berger et al., 2002). 
[PI(3,5)P2] is one of the other PIs localised on the endosomal membranes, although 
in a concentration almost 100-fold lower than [PI(4,5)P2]. Concentration of 
[PI(3,5)P2] is tightly regulated by the PAS complex, containing both a 
phosphoinositide kinase and phosphatase. Part of the phosphatase contains the FIG4 
protein, mutated in recessive demyelinating CMT (McCartney et al., 2014) and will 
be more extensively discussed in Chapter 4.  
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Regulating the same pathway, SIMPLE/LITAF was first linked to the late endosome, 
identifying as an E3 Ubiquitin ligase due to a C-rich domain resembling the RING 
finger motif. However, recent studies suggest it is an early endosomal membrane 
protein, regulating cell signalling by promoting endosome-to-lysosome trafficking 
and degradation of signalling receptors (Lee et al., 2012; Chin et al., 2013). 
Mutations will result in mislocalisation to the mitochondria, inhibiting endosomal 
trafficking and lysosomal degradation of proteins (Lacerda et al., 2014). Again, this 
will lead to a demyelinating phenotype.  
 
Lastly, LRSAM1 has been identified as an E3 Ubiquitin ligase exhibiting an 
opposite effect on the pathway. Ubiquitination by LRSAM1 will cause the 
disassembly of sorting complexes, leading to a prolonged signalling of the activated 
receptors (Engeholm et al., 2014). Mutant forms will lead to an axonal phenotype in 
patients, with both dominant and recessive cases being reported (Guernsey et al., 
2010; Engeholm et al., 2014). The regulation of cell surface receptors throughout the 
endocytic pathway will modulate the intensity and duration of signal transduction in 
cells.  
 
None of these proteins are exclusively expressed in neuronal cell types and the 
occurrence of demyelinating CMT indicates Schwann cells might be particularly 
susceptible to defects in endosomal trafficking. Whilst in some cases, direct links 
could be found with ERK1/2 activation, leading to demyelination (Lee et al., 2012), 
the link between endocytic dysregulation and axonal neuropathies is less clear.  
1.3.3 Axonal transport Altered Transport Processes 
Axonal transport regulates the movement of different cell organelles such as 
mitochondria, vesicles or lipids and proteins throughout the axon in a bidirectional 
way. Anterograde transport directs the cargo from the cell body to the periphery, 
with retrograde transport being responsible for transferring cargo along the 
microtubule from to periphery to the cell body.  
 
Anterograde transport uses a class of motor proteins called kinesins to drive the 
cargo over the microtubule towards the plus end, located at the periphery (Fig. 1.2). 
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Each step is catalysed by the hydrolisation of ATP into ADP, releasing energy 
(Hirokawa et al., 2005).  Multiple members exist in the human kinesin superfamily, 
exhibiting individual functions. In relation to CMT, only one family has been found 
with a mutation in the KIF1B gene, causing axonal neuropathy (Zhao et al., 2001). 
Two different isoforms are encoded by the KIF1B gene and show affinity for 
different cargos. KIF1B-α mediates transport of mitochondria, while KIF1B-β 
associates with synaptic vesicles precursors. The mutation is located in the ATP 
binding domain, which is part of both isoforms but heterozygous mice only showed 
a defect in synaptic vesicle transport together with progressive muscle weakness. 
This led to the suggestion that haploinsufficiency of the protein and impaired 
transport of synaptic vesicle precursors could lead to the axonal neuropathy. Many 
years later, truncating, recessive mutations in KIF1A were linked to patients with 
HSAN. All mutations were found downstream of the motor domain, in an 
alternatively spliced exon of KIF1A mainly expressed in the nervous system. KIF1A 
is responsible for fast anterograde transport of synaptic vesicles and Y2H studies 
indicated KIF1A interacted with the HSN2 exon of WNK1, another gene implied in 
HSAN (Riviere et al., 2011).  
 
In the same way for retrograde transport, dynein-dynactin complexes function as 
motor proteins, transporting the cargo from the periphery to the cell body. The first 
mutation was reported in DCTN1 in 2003, in patients with dHMN (Puls et al., 2003). 
Dynactin links the specific cargo with the microtubule and cytoplasmic dynein. 
Mutant forms have shown a lower affection for microtubule, impairing the dynactin 
function and leading to aggregates that associate with mitochondria and induce cell 
death (Levy et al., 2006). Axonal transport will both be inhibited by the lower 
interaction and the toxic gain-of-function effect from the aggregates, leading to 
axonal neuropathy. More recently, mutations in DYNH1C1, the heavy chain of 
dynein, were found in CMT2 patients (Weedon et al., 2011). One year later, different 
mutations in the same gene were appointed as the cause for SMA-LED (Tsurusaki et 
al., 2012). All of these mutations are located in the homodimerisation domain, 
resulting in a decreased affinity of dynein for the microtubule during the ATP step, 
impairing motor domain co-ordination and subsequently reducing dynein-driven 
retrograde transport (Harms et al., 2012).  
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Figure 1-2 Proteins in axonal transport or cytoskeleton, implicated in CMT. 
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Further research showed profoundly modified mitochondrial morphology and 
respiration due to these mutations, indicating that dynein is required for the 
maintenance of mitochondrial morphology (Eschbach et al., 2013). Whilst dynein is 
ubiquitously expressed, motor neurons seem to be most vulnerable to defects in 
dynein function.  
Important factors in the regulation of dynein-based vesicle motility, function and 
localisation are a group of proteins called Bicaudal D. These were first identified in 
Drosophila flies and have two homologs in mammals: BICD1 and BICD2 (Kardon 
et al., 2009). Mutations in the latter have been found in patients with a very similar 
phenotype to DYNC1H1-associated SMA-LED, indicating the pathogenicity of these 
mutations (Oates et al., 2013; Peeters et al., 2013; Neveling et al., 2013). This will be 
further discussed in Chapter 5.  
 
Another way to regulate mitochondrial transport is through the levels of Ca
2+
 along 
the neuron. High Ca
2+
 levels will recruit more mitochondria to take up the excess 
Ca
2+
 through the uniporter into intracellular stores. Mutations in TRPV4, a cation 
channel mediating calcium influx, result in a dominant axonal neuropathy and 
different hypothesis have been suggested in regards to the pathomechanism of these 
mutations. Whilst initial studies showed a loss of function due to cytoplasmic 
retention of the channels and decreased calcium channel activity of the mutant form 
(Auer-Grumbach et al., 2010), other studies proposed a gain of function mechanism, 
showing physiological localisation and an increased calcium channel activity, 
leading to an increased intracellular calcium influx (Fecto et al., 2011). Apart from 
causing dominant axonal neuropathies, mutations in this gene can lead to a range of 
skeletal and neuromuscular disorders, with a high variability even within families 
(Auer-Grumbach et al., 2010).   
1.3.4 Alterations of the Cytoskeleton 
Not only can mutations occur directly in the molecular motors for axonal transport or 
their modulators, mutations in proteins of the cytoskeleton can indirectly influence 
the working of axonal transport. Alterations in the cytoskeleton will result in an 
impaired axonal transport, reduced axon diameter and a reduced capacity for nerve 
regeneration. One of the major components of the neuronal cytoskeleton is 
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neurofilament, which functions to provide structural support and regulate the axon 
diameter (Lariviere et al., 2004). Neurofilament is built from three building blocks, 
with names based on the molecular weight of each subunit: Neurofilament light 
chain (NF-L: 62 kDa), medium chain (NF-M: 168 kDa) and heavy chain (NF-H: 200 
kDa). After synthesis in the cell body, neurofilament will be transported along the 
microtubule to the nerve terminals, where NF-L functions as a scaffold for the 
assembly of NF-M and NF-H (Ching et al., 1993; Xia et al., 2003). More than a 
decade ago, the first mutations in the neurofilament light chain gene (NEFL) were 
found to cause axonal CMT2, with further reports expanding the phenotype to 
demyelinating CMT1 (Mersiyanova et al., 2000; Jordanova et al., 2003). Different 
NEFL mutations exert various effects on NF biology, such as interference with the 
transport of mitochondria, axonal transport of mutant neurofilament and 
neurofilament assembly (Brownlees et al., 2002; Perez-Olle et al., 2004), but no 
genotype/phenotype correlations have been established so far (Miltenberger-Miltenyi 
et al., 2007). NEFL knockout mice did not exert a CMT2 phenotype, whilst the 
introduction of missense mutations led to a severe peripheral neuropathy, indicating 
the dominant missense mutations do not cause loss-of-function (Zhu et al., 1997; Lee 
et al., 1994). In one of our families with axonal neuropathy, mutations were found in 
the neurofilament heavy chain, which will be discussed in Chapter 5. Interestingly, 
studies have shown that dynein is partially responsible for the movement of 
neurofilament along the axons, via an interaction with NF-M. Inhibition of the 
dynein/dynactin complex leads to accumulation of neurofilaments in the axon 
(Wagner et al., 2004; Motil et al., 2007).  
 
The organisation of the neurofilament network requires the assistance of small heat 
shock proteins such as HSP27, encoded by HSPB1, that regulate interactions that 
occur between filaments in their cellular networks (Perng et al., 1999). Mutations in 
HSPB1 disrupt the neurofilament network (Evgrafov et al., 2004) by 
hyperphosphorylation of the neurofilaments, reducing anterograde transport and 
subsequently leading to dominant axonal neuropathy or dHMN (Holmgren et al., 
2013). The role of HSP22, another protein implicated in CMT, has not been 
characterised as extensively. Even though it does not directly interact with 
neurofilament, it might play a role in the architecture of the cytoskeleton via 
interaction with HSP27 (Sun et al., 2004). NF-L metabolism is also regulated by 
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TRIM2, an E3 Ubiquitin ligase. Studies have shown TRIM2 is responsible for the 
ubiquitination of NF-L and mutant forms lead to a reduction of NF-L ubiquitination 
with subsequent NF-L accumulation in aggregates (Balastik et al., 2008). Only one 
patient with axonal neuropathy has been found so far with compound heterozygous 
mutations in this gene (Ylikallio et al., 2013).  
 
Most of the mutated genes implied in the neuronal cytoskeleton metabolism will 
result in axonal CMT with the exception of NF-L, which has been shown to also lead 
to demyelinating CMT. However, no consistent differences could be found in 
between the mutations causing either axonal or demyelinating CMT, with several 
mutations causing both (Miltenberger-Miltenyi et al., 2007).  
 
A characteristic component of the cytoskeleton for all cell lines is microfilament, 
consisting of linear polymers of actin which, in neurons, are located at nodes of 
Ranvier and post synaptic densities and in dendritic spines. They are situated right 
under the plasma membrane of the axon and provide mechanical strength to the cell 
or link transmembrane proteins to cytoplasmic proteins. Multiple genes have been 
found to be mutated in demyelinating CMT or HSAN that influence the actin 
cytoskeleton as mentioned before, such as CCT5  –involved in the folding of actin–, 
DST –linking actin filaments to microtubule-, and FGD4 –mediating actin 
cytoskeleton changes (Bouhouche et al., 2006; Edvardson et al., 2012; Delague et al., 
2007). All of these present with a recessive mode of inheritance but so far, none have 
been extensively studied to hypothesise the pathogenic pathway involved.  
1.3.5 Mitochondrial network dynamics and ATP production 
Another concept important in the maintenance of axons is the dynamics of the 
mitochondrial network. Due to high energy requirements and low intrinsic energy 
reserves, neurons require a constant delivery of mitochondria, producing ATP. Not 
only low ATP levels, but also high Ca
2+
 levels attract a flux of mitochondria, which 
will take up the excess Ca
2+
 through the mitochondrial Ca
2+
 uniporter, as mentioned 
before. Mutations in different genes affecting the function, transport, fusion, fission 
or interactions with mitochondria have been found in patients with CMT. 
Mitochondria are known as the ‘Powerhouses of the cell’ and defects in their 
function can lead to a broad spectrum of diseases, most commonly called 
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mitochondrial diseases. Mitochondrial diseases tend to present as multisystemic 
disorders and are generally progressive. Despite the phenotypic variability, more 
cases of neurodegenerative disorders due to mitochondrial defects are being 
discovered, such as Alzheimer’s disease, Amyotrophic lateral sclerosis, Huntington 
disease and hereditary spactic paraplegia (Lin et al., 2006; Schon et al., 2011).  
 
Whilst initially these disorders were mainly characterised by defects in 
mitochondrial respiration, genes are being discovered that lead to faults in 
mitochondrial trafficking, interorganellar communication and quality control defects 
when mutated. Section 1.3.3 already showed examples of cases were the transport of 
mitochondria was affected due to mutations in motor proteins, but many more are 
implied in the context of CMT. As mentioned before, MFN2 is a GTPase located in 
the outer membrane of the mitochondria and regulates mitochondrial fusion and 
tethering. The fusion/fission process plays a critical role in maintaining healthy 
mitochondria, for example after metabolic or environmental stress. Fusion will help 
to diffuse stress by mixing contents of healthy mitochondria with partially damaged 
mitochondria, whilst fission is needed to create new mitochondria. Mutant forms of 
MFN2 will not only cause defects in the fusion of mitochondria (Detmer et al., 
2007), but also compromise the axonal transport of mitochondria leading to 
mitochondrial clustering in the perikaryon (Baloh et al., 2007). Axonal degeneration 
correlated with the alteration of proper mitochondrial distribution along the axon, 
due to disruption of local axonal energy sensing and positioning mechanisms. Initial 
hypothesis explained the vulnerability of long axons to the delay or prevention of 
newly synthesised mitochondria from reaching the most distal ends, but more recent 
data suggests this might be due to a deficit in the regulation of local transport and 
distribution of mitochondria (Misko et al., 2012). Additionally, mutations in MFN2 
resulted in a reduced mitochondrial membrane potential together with an energetic 
coupling defect (Loiseau et al., 2007). 
 
Even though mutations in MFN2 lead to axonal CMT, mutations in the 
mitochondrial fission protein GDAP1 most frequently lead to demyelinating CMT 
and in some cases to intermediate or axonal forms.  Phenotypically, recessive 
mutations result in a more severe disease than dominant mutations. Recessive mutant 
forms have lost mitochondrial fragmentation activity (Niemann et al., 2005), whilst 
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dominant forms interfere with mitochondrial fusion and result in an increased 
production of reactive oxygen species (Niemann et al., 2009). Silencing of GDAP1 
also influences Ca
2+
 homeostasis by reducing Ca
2+
 inflow through store-operated 
Ca
2+
 entry (Pla-Martin et al., 2013). However, the exact pathological changes that 
lead to axonal or demyelinating changes have not been elucidated yet. Knockout 
mouse models have been developed, showing progressive decreased nerve 
conduction velocities, accompanied by mild hypomyelination. Investigations show 
larger mitochondria in knockout mice axons and cultured sensory neurons showed 
impaired mitochondrial transport (Niemann et al., 2014).  
 
GDAP1 fission is dependent on Drp1 (also known as DNM1L), a highly conserved 
mitochondrial fission factor that regulates the interaction between mitochondria and 
ER, and silencing Drp1 expression resulted in mitochondrial elongation and reduced 
fragmented mitochondria (Niemann et al., 2009). Whilst mutations in this gene are 
lethal, one of the upstream regulators, inverted formin 2 (INF2), has been shown to 
be mutated in intermediate CMT. One postulation is that ER-localised INF2 
assembles actin at the mitochondria-ER constriction sites, providing initial 
mitochondrial constriction and enhancing further constriction by Drp1 before rapidly 
depolymerizing actin (Korobova et al., 2013). Originally, mutations in INF2 were 
found to cause focal segmental glomerulosclerosis (FSGS) after which the phenotype 
was expanded to dominant intermediate CMT with FSGS (Boyer et al., 2011).  
 
Secondly, mutations can also interfere with the production of ATP in the 
mitochondrion itself. When pyruvate is transported along the mitochondrial 
membrane it enters the Krebs cycle after conversion to acetyl CoA, and results in 
ATP and reduced FADH2 and NADH that will be transported to the electron 
transport chain. CMT2-causing genes have been found at different stages of this 
process, all leading to a neuropathy. The first step of oxidative decarboxylation of 
pyruvate is catalysed by the pyruvate dehydrogenase complex (PDC). PDC 
deficiency normally leads to developmental delay, hypotonia, seizures and abnormal 
cerebral neuroimaging with selected cases associated with peripheral neuropathy 
(Patel et al., 2012). This complex is regulated by four pyruvate dehydrogenase 
kinase isoenzymes (PDKs), each exhibiting tissue-specific expression. PDK3, the 
isoenzyme expressed in brain and spinal cord, has been found mutated in one family 
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with X-linked CMT, resulting in overactivity of the isoenzyme leaving PDC in a 
predominantly phosphorylated inactive state, which may lead to impaired ATP 
production (Kennerson et al., 2013).  
 
Although extremely rare, cases have been reported with mutations in the enzymes of 
the Krebs cycle, leading to metabolic diseases (Rustin et al., 1997). The first and 
only mutation leading to axonal neuropathy was found in the dehydrogenase e1 and 
transketolase domains-containing protein 1 (DHTKD1) which has been postulated to 
function as a 2-oxoglutarate-dehydrogenase E1 component in the Krebs cycle. 
Silencing of this protein resulted in severely reduced levels of ATP and NADH and 
haploinsufficiency due to rapid mRNA degradation via nonsense mediated decay of 
the nonsense mutation is suggested to lead to insufficient energy production and 
dysfunction of peripheral nerves (Xu et al., 2012). 
 
In Chapter 3, the mitochondrial oxidative phosphorylation system and discovery of 
mutations in complex V will be discussed extensively. There we found mutations in 
CMT2 patients in the mitochondrially encoded ATP6 gene, normally known to cause 
mitochondrial disorders such as Leigh syndrome or NARP. Not long after that 
discovery, mutations in a different gene in the same pathway that normally causes 
Leigh syndrome were found in patients with recessive, demyelinating CMT 
(SURF1). All three patients presented with an isolated peripheral neuropathy and 
very little multisystem involvement (Echaniz-Laguna et al., 2013). SURF1 is one of 
the at least 6 assembly factors of Cytochrome c oxidase (COX), also known as 
complex IV in the electron transport chain, and mutant forms result in a markedly 
reduced assembly and activity of COX. The exact pathways that lead from a COX 
defect to an isolated peripheral neuropathy have not been elucidated yet.  
1.3.6 tRNA synthetase genes  
Aminoacyl tRNA synthetases are enzymes responsible for charging the appropriate 
amino acid to their cognate tRNA before transferring the amino acid onto a growing 
peptide. The first amino-acyl tRNA synthetase discovered to cause axonal 
neuropathy was glycyl tRNA synthetase (Antonellis et al., 2003). This led to the 
subsequent discovery of an additional five amino-acyl tRNA synthetases implicated 
in peripheral neuropathy: tyrosyl-tRNA synthetase (Jordanova et al., 2006); alanyl-
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tRNA synthetase (Latour et al., 2010); lysyl-tRNA synthetase (McLauglin et al., 
2010); histidyl-tRNA synthestase (Vester et al., 2013) and methionyl-tRNA 
synthetase (Gonzalez et al., 2013). Different hypothesis have been suggested to 
explain the pathogenicity of mutations in tRNA synthetase genes and have been 
predominantly studied in GARS, due to the earlier discovery and the majority of 
mutations being located in this gene. Considering the mutation in AARS was present 
in the editing domain, misincorporation of amino acids has been observed, leading to 
misfolded proteins and the activation of the unfolded protein response which could 
lead to the observed neurodegeneration (Lee et al., 2006). However, GARS does not 
have an editing domain since the active site is conformationally constrained to only 
accept glycine and only few mutations would adjust the dimer interface leading to 
misincorporation, suggesting this would not be the pathological mechanism (Stum et 
al., 2011). Most functional approaches to prove pathogenicity of these ARS enzymes 
involve aminoacylation and yeast growth assays. When performed on nine different 
GARS mutations, all mutations affected the aminoacylation activity of the protein in 
comparison with wild type and the majority of mutations also dramatically reduced 
yeast cell viability (Griffin et al., 2014). Whilst this indicates pathogenicity of novel 
mutations and insight in the functional consequences, it provides no further 
elucidation about the pathomechanism in axons. Research has suggested a role in 
local translation in axons (Giuditta et al., 2002) and studies have shown a punctate 
structure of wild type endogenous GARS in peripheral axons, which is impaired in 
certain mutated forms (Griffin et al., 2014). However, additional research needs to be 
performed to establish a link between impaired function and the observed axonal or 
intermediate neuropathy in these six ARS found so far.  
1.3.7 Unknown pathways 
Apart from the previous recurring themes in the pathogenicity of peripheral 
neuropathies, there are multiple genes involved that do not fit in any of these 
pathways or have not had their pathogenic role clarified yet. Some of them affect the 
same pathway, indicating the importance in neuropathy; others stand alone with a 
function not related to other proteins mutated. Examples are proteins involved in 
RNA metabolism (HINT1, IGHMBP2, CTDP1), sphingolipid biosynthesis (SPTLC1, 
SPTLC2) or development (WNK1, IKBKAP,FBXO38) or isolated proteins such as 
LMNA, HK1 or SLC5A7. The majority of genes implicated in CMT are not restricted 
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to one specific function and in many cases, it is not clear which exact function is 
impaired in the mutant forms of the protein.  
 
1.4 Thesis aims  
The aim of this thesis was to contribute to the knowledge of the genetic 
heterogeneity and mechanism of disease of inherited neuropathies, in particular, 
CMT. My work combined the use of genetic studies and functional analysis with the 
overall aims of: 
1. Investigating the presence of mutations in the mitochondrial genome leading 
to CMT (Chapter 3). 
2. Estimating the frequency of newly discovered genes in selected cohorts 
(Chapter 4). 
3. Screening new candidate genes in appropriate cohorts by the use of Sanger 
sequencing (Chapter 4). 
4. Using exome sequencing to establish the genetic cause of disease in 
undiagnosed families with inherited neuropathy (Chapter 5). 
5. Investigating the molecular mechanism of mutations in IGHMBP2 leading to 
both SMARD1 and CMT2 (Chapter 6). 
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Chapter 2:  
Material and methods 
Materials: The country of origin is only indicated for companies that do not have 
registered UK subsidiaries. 
2.1 Genetic studies  
2.1.1 Ethical approval and patient selection 
This study has been granted ethical approval by the National Research Ethics Service 
Committee of the National Hospital for Neurology and Neurosurgery (NHNN) in 
Queen Square, London, UK. Written informed consent was obtained from all 
patients, parental guardians and/or included family members. Patients were 
identified by Professors Mary Reilly and Henry Houlden primarily and 
collaborations were made with several additional clinicians around the world.  
2.1.2 DNA extraction 
DNA extraction was performed in the neurogenetics lab by the clinical diagnostic 
service of the National Hospital for Neurology and Neurosurgery. This was 
performed using either automated purification of DNA from 1–5 ml or 5–10 ml 
samples of fresh or frozen whole blood using Autopure reagents on the Autopure LS 
or by manual extraction with the Qiagen Flexigene kit (Qiagen).   
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2.1.3 DNA concentration and purity  
DNA concentration and purity were assessed using the NanoDrop ND-1000 
spectrophotometer as per the manufacturer’s instructions (NanoDrop Technologies). 
Concentration was assessed at 260 nm. Purity was estimated by the 260/280 and 
260/230 absorbance ratios, to assess contamination with respectively proteins or 
other contaminants such as phenol, ethanol or other compounds. Absorbance ratios 
between the spectrum of 1.8-2 and 1.8-2.2 respectively were required for DNA of 
decent quality.  
2.1.4 Polymerase Chain Reaction (PCR)  
Human genome sequences were obtained from Ensembl Genome Browser 
(http://www.ensembl.org/index.html), genome assembly build 37 (GRCh37; 
GCA_000001405.14).  Transcripts were chosen according to the project, depending 
on previous papers or the full length of the transcript. Genes for which the whole 
gene was sequenced are listed below (Table 2.1). Transcripts for exome sequencing 
variants were chosen according to the exome data.  
 
Gene  Transcript  
MT-ATP6  ENST00000361899 
MT-ATP8 ENST00000361851 
FIG4 ENST00000230124 
C9orf72 ENST00000380003 
HINT1 ENST00000304043 
ARL1 ENST00000261636 
ARL6ip1 ENST00000304414 
SCN9A ENST00000409672 
BICD2 ENST00000356884 
TRAK2 ENST00000332624 
ADD3 ENST00000356080 
IGHMBP2 ENST00000255078 
Table 2-1 List of transcripts used for sequencing of genes. 
Designing of primers   
Primers were designed using the Primer3 software (http://primer3.ut.ee/, Rozen and 
Skaletsky, 2000) unless stated otherwise, to amplify the exons and exon-intron 
boundaries. Primers were chosen to be a length of 18-23 basepares long, resulting in 
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a product size between 500-700 basepares. Melting temperatures were between 57°C 
and 62°C and the percentage of G or C bases in the primer was  ̴50%. Primers with a 
high self-complementarity were excluded. All primers are available on request.  
Nuclear DNA  
PCR reaction mix was made up to a volume of 25 μL with sterile deionised H20 and 
included 10 μmol of each primer, 20 to 50 ng DNA and 12.5 μL of FastStart PCR 
master (Roche). When necessary, 10% DMSO was included in the PCR reaction. 
PCR was performed on an Eppendorf Mastercycler thermal cycler at a previously 
determined optimal annealing temperature. Cycling conditions used for PCR 
amplification reactions are described in Table 2.2. PCR reactions were maintained at 
4°C after cycling and stored at -20°C.  
 
Step Reactionstep Time Temperature 
1 Initial denaturation 10 min 95°C 
2 Denaturation  30 sec 94°C 
3 Annealing primers  30 sec  60°C (-0.4°C/cycle) 
4 Elongation  45 sec  72°C 
5 Denaturation  30 sec 94°C 
6 Annealing primers  30 sec 50°C 
7 Elongation  45 sec  72°C 
8 Final elongation  10 min  72°C 
Table 2-2 Standard 60-50 touchdown PCR reaction. Steps 2 to 4 were 
repeated 25 times; steps 5-7 were repeated 12 times. Annealing temperature 
in step 3 was 60°C (-0.4°C/cycle) for the majority of exons sequenced. 
Mitochondrial DNA 
The whole length of 841 nucleotides of the ATPase 6 and ATPase 8 genes, with a 
surrounding hundreds of nucleotides, was divided into three overlapping fragments 
(Table 2.3). Primer sequences were originally designed as a set to screen the 
complete mitochondrial genome in overlapping segments and the remaining primers 
are available on request. All forward primers had a -21 M13 primer tail 
(TGTAAAACGACGGCCAGT) and all reverse primers a M13 reverse tail 
(CAGGAAACAGCTATGACC). PCRs were made up to a volume of 25 μL with 
sterile deionised H20 and included 10 pmol of each primer, 50 ng DNA and 12.5 μL 
of Amplitaq Gold 360 Mastermix (ABI) with conditions listed in Table 2.4   
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Fragment Primer Forward  Length 
(nt) 
Nucleotide 
location Primer Reverse 
1 5’- acagtttcatgcccatcgtc-3’ 530 8196-8726 
3’- gttcgtcctttagtgttgtg -5’  
2 5’- ccgactaatcaccacccaac -3’ 598 8646-9244 
3’- ggttttactatatgataggc -5’  
3 5’- atccaagcctacgttttcac -3’ 593 9151-9744 
3’- ctgaggcttgtaggagggta -5’  
Table 2-3 Primer sequences for the ATPase6 and 8 genes. 
Step Reactionstep Time Temperature 
1 Initial denaturation 10 min 95°C 
2 Denaturation 30 sec 95°C 
3 Annealing primers 30 sec 58°C 
4 Elongation 30 sec 72°C 
5 Final Elongation 7 min 72°C 
Table 2-4 PCR reaction. Steps 2 to 4 were repeated 30 times. 
2.1.5 Agarose gel electrophoresis of PCR products 
1.3% w/v agarose gel was prepared by adding 1g of agarose powder (Roche) to 75 
mL of 1xTBE buffer (10x TBE: 121.1 g Tris (Sigma-Aldrich), 61.8 g anhydrous 
boric acid (Merck-Millipore), 7.4 g EDTA (VWR), made up with dH2O; pH to 8.3) 
and heating up the mixture in the microwave to dissolve. After cooling, 2 μL of 10 
mg/mL ethidium bromide (Promega) was added to visualise DNA by intercalation 
between the strands. After PCR amplification, length of PCR products was verified 
by loading 5 μL of the PCR product mixed with 2 μL Orange G loading dye (60% 
glycerol, 40% dH2O, teaspoon of orange G powder (Sigma-Aldrich)). 
Electrophoresis was run on 80V for 30 minutes to allow a good separation of the 
bands and visualised under a UV transilluminator. Digital photographs were 
obtained using the Syngene GeneGenius image acquisition system and GeneSnap 
software (Synoptics).  
2.1.6 DNA purification  
To ensure PCR products were free of unincorporated single strand DNA 
oligonucleotides and dNTPs, two different methods were used. Millipore 
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multiscreen
hts
 PCR filter plates were used up until 5/2/13, after this date ExoSap was 
used.  
Millipore  
Vacuum at 25 inches Hg was applied for 5-10 minutes after which the samples were 
reconstituted in 50 μL of nanopure water. Samples were mixed on a plate mixer for 
30 minutes, where after the purified PCR product was retrieved from each well.  
ExoSap 
PCR products were purified using 2μL of Exo-Fast (50µL Exo I, 200µL Fast-AP, 
750µL Water) per 5 µL of amplified DNA by incubating at 37°C for 30 minutes and 
80°C for 15 minutes. The resulting product was stored at 4°C before sequencing 
reaction was performed.  
2.1.7 Sequencing 
Bi-directional sequencing was performed using a DNA sequencing kit (Big Dye 
Terminator 3.1; Applied Biosystems). Each reaction was made up to 10 μL of sterile 
deionised H2O and included 3.2 μmol of primer, 3.5 μL of PCR product, 2 μL of 5X 
BigDye Terminator v3.1 sequencing buffer (Life Technologies) and 0.5 μL of 
BigDye Terminator v3.1 reaction mix (Life Technologies). The cycling conditions 
were the following: (96°C, 10 sec.; 50°C, 5 sec.;  60°C,4 min) x25. 
2.1.8 Clean-up reaction 
To remove unincorporated dye terminators from the sequencing reaction, two 
different methods were used. Before February 2013, the dye terminator removal kit 
(Thermo Fisher Scientific) was used according to the manufacturer’s protocol. 
Before loading onto the separation plate, samples were adjusted to 20 μL with water. 
After centrifugation for 3 min at 950xg the samples were collected in a sterile 96 
well plate.  
 
After February 2013, Corning® FiltrEX™ 96 well filter plates, 0.66 mm glass fibre 
filter, polystyrene (Sigma-Aldrich) were used and columns were manually created 
with 350µL of Sephadex G-50 Bioreagent (Sigma-Aldrich) by dissolving 1.9g of 
Sephadex in 40mL of sterile deionised water per plate. Plates were spun for 3 
minutes at 750xg before adding the samples. After adding the entire volume of the 
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sequencing reaction (10µL) onto the Sephadex columns, plates were spun for 5 
minutes at 910xg and samples were collected in a sterile 96 well plate.  
2.1.9 Sequence analysis  
Samples were run on the ABI PRISM 3730xl Genetic Analyzer and were manually 
analysed using the SeqScape v2.5 program (ABI).  
2.1.10 Restriction endonuclease analysis 
 A fragment of the ATPase 6 gene, which includes the mutation site, was amplified 
using the sense mismatch primer (9,161-9,184) 
ACGTTTTCACACTTCTAGTGGGCC, and antisense Primer (9,273–9,253) 
AGAGGGCCCCTGTTAGGGGTC, hereby introducing a BSP12OI restriction site 
(GGGCCC) in the mutant but not in the wild type mtDNA. To calculate the 
percentage of heteroplasmy, a FAM fluorophore (6-carboxyfluorescein) was 
attached to the 5’ end of the antisense primer. The same conditions as stated above in 
Table 2.4 were used, with an annealing temperature of 57°C and a repetition of steps 
2-4 for 18 times.  
 
Following amplification, restriction enzyme digestion by 10 units of BSP12OI was 
performed to cleave the 113 nucleotides PCR product of mutant DNA into 89 and 24 
nucleotide fragments. The reaction mix was then incubated for two hours at 37°C.  
To denature the PCR products, 12μL of formamide was added to 1 μL of product. 
0.3 μL of Liz 600 (ABI) was used as a size standard. The resulting mixture was 
heated at 95°C for 3 minutes, after which it was put on ice immediately. It was then 
loaded on the 3730xl DNA analyser and the ratio of cut to uncut DNA was 
calculated with the GeneMapper (ABI) program. This was all performed in triplicate, 
after which the mean value was calculated.  
2.1.11 Fragment analysis to look at the C9orf72 expansion repeat  
The repeat expansion was assayed with a repeat-primed PCR which included a gene-
specific fluorescently labelled forward primer in the C9orf72 exon 1a and two 
reverse primers. The use of triplet-primed PCR (TP-PCR) for the detection of repeat 
expansions was first suggested by Warner et al. in 1996, with the principle of the 
technique relying on the use of locus-specific PCR primers in combination with a 
primer designed across the repeated sequence. After PCR reaction, products of 
different sizes will be produced, according to the number of repetitions. If an 
70 
 
expansion occurs, a continuous ladder of PCR amplification fragments exceeding the 
normal range will be visualised. For this project, one reverse primer consisted of four 
GGGGCC repeat units and an anchor sequence, while the second reverse primer 
contained the anchor sequence. Before PCR reaction, a primer mix was constituted 
according to volumes stated in Table 2.5. 1 µL of this primer mix was used in 
combination with 10 µL of Extensor mix, 10 µL of Betaine and 1 µL of DNA. PCR 
conditions are stated in Table 2.6. A cohort of 185 patients with dHMN was 
screened.  
 
Primermix  V (μL) 
F1: 6fam-agtcgctagaggcgaaagc 20 
R1: tacgcatcccagtttgagacgggggccggggccggggccggggccgggg 10 
R2: tacgcatcccagtttgagacg 10 
H2O 50 
Table 2-5 Primer sequences for the C9orf72 expansion repeat (5’ to 3’). 
Step Reactionstep Time Temperature 
1 Initial denaturation 10 min 98°C 
2 Denaturation  35 sec 97°C 
3 Annealing primers  2 min  53°C  
4 Elongation  2 min  68°C 
5 Denaturation  35 sec 97°C 
6 Annealing primers  2 min 53°C 
7 Elongation  2 min  68°C 
8 Final elongation  10 min  68°C 
Table 2-6 PCR reaction for the C9orf72 expansion repeat. Steps 2-4 were 
repeated 10 times, steps 5-8 were repeated 25 times.  
To denature PCR products, 9.2μL of formamide was added to 1.5 μL of product. 0.3 
μL of Liz 500 (ABI) was used as a size standard. The resulting mixture was heated at 
95°C for 3 minutes, after which it was put on ice immediately. It was then loaded on 
the 3730xl DNA analyser and allele identification and scoring was accomplished 
using GeneMapper v3.7 software (ABI). 
2.1.12 Exome Sequencing  
Enrichment of coding exons and flanking intronic regions was performed externally 
with the use of the Illumina’s TruSeq Exome Enrichment Kit, Nimblegen EZ 
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Capture og Agilent SureSelect in combination with HiSeq2000 sequencing. Poor 
quality samples were repeated with the same technology or done in-house with the 
HiSeq 2500 in High output mode. Primary data analysis including image analysis, 
base calling, alignment and variant calling, copy number variations and structural 
variations was performed by AROS or in-house. The exome sequencing performed 
in-house by Dr Deborah Hughes and Dr Alan Pittman at the UCL ION was mapped 
to the human reference genome build UCSC hg19 by Novoalign Software 
(Novocraft, Malaysia). After removal of PCR duplicates using Picard 
(http://picard.sourceforge.net) as well as reads without a unique mapping location, 
variants were extracted using the Maq model in SAMtools and filtered by the 
following criteria: consensus quality >30, SNP quality >30 and root mean square 
mapping quality >30. These variants were further filtered against the dbSNP 135 and 
1000 Genomes databases by use of Annovar (http://www.openbioinformatics.org 
/annovar/). The data filtering of the results were performed by me. Depending on the 
location in the genome, some genes, exons or genomic areas may not be covered 
fully by the hybridisation probe design, leading to a variable number of independent 
reads at a particular base pair, the read depth. Therefore, gene coverage and read 
depths of known disease-associated genes and candidates genes were determined by 
exploring BAM files using the GenomeBrowse software (Golden Helix, USA). A 
base was considered poorly covered if it had less than 15-20 times coverage. These 
were still included in the analysis but were regarded as potentially false positives. 
  
After confirming known mutations causing CMT disease or variants in candidate 
genes were not present, SNPs present in public databases with a frequency higher 
than 0.5% or a segmental duplication region higher than 0.96 were omitted, as 
variants within these regions are frequently false positive calls. Synonymous SNPs 
were excluded and the appropriate disease model was applied to the remaining list of 
variants. Shared variants files were made in the event where multiple patients were 
available. Further prioritising of variants was done by combining linkage analysis 
results or based on individual gene function and expression. In-silico predictions of 
pathogenicity and conservation between species were assessed and details of gene 
expression in various tissues and location of the mutated amino acid within the 
protein were examined to prioritise candidate gene lists.  
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2.1.13 Linkage analysis  
Genotyping was performed on the Illumina CytoSNP 12 array with a complete panel 
of 200,000 genome-wide tag SNPs and markers targeting all regions of known 
cytogenetic importance.  Raw data was processed using GenomeStudio software 
(Illumina, San Diego, CA). Uninformative markers with low call rates (<90%) and 
monomorphic SNPS (MAF <0.5%) were removed and a subset of 5000-6000 
randomly select markers was extracted for use in linkage analysis with PLINK 
(Purcell et al., 2007;  http://pngu.mgh.harvard.edu/purcell/plink/). Parametric linkage 
analysis was run on MERLIN (Abecasis et al., 2002) for an autosomal dominant 
model, specified with an estimated allele frequency of 0.0001 and 90% penetrance.  
2.1.14 Haplotyping  
Haplotype sharing analysis between families with the c.Cys46Ter mutation in 
IGHMBP2 was performed using five microsatellite markers (D11S1889, D11S4178, 
D11S4113, D11S4095, D11S4139) surrounding the IGHMBP2 region. These were 
amplified with fluorescently labelled primers (Table 2.7) and denatured by adding 
9.2μL of formamide to 1.5 μL of PCR product. 0.3 μL of Liz 500 (ABI) was used as 
a size standard. The resulting mixture was heated at 95°C for 3 minutes, after which 
it was put on ice immediately. It was then loaded on the 3730xl DNA analyser and 
the results were analysed with the GeneMapper (ABI) program. 
 
Microsatellite 
Marker 
Chromosome 
location 
Allele size Primers  Sequence  
D11S1889 11:67313143-
67313325 
183-207  Forward 5’- agctggactctcacagaatg - 3’ 
  Reverse 5’- caagaggctggtagaaggtg- 3’ 
D11S4178 11:68189108-
68189359 
237 - 260 Forward 5’- caggcccagtctcttg - 3’ 
  Reverse 5’- cgtgtccagatgaaagtg - 3’ 
D11S4113 11:68765634-
68765859 
218 - 262 Forward 5’- acctcacggtgtaatccc - 3’ 
  Reverse 5’- cttgaagcccatctttgc - 3’ 
D11S4095 11:69268159-
69268361 
173 - 205 Forward 5’- tccctggctatcttgaatc - 3’ 
  Reverse 5’- cttgactgggtccacg - 3’ 
D11S4139 11:70504269-
70504461 
151 - 195 Forward 5’- tatagacttcagccctgctgc - 3’ 
  Reverse  5’- cctctgtaggatgcagttgg - 3’ 
Table 2-7 Microsatellite markers used for haplotyping of the c.Cys46Ter mutation in the IGHMBP2 
gene. 
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2.2 Cell Culture  
2.2.1 Fibroblast culture  
With ethical approval and informed consent, punch biopsies were taken from the 
upper arm of controls, carriers and affected individuals using a standard technique. 
This tissue was dissected and the fibroblasts grown under standard tissue culture 
conditions at 37 °C in 5% CO2 in DMEM with 1% L-Glutamine (Invitrogen) 
supplemented with 10% fetal bovine serum (Heat-inactivated, Life Technologies) 
and 1% PenStrep (Penicillin + Streptomycin; Invitrogen). Controls were obtained 
from the MRC Centre for Neuromuscular Disorders Biobank Dubowitz Centre, UCL 
Institute of Child Health (ICH) by Dr Diana Johnson, or were sent to us by our 
collaborators. Patients and controls for the ADD3 project were provided by Dr. 
Kruer’s lab. Patients II.1 and II.2 of family O were send to us by Dr. Vedrana Milic 
Rasic and patient S1 was a contribution of Prof. Rita Horvath. S2 was obtained from 
GOSH and S3 + S4 were send to us by Dr. Katja Von Au from Germany.  
 
Cells were grown in standard 75 cm
2
 flasks and media was changed every 2-3 days. 
Cultures were passaged after reaching 70-80% confluency. Media was removed from 
the flasks and 5mL of sterile NaCl/Pi (Life technologies) was used to wash. 2 mL of 
0.05% 1x Trypsin-EDTA (Life technologies) was added and flasks were placed in 
the incubator at 37°C for 5 minutes. In case of unsufficient detachment, flasks were 
tapped against the surface before adding 7 mL of pre-warmed media to stop the 
reaction. To split cells, 3 mL was added to three new 75 cm
2
 flasks and medium was 
topped up to 15 mL. To freeze cells, contents of the flask were collected and 
centrifuged at 1,200 rpm for 5 minutes after which media was discarded. Cell pellet 
was resuspended in 3 mL of FBS with 10% DMSO (Sigma-Aldrich) and added to 
cryovials (1 mL per cryovial). Cryovials were placed in a Mr. Frosty freezing 
container (Thermo scientific) to achieve a rate of cooling very close to -1°C/minute, 
the optimal rate for cell preservation, and frozen at -80°C. For long-term storage, 
cells were transferred to liquid nitrogen. For usage, cells were defrosted in a 37°C 
water bath and resuspended in 5 mL of media before centrifugation at 1,200 rpm for 
5 minutes. Supernatant was removed, 5 mL of media was added to the pellet and 
cells were seeded in a new flask.  
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2.2.2 HEK293T Cell culture 
HEK293T cells were obtained from ATCC (line identiﬁer CRL-1573) and grown 
under standard tissue culture conditions at 37 °C in 5% CO2 in DMEM (Invitrogen) 
supplemented with 10% fetal bovine serum (Life Technologies). HEK293 cells are a 
specific cell line originally derived from human embryonic kidney cells grown in 
tissue culture and were chosen due to their easiness to work with and to transfect. 
Cell culture techniques were the same as fibroblast techniques, although grown in 
175 cm
2
 flasks. For passaging, 3 mL of .05% 1x Trypsin-EDTA (Life technologies) 
was added and flasks were placed in the incubator at 37°C for 5 minutes. 9 mL of 
pre-warmed media was added to stop the reaction and 4 mL of the solution was 
added to three new 175 cm
2
 flasks to split cells. These were topped up to 25 mL.  
2.2.3 Lymphoblast cell culture  
Peripheral blood mononuclear cells were isolated from ACD blood by the Ficoll-
Hypaque method (BD vacutainer CPT) and were send off to the European Collection 
of Cell Cultures (ECACC) for transformation with the Epstein Barr Virus. Two 
immortalised SMARD1 lymphoblastoid cell lines were send to us by Dr. Katja Von 
Au. Immortalised cells were grown in suspension in 75 or 175 cm
2
 flasks in an 
upright position, in approximately 15 or 30 mL of RPMI-1640 (Invitrogen) medium 
that contained 2 mM L-glutamine and  20% (v/v) fetal bovine serum (FBS) and 
maintained in a humidified 5% CO2 incubator at 37 °C. Media was routinely 
changed every 2 days by removing the medium above the settled cells and replacing 
it with an equal volume of fresh medium. Cells were counted by adding 10 µL of 
suspension to 10 µL of 0.4% trypan blue (Sigma-Aldrich). The result was pipetted 
onto a disposable slide and counted with an automated cell counter (Life 
technologies). For freezing, 1 mL of freezing media, consisting of RPMI-1640 with 
10% DMSO, was added per 6 million cells and placed in a microvial.  
 
2.3 Molecular biology  
2.3.1 Constructs and generation of mutations by site-directed mutagenesis 
FLAG epitope tagged wild type IGHMBP2 construct was a kind contribution of 
Prof. Fischer in Germany. The backbone for this construct was a pCMV-Tag 4b 
(Fig. 2.1). To generate mutant forms of IGHMBP2, site directed mutagenesis was 
carried out using the QuikChange II mutagenesis kit (Agilent, Santa Clara, CA, 
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USA) according to the manufacturer's instructions. PCR product was then incubated 
with the restriction endonuclease Dpn1 for 1 hr at 37 °C to digest the parental 
supercoiled dsDNA and subsequently transformed into competent Top10 cells 
(Section 2.3.2). Constructs were sequenced prior to use and primer sequences used 
for the mutagenesis are listed in Table 2.8. 
 
Figure 2-1 Circular map of the pCMV-Tag 4 vector. 
Source: Instruction manual catalog #211174, Agilent 
technologies.  
 
Mutation Primer  Sequence 
c.238A>G 
 
Forward 5’ – cgcggcagctcttcccggtaacagctttacttc – 3’ 
Reverse  5’ – gaagtaaagctgttaccgggaagagctgccgcg – 3’ 
c.1591C>A 
 
Forward 5’ – ggtggacgctggtgttacagcccgtg – 3’ 
Reverse  5’ – cacgggctgtaacaccagcgtccacc – 3’ 
c.1738G>A 
 
Forward 5’ – ccgtgatactgtccttcatcagatccaacaggaaa – 3’ 
Reverse  5’ – tttcctgttggatctgatgaaggacagtatcacgg – 3’ 
Table 2-8 Primer sequences for mutagenesis of the IGHMBP2 construct. 
2.3.2 Heat-shock transformation of competent Top10 E.Coli  
Constructs were transformed into One Shot TOP10 Chemically Competent E.Coli 
cells (Invitrogen) using the manufacturer’s protocol. 50 ng of DNA was added to 25 
µL of competent cells and kept on ice for 30 minutes. The mixture was then placed 
in a 42°C water bath for 30-40 seconds to perform the heat-shock and returned on ice 
for a further 2 minutes. 200 µL of LB medium without antibiotics (20 g of LB broth 
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powder (Sigma-Aldrich) dissolved in 1 L dH2O, followed by autoclaving) was then 
added under sterile conditions and was incubated in a shaker for 1 hour at 37°C. 
After this, transformed bacteria were grown on kanamycin-selective LB-agar plates 
(35 g of LB agar powder (Sigma-Aldrich) dissolved in 1 L dH2O, followed by 
autoclaving) by spreading 100 µL of the mixture on the plate and incubating it at 
37°C overnight.  
2.3.3 Purification  
Single bacterial colonies from agar plates were selected from LB-plates and added to 
5 mL of LB broth containing 50 µg/mL of kanamycin. The cells were incubated 
overnight at 37°C under constant agitation. 2 mL of the resulting mixture was 
pelleted by centrifugation at 9000g for 3 minutes and DNA was extracted using the 
Qiagen GenElute
™
 Plasmid Miniprep Kit (Qiagen) according to the manufacturer’s 
protocol. Glycerol stocks were made by adding 500 µL of 50% glycerol to 500 µL of 
bacterial mixture.  
 
For large scale purification, 5mL of LB broth from the bacterial colony was 
incubated for 8 hours before inoculating a larger flask consisting of 150 mL of LB 
broth and containing 50 µg/mL of kanamycin with 300 µL of starter culture. This 
was incubated with vigorous shaking overnight and harvested the next morning by 
centrifugation at the maximum speed for 20 minutes. DNA was extracted using the 
Qiagen QiaFilter Plasmid Maxi kit (Qiagen) according to the manufacturer’s 
protocol. Pelleted DNA was resuspended in 50 µL of sterile deionised water and 
concentration/ purity was measured according to section 2.1.2.   
2.3.4 Stable transfection for Co-immunoprecipitation  
2 µg of plasmid DNA and 4 µL polyethylenimine (PEI, Polysciences, Warrington, 
PA, USA) were each dissolved in 250 µL DMEM in a separate sterile eppendorf 
tube before mixing the two solutions together and leaving them to incubate for a 
minimum of 20 minutes at room temperature. During this incubation period, one or 
more 80% confluent 175 cm
2
 flasks of HEK293T cells were trypsinised and 
collected in a 15 mL sterile tube. One 175cm
2
 flask is sufficient for four 10 cm
2
 
dishes. After 20 minutes, the resulting mixture was plated on the appropriate number 
of 10 cm
2
 dishes by covering the surface with drops. 3mL of suspended HEK293T 
cells were added to one 10cm
2
 dish and media was topped up to 10mL. Transfected 
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cells were incubated for 48 hr post-transfection to obtain maximal levels of gene 
expression. PEI solution treated HEK293T cells were used throughout the study as 
control samples.  
2.3.5 Stable transfection for ATPase assay   
10 µg of plasmid DNA and 20 µL polyethylenimine (PEI, Polysciences, Warrington, 
PA, USA) were each dissolved in 500 µL DMEM in a separate sterile eppendorf 
tube before mixing the two solutions together and leaving them to incubate for a 
minimum of 20 minutes at room temperature. During this incubation period, three 
80% confluent 175 cm
2
 flasks of HEK293T cells were trypsinised and collected in a 
50 mL sterile tube. One 175cm
2
 flask is sufficient for two 15cm
2
 dishes.  After 20 
minutes, the resulting mixture was plated on the appropriate number of 15cm
2
 dishes 
by covering the surface with drops. 5mL of suspended HEK293T cells were added to 
a 15 cm
2
 dish and media was topped up to 20mL. Transfected cells were incubated 
for 48 hr post-transfection to obtain maximal levels of gene expression. PEI solution 
treated HEK293T cells were used throughout the study as control samples.  
 
2.4 Protein Biochemistry for HEK293T cell lines  
2.4.1 Cell harvesting for Co-immunoprecipitation  
Forty-eight hours after transfection, 10 cm
2
 dishes of transfected HEK293T cells 
were washed with 2mL of ice-cold phosphate buffered saline (NaCl/Pi) prior to lysis. 
Cells were gently scraped off in NaCl/Pi, placed in a sterile Eppendorf tube and spun 
down for 1 minute at 4000 rpm. Pellet was resuspended in 350 µL of NP40
+
 buffer 
(50 mMTris pH 8, 150 mM NaCl, 0.5% NP40
+
) containing 1 ×  complete protease 
inhibitor cocktail (Roche, Indianapolis, IN, USA). Subsequently cell lysates were 
incubated for 10 minutes at 4 °C and freeze-thawed twice before spinning them at  
14 000xg for 10 minutes to remove cell debris by centrifugation at maximum speed 
for 10 minutes. Supernatant was used straight away or stored at -80°C. 
2.4.2 Co-immunoprecipitation  
Lysates were thawed on ice or used straight after harvesting. 0.2% (v/v) RNase A 
was added and incubated at 37°C to detect RNA-independent interactions. 
Meanwhile, 30µL of ANTI-FLAG® M2 Affinity Gel (Sigma-Aldrich) was washed 
with 1mL of NP40
+
 buffer for 10 minutes at RT. Beads were spun down by 
centrifugation at 8000 rpm for 1 minute. 250 µL of the wild type and IGHMBP2 
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transfected cell lines was added to the beads and incubated overnight at 4 °C. The 
remaining 100 µL was kept for western blotting purposes. Depending on the species 
of the primary antibody (Table 2.9), goat anti-mouse IgG-HRP or goat anti-rabbit 
IgG-HRP was used in a 1:5000 dilution for the secondary antibody (Santa Cruz).  
 
Primary antibody Species Concentration 
Hint1, (Sigma-Aldrich) Rabbit Polyclonal 1:1000 
TDP43, clone AC-40 (Proteintech) Rabbit Polyclonal 1:3000 
FUS, AV40278 (Sigma-Aldrich) Rabbit Polyclonal 1:10 000 
SOD1, ADI-SOD-100 (Enzo Life sciences) Rabbit Polyclonal 1:1000 
HSP27, #2402 (Cell Signalling)  Mouse monoclonal 1:500 
LAS1l, SAB1409160 (Sigma-Aldrich) Mouse polyclonal 1:5000 
Table 2-9 Antibodies used for western blotting to detect interactions with the IGHMBP2 
protein after Co-immunoprecipitation. 
2.4.3 Cell harvesting for ATPase assay  
Forty-eight hours after transfection, 15 cm
2
 dishes of transfected HEK293T cells 
were washed with ice-cold phosphate buffered saline (NaCl/Pi) prior to lysis. This 
was achieved by gently scraping off cells in 3 mL of NaCl/Pi, placing the solution in 
2 sterile Eppendorf tubes and spinning down for 1 minute at 4000 rpm. Pellet was 
resuspended in 1 mL of NP40
+
 buffer (50 mMTris pH 8, 150 mM NaCl, 0.5% 
NP40
+
) containing 1 ×  complete protease inhibitor cocktail (Roche, Indianapolis, 
IN, USA). Subsequently cell lysates were incubated for 30 minutes at 4 °C and 
freeze-thawed twice before spinning them at 14 000xg for 10 minutes to remove cell 
debris by centrifugation at maximum speed for 30 minutes. Supernatant was used 
straight away or stored at -80°C. 
 2.4.4 ATPase assay 
Frozen down lysates were thawed on ice or used straight after harvesting. 900 µL of 
the wild type and mutant IGHMBP2 supernatants were incubated with 40 µL ANTI-
FLAG® M2 Affinity Gel (Sigma-Aldrich) overnight at 4 °C, after preparing the 
beads by washing 2x with cold PBS. The next day beads were washed 2 ×  in each of 
three wash buffers (20 mM Tris, 1000-200 mM NaCl, 1% Triton) before being 
eluted in elution buffer (50 mMTris pH 8, 150 mM NaCl, 0.5% NP40
+
, 1x protease 
inhibitor cocktail) with 150 ng·μL−1 FLAG peptide (Sigma-Aldrich) for 40 minutes at 
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4 °C. Eluted protein was then incubated with assay buffer (20 mM Hepes, pH 7.2, 
2 mM MgCl2, 1 mM dithiothreitol and 0.05% BSA) and [α32P]ATP (5 μCi; Perkin 
Elmer, Waltham, MA, USA) was added to each reaction. Samples were incubated at 
37 °C with vigorous shaking and 2 μL aliquots were removed at time points from 0 
to 120 minutes and spotted onto TLC plates (Sigma-Aldrich). Samples were then 
subjected to rising TLC under 1 M formic acid and 1.2 M LiCl. After drying the 
plates they were exposed to Kodak biomax films (Kodak, Rochester, NY, USA) 
overnight and developed the following day using a Kodak developer. The remaining 
samples were denatured in 4 ×  SDS loading buffer (NuPage SDS sample buffer, 
Life Technologies) with 1% DTT at 75 °C for 10 minutes and loaded onto 4–12% 
Bis Tris gels (Life Technologies). Proteins were then transferred to Hybond ECL 
Nitrocellulose membrane (GE life sciences), blocked with 5% milk in NaCl/Pi-
Tween (NaCl/Pi + 1% Tween-20) and probed with primary antibodies at 4 °C 
overnight (1: 1000 Mouse anti-IGHMBP2, clone mAb11-24, millipore). The next 
day membranes were washed three times in NaCl/Pi-Tween and incubated for 1 h 
with secondary antibodies in 1% milk in NaCl/Pi-Tween at room temperature 
followed by another three washes and incubation with Pierce ECL substrate. Finally 
membranes were exposed to Kodak biomax films (Kodak, Rochester, NY, USA) and 
developed on a Kodak developer according to the manufacturer's instructions. 
 
2.5 Protein biochemistry for fibroblast cell lines  
2.5.1 Cell harvesting for mRNA extraction  
2 mL of 0.05% 1x Trypsin-EDTA (Life technologies) was added to a confluent 
75cm
2
 flask of fibroblasts and placed in the incubator at 37°C for 5 minutes. In case 
of unsufficient detachment, flasks were tapped against the surface before adding 7 
mL of pre-warmed media to stop the reaction. Cell were pelleted by centrifugation at 
1200 rpm for 5 minutes and resuspended in 6mL of media. 1mL was added in 
duplicate to 1 well of a 6 well plate and remaining solution was used to passage the 
cell line. After 24-48h, cells were harvested by adding 1mL of cold NaCl/Pi on ice, 
gently scraping off the cells to transfer to a new sterile Eppendorf tube and spinning 
down the pellet by centrifugation at 4000 rpm for 1 minute. Pellet was resuspended 
in 350 µL of QIAzol
® 
reagent (Invitrogen, United States) and used straight away or 
kept at -80°C.  
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2.5.2 mRNA extraction  
RNA was extracted from fibroblasts using the miRNeasy Mini kit (Qiagen). An 
amount of 1 million cells was used, correlating to the amount of cells in a confluent 
well of a 6-well plate. A volume of 350 µL of 70% ethanol was added to the 
QIAzol
®
 cell suspension and mixed well by pipetting up and down. Sample was 
transferred to a RNeasy mini spin column placed in a 2mL collection tube and 
centrifuged at 8000g for 15 minutes. RNA was extracted following the 
manufacturer’s protocol, and eluate was suspended in 50 µL of RNase-free water. 
Concentration and purity was estimated as stated in section 2.1.2 with altered 
absorbance ratios for RNA. Samples were expected to have a value of >2.0 for the 
260/280 ratio and in the range of 2.2-2.2 for 260/230.  
2.5.3 cDNA synthesis  
cDNA was synthesised using 500 ng total RNA, random primers and SuperScript II 
reverse transcriptase (Invitrogen, United states) following the manufacturer’s 
protocol. The resulting cDNA was used to perform a standard PCR reaction with 
cDNA primers spanning the exon/intron boundaries. Subsequent agarose gel 
electrophorese was used to confirm the expression of cDNA in the fibroblasts. 
Sequencing analysis was performed to investigate the presence of genomic DNA 
mutations in the RNA of patients and to assess nonsense mediated decay.  
2.5.4 Quantitative PCR  
The IGHMBP2 cDNA transcript levels were determined in triplicate using 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and hypoxanthine 
phosphoribosyltransferase 1 (HPRT1) as reference genes. 1µL of cDNA at 500 
ng/µL was added to 12.5 µL of SybrGreen, 1 µM of each primer and topped up to 25 
µL with RNase-free water. Primers used for IGHMBP2 cDNA levels were used from 
the paper by Guenther et al., in 2009. Reference genes primers were validated 
beforehand by other groups in the department. Accumulation of PCR products was 
monitored through SYBR green incorporation on an Stratagene/Agilent MX3000P 
with the protocol stated in Table 2.10.  
 
 
 
 
81 
 
Step Reactionstep Temperature Time  
1 Carryover prevention 50°C 2 min 
2 PCR initial activation step 95°C 10 min 
3 Denaturation  95°C 15 sec 
4 Annealing primers  60°C 30 sec 
5 Elongation  72°C 30 sec 
6 Final elongation 72°C 10 min  
Table 2-10 Protocol for quantitative PCR. Steps 3-5 were repeated 40 times. 
Relative quantities were calculated with the ΔΔCt method (Schmittgen et al., 2008) 
in relation to the two housekeeping genes. Gene expression levels were calculated by 
the ratio between the amount of target gene and two endogenous reference genes, 
which is present in all samples. The Ct threshold value is chosen as the cycle in 
which there is a significant increase in reporter signal. This value is related to the 
initial amount of DNA in inverse proportion to the expression level of the gene (Fig.  
2.2). Firstly, the ΔCt between the target gene and the reference genes was calculated 
for each sample (ΔCt = Cttarget – Ctreference gene). Then the difference between the ΔCt 
of the patient and the ΔCt of the controls was calculated, giving the ΔΔCt value: 
ΔΔCt = (Cttarget – Ctreference)control – (Cttarget – Ctreference)patient. The normalised target 
amount in the sample is then equal to 2
-ΔΔCt
 and can be used to compare expression 
levels in samples. The data were depicted as a mean with standard deviation.  
 
Figure 2-2 Sample plot of the amplification curves (left) and the dissociation curves (right) for the 
selected primers of the qPCR experiment in lymphoblasts. The orange-coloured curves not reaching 
the threshold of detection represent the “no template” controls. 
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2.5.5 Cell harvesting for western blot  
2 mL of 0.05% 1x Trypsin-EDTA (Life technologies) was added to a confluent 
75cm
2
 flask of fibroblasts and placed in the incubator at 37°C for 5 minutes. In case 
of unsufficient detachment, flasks were tapped against the surface before adding 7 
mL of pre-warmed media to stop the reaction. Cell were pelleted by centrifugation at 
1200 rpm for 5 minutes and washed in 1 mL of cold NaCl/Pi. Cells were pelleted 
again by centrifugation at 4000 rpm for 1 minute and resuspended in 50 µL of NP40
+
 
buffer (50 mMTris pH 8, 150 mM NaCl, 0.5% NP40
+
) containing 1 ×  complete 
protease inhibitor cocktail (Roche, Indianapolis, IN, USA). Subsequently cell lysates 
were incubated for 10 minutes at 4 °C and freeze-thawed twice before spinning them 
at 14 000xg for 10 minutes to remove cell debris by centrifugation at maximum 
speed for 10 minutes. Pellet was stored in -80 °C and supernatant was used straight 
away or stored at -80°C. 
2.5.6 Protein estimation   
1 µL of each sample was pipetted in triplicate on a 96-well plate together with a 
BSA standard ranging from 0-7 µg/µL. 1 µL of NP40
+
 buffer was added to each well 
of the standard to account for background signal. RC DC™ Protein Assay (BioRad) 
was used according to the manufacturer’s protocol and cell sample protein 
concentrations were calculated from the standard curve prepared by plotting the 
average blank-corrected 562nm measurement for each BSA standard vs. its average 
concentration in µg/µL. 
2.5.7 Western blot  
60 μg of protein was mixed with 1x NuPage LDS sample buffer (Invitrogen), 1% 
DL-Dithiothreitol (Invitrogen) and made up to the same volume with the NP40
+
 
buffer before denaturation at 75°C for 10 minutes. Samples, accompanied by a 
marker, were run on a 4-12% Bis-Tris gel for 90 minutes under 150 V in 1xMES 
running buffer (100 mL 20x NuPAGE MES SDS running buffer (Life Technologies) 
in 1,900 mL dH2O.). All gels were electro-blotted to Hybond ECL membrane (GE 
lifesciences) in transfer buffer (20% methanol, 10% Tris-glycine electroblotting 
buffer 10X (National Diagnostics, USA) and 70% dH2O) and the membrane was 
immersed in Ponceau red (Sigma-Aldrich) to verify protein transfer. Blocking was 
performed in 5% (w/v) milk powder in 1x NaCl/Pi (1 PBS tablets (Life 
Technologies) dissolved in 500 mL of dH2O) for 1 hr at room temperature. 
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Membranes were incubated overnight with the primary antibody at 4°C, diluted to 
their respective concentrations in 1% milk in NaCl/Pi-Tween (Table 2.11).  The 
following day, after 3x washing in 1x NaCl/Pi –Tween for 10 minutes, the membrane 
was incubated for 60 min at room temperature with horseradish peroxidase-
conjugated secondary antibody (Santa Cruz). Depending on the species of the 
primary antibody, goat anti-mouse IgG-HRP or goat anti-rabbit IgG-HRP was used 
in a 1:5000 dilution. An ECL kit with each ECL reagent at a 1:1 ratio (Thermo 
Fisher Scientific) was used as a substrate and antibody binding was detected in a 
dark room on Super Rx X-ray film (Fujifilm, Japan) in an Amersham 
autoradiography cassette (GE Healthcare). β-Actin was used as a loading control for 
normalisation and analysis was performed with the ImageJ program (Rasband, W.S., 
ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, USA, 
http://imagej.nih.gov/ij/, 1997-2014).  
 
Primary antibody Species Concentration 
IGHMBP2, clone mAb11-24 (Millipore)  Mouse monoclonal 1:1000  
Β-Actin, A3853 (Sigma-Aldrich) Mouse monoclonal 1:20 000 
TDP43, clone AC-40 (Proteintech) Rabbit polyclonal 1:3000 
Table 2-11 Primary antibodies used for western blotting. 
2.6 Immunocytochemistry  
2.6.1 Subcellular localisation of proteins in patient fibroblasts  
Fibroblasts were cultured onto 13 mm autoclaved glass coverslips in 24-well plates 
in standard DMEM + Glutamax media supplemented with 10% FBS and 1% 
PenStrep after placing the plate under UV light for at least 20 min. After 24h, cells 
were washed with cold NaCl/Pi and fixed in 4% paraformaldehyde (PFA) for 15 
minutes. Cells were washed again with NaCl/Pi and permeabilised in 0.05% Triton 
X-100 for 10 minutes. After three more washes with NaCl/Pi, cells were then 
blocked in 10% FBS in NaCl/Pi for one hour. Cover slips were incubated with 40 µL 
of primary antibody for 60 minutes (Table 2.12), washed three times with NaCl/Pi 
and incubated with the appropriate Alexa Fluor secondary antibody for 60 minutes 
(Invitrogen, United States).  Following, the cover slips were washed with NaCl/Pi 
and mounted on microscope slides with Prolong Gold Antifade with 4’,6-diamidino-
2-phenylindole (DAPI) (Life Technologies) and imaged using a Zeiss 710 confocal 
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microscope (Carl Zeiss AG, Germany) with the 63x oil immersion objective. A 
negative control (incubated overnight in blocking solution only, with no primary 
antibody) was included to assess the specificity of the secondary antibody. 
 
Antibody Species Concentration 
TRAK2 Antibody 13770-1-AP (Protein Tech)  Rabbit polyclonal 1:1000 
TDP43, clone AC-40 (Proteintech) Rabbit monoclonal  1:3000 
IGHMBP2, clone mAb11-24 (Millipore) Mouse monoclonal 1:1000 
Alexa Fluor 488-A11008 secondary antibody Goat anti- rabbit  1:2000 
Alexa Fluor 488-A11001 secondary antibody Goat anti-mouse 1:2000 
Alexa Fluor 555-A21428 secondary antibody Goat anti-rabbit 1:2000 
Table 2-12 Primary and secondary antibodies used for Confocal imaging. 
2.6.2 Colocalisation  
Fibroblasts were prepared as described in section 2.6.1. After cells were blocked in 
10% FBS in NaCl/Pi for one hour, cover slips were incubated with 40 µL of the 
combined primary antibodies for 60 minutes (Table 2.12), washed three times with 
NaCl/Pi and incubated with a combination of Alexa Fluor secondary antibodies for 
60 minutes (Invitrogen, United States).  Following, the cover slips were washed with 
NaCl/Pi and mounted on microscope slides with Prolong Gold Antifade with 4’,6-
diamidino-2-phenylindole (DAPI) (Life Technologies) and imaged using a Zeiss 710 
confocal microscope (Carl Zeiss AG, Germany) with the 63x oil immersion 
objective. A negative control (incubated overnight in blocking solution only, with no 
primary antibody) was included to assess the specificity of the secondary antibody. 
Image processing and evaluation were performed using the Volocity software 
(Perkin Elmer). Thresholds were set manually by drawing a region of interest and the 
global Pearson’s correlation coefficients were extracted. The experiment was 
performed in triplicate and the average global Pearson’s correlation coefficient of 
selected cells of the field of view was calculated from 3 images per cover slip.  
2.6.3 Endocytosis investigation  
Fibroblasts were grown overnight on 13 mm cover slips in standard DMEM + 
Glutamax media supplemented with 10% FBS and 1% PenStrep. Cover slips were 
then incubated at 37°C in labelling medium (F12 containing 10 mM HEPES, pH 7.3 
and 0.2% w/v BSA) for 1h, where after they were labelled for 1h on ice with 50 
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μg/mL Alexa-Fluor 488-transferrin (Invitrogen) in labelling medium. Excess label 
was washed off by rinsing twice with warm labelling medium and cells were 
incubated for either 20 or 30 minutes at 37°C to allow transferrin uptake. Following, 
the cells were fixed with 2% paraformaldehyde in NaCl/Pi for 30 minutes at room 
temperature, washed twice with 1x NaCl/Pi and mounted on microscope slides with 
Prolong Gold Antifade with DAPI and imaged using a Zeiss 710 confocal 
microscope (Carl Zeiss AG, Germany) with the 63x oil immersion objective.  
Image processing and evaluation were performed using the Volocity software 
(Perkin Elmer). The experiment was performed in duplicate and triplicate for the 
respective incubation times of 20 and 30 minutes and the average fluoresce/volume 
of selected cells of the field of view was calculated from 9 images after an 
incubation time of 30 minutes.  
2.6.4 Basal mitochondrial membrane potential  
The basal mitochondrial membrane potential (ΔΨm) was measured using the 
tetramethylrhodamine methyl ester (TMRM) lipophilic cationic dye. This dye 
accumulates in the mitochondria and is released in the cytosol when the 
mitochondria become depolarised, which results in a decrease of signal intensity. 
The fluorescence intensity of the dye is representative of the ΔΨm as a more 
polarised (more negative) ΔΨm will accumulate more dye and give a stronger 
fluorescence signal, whereas depolarised mitochondria accumulate less dye and 
exhibit a lower TMRM signal. Patient and control fibroblasts were grown in standard 
media and plated overnight on 25 mm cover slips in 6 well plates. An extra cell line 
with fibroblasts from the patient with the p.Ser700Ile variant was used as a control. 
Fibroblasts were incubated for 40 minutes at room temperature with 25 nM TMRM 
(Invitrogen) in a HBSS solution composed of 156 mM NaCl, 3 mM KCl, 2 mM 
MgSO4, 1.25 mM KH2PO4, 2 mM CaCl2, 10 mM glucose and 10 mM HEPES; pH 
adjusted to 7.35 with NaOH.  The dye was present throughout the experiment. The 
Zeiss 710 confocal microscope (Carl Zeiss AG, Germany) was used to obtain z-stack 
images using a 63x oil immersion objective and a 560 nm laser to excite the dye. 
Data was analysed using the Zeiss image analysis software (Zeiss). To control for 
mitochondrial mass, the TMRM signal was averaged across all the voxels 
corresponding to mitochondria whose fluorescence was greater than the set 
threshold.  
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2.6.5 Response to mitochondrial toxins  
For analysis of response to mitochondrial toxins, 25 mm cover slips were used after 
measurement of the mitochondrial membrane potential. Images were recorded 
continuously from a single focal plane and a time-series was used to add the 
mitochondrial toxins. After measuring baseline TMRM intensity for 2-3 min, 
oligomycin from Streptomyces diastatochromogenes (2 g/mL; Sigma-Aldrich) was 
added and fluorescence measured until a plateau was reached, after which rotenone 
(10 M; Sigma-Aldrich) was added. Lastly, 1 M FCCP (≥98%; Sigma-Aldrich) 
was added and recordings were stopped when the mitochondria had fully 
depolarised. The effects of each drug are the following:  
Oligomycin:  Complex V inhibitor  
If ATPase function is reversed to maintain the ΔΨm, there will be a 
decline in TMRM fluorescence  
Rotenone:  Complex I inhibitor 
This will cause a small decline in TMRM fluorescence; if cells rely 
more on complex I than complex II, there will be a greater decline.  
FCCP:  Uncouples oxidation from phosphorylation so ATP synthesis cannot 
occur. This will result in an immediate depolarisation of the ΔΨm and 
loss of fluorescence.  
Time-series data were analysed using the Zeiss Zen software (Carl Zeiss AG). A 
total of 10-20 areas were selected for analysis and the average dye intensity across 
these areas was plotted on the y-axis against time on the x-axis. The change in 
TMRM intensity after addition of each toxin was expressed as a percentage of basal 
intensity (basal=baseline Δψm - Δψm after FCCP).  
 
2.7 Statistical analysis  
All statistical analyses were performed using GraphPad Prism version 6.00 for 
Windows/Mac (GraphPad Software, La Jolla California USA, www.graphpad.com). 
For comparison of means of two groups, parametric student t-test was used and 
statistical significance expressed as * p < 0.05; ** p < 0.01. For comparison of 
means of > two groups, a bonferroni post-hoc analysis was used after a one-way 
analysis of variance (ANOVA). Unless otherwise stated, experiments were 
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performed at least three times and data presented as mean ± standard error of the 
mean (S.E.M.). 
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Chapter 3:  
Mitochondrial mutations 
in CMT2  
3.1 Introduction 
3.1.1 A role for mitochondria in neurodegenerative diseases  
As seen in Chapter 1, an essential process in the maintenance of neurons is the 
provisioning of ATP, which will maintain the neuronal plasma membrane potential. 
As mitochondria are the main source of ATP, correct mitochondrial function is 
crucial for efficient axonal transport of all cargoes (Schon et al., 2011). Since the 
central and peripheral nervous systems have intense metabolic requirements and are 
particularly ATP dependent, any deficit in energy generation can have catastrophic 
effects on neural functioning. It has already been shown that mitochondrial 
dysfunction plays a relevant role in the pathogenesis of neurological and 
neuromuscular diseases such as CMT (Palau et al, 2009) and apart from the 
dysfunction of mitochondrial dynamics that can lead to CMT, impaired 
mitochondrial function, communication with other organelles and mitochondrial 
turnover can lead to neurodegenerative diseases such as Parkinson's disease (PD), 
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spinocerebellar ataxias (SCA), HSP, Huntington's disease (HD), Amyotrophic lateral 
sclerosis (ALS) and progressive epilepsy (Zsurka et al., 2013).  
3.1.2 The oxidative phosphorylation system  
The oxidative phosphorylation system (OXPHOS) is a set of biochemically linked 
multisubunit complexes (complexes I to V) and two electron carriers 
(ubiquinone/coenzyme Q and cytochrome c) that, together with the tricarboxylic acid 
(TCA) cycle,  provides a mechanism for the production of ATP through a proton 
gradient (Fig. 3.1). The complexes form an electron transport chain (ETC) in the 
inner mitochondrial membrane, where complexes I-IV reduce molecular oxygen to 
water by the sequential transfer of electrons, called oxidative phosphorylation. These 
redox reactions release energy to form a proton gradient across the inner 
mitochondrial membrane that will catalyse the formation of ATP from ADP and 
inorganic phosphate by the ATP synthase or respiratory chain complex V (Capaldi et 
al., 1994; Nijtmans et al., 1995). 
 
Complex I is the first enzyme in the ETC and is responsible for the oxidation of 
NADH by transferring electrons to ubiquinone, a lipid soluble electron carrier 
embedded in the lipid bilayer of the inner mitochondrial membrane. It is made of 45 
proteins of which seven are encoded by the mitochondrial genome. This enzyme 
consists of three different domains and is also known as NADH-coenzyme Q 
oxidoreductase. The dehydrogenase domain will transfer two electrons from reduced 
Nicotineamide Adeninedinucleotide (NADH), oxidizing it to NAD+, via Flavin 
mononucleotide (FMN) to iron sulphur clusters. In the hydrogenase domain, these 
will reduce ubiquinone to ubiquinol. This electron transfer is coupled to the transfer 
of 4 protons in the transporter domain from the inner membrane of the matrix to the 
intermembrane space (Lenaz et al., 2006; Fato et al., 2008). Complex I can be 
inhibited by more than 60 different families of compounds, one of which is rotenone, 
regularly used as an inhibitor of complex I in mitochondrial membrane imaging.  
 
Complex II, also known as Succinate-Q oxidoreductase, consists of four subunits 
and is the only complex in the ETC that lacks subunits encoded by the mitochondrial 
genome. It is also the only enzyme that plays a role in both the ETC and the TCA 
cycle, linking the two essential energy-producing processes of the cell.  
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Figure 3-1 The oxidative phosphorylation system in the inner mitochondrial membrane. Cyt c= Cytochrome c; FAD= Flavine Adeninedinucleatide; NAD= Nicotineamide 
Adeninedinucleotide; Q= Ubiquinone; QH2= Ubiquinol. 
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As part of the TCA cycle, complex II oxidises the metabolite succinate to fumarate 
in the mitochondrial matrix by transferring the electrons to flavin adenine 
dinucleotide (FAD), resulting in the formation of FADH2. The two electrons 
generated will enter the ETC by passing them on to three Fe-S clusters and 
cytochrome b and sub sequentially transforming ubiquinone to ubiquinol in the 
mitochondrial inner membrane (Cecchinni, 2003; Kluckova et al., 2013). 
 
Complex III is composed of 11 subunits; cytochrome b is encoded by mitochondrial 
DNA, with the remainder of the subunits being encoded by nuclear DNA genes. This 
enzyme is a dimer, with each subunit complex containing the 11 protein subunits, an 
iron–sulfur cluster and three cytochromes: one cytochrome c1 and two b 
cytochromes. Also known as Q-cytochrome c oxidoreductase, this complex will 
catalyse the transfer of electrons from reduced ubiquinone to cytochrome c and will 
utilise the energy to translocate protons from the mitochondrial matrix to the 
intermembrane space, adding to the proton gradient (Berry et al., 2000; Barel et al., 
2008).  
 
Complex IV is the last complex of the ETC, also known as cytochrome c oxidase. 
This complex contains three mitochondrial encoded subunits and ten nuclear 
encoded ones and has a complicated structure that includes two copper-containing 
redox centres, and two cytochromes, aa3, containing heme a moieties. It catalyses 
the oxidation of cytochrome c and the reduction of oxygen by transferring electrons 
to the terminal electron acceptor oxygen, reducing it to water. This will again 
contribute to the proton gradient (Calhoun et al., 1994). 
 
Human F0F1-ATP synthase (Complex V of the oxidative phosphorylation system) 
couples the synthesis of ATP from ADP and inorganic phosphate with the passage of 
protons from the intermembrane space to the matrix (Noji et al, 2001; Jonkheere et 
al., 2012) (Fig. 3.2). This complex is comprised of 16 subunits, of which 14 are 
encoded by the nuclear genome and two by nucleotides 8527-9207 of the 
mitochondrial genome (ATPase 6 and ATPase 8). Complex V is a massive structure 
consisting out of a ‘stalk’ - the F0 particle – that is embedded in the mitochondrial 
membrane and forms the proton channel, and a ‘head’ - the F1 particle – as the site 
of ATP synthesis. During ATP synthesis, protons are transferred through the 
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channel, causing rotation of the F1 particle, which condenses ADP and inorganic 
phosphate to form ATP.  
3.1.3 Mutations in the OXPHOS genes in patients with peripheral 
neuropathy  
Peripheral neuropathies have been linked to mutations in the OXPHOS genes; 
however, the neuropathy is rarely the presenting or predominant clinical 
manifestation of the disease. In contrast, patients presenting with mutations in 
nuclear-encoded mitochondrial genes such as MFN2 or GDAP1 typically present 
with an isolated peripheral neuropathy.  
 
 
Figure 3-2 The human ATP synthase. F1 is composed of three copies of each of subunits α and β, and 
one each of subunits γ, δ and ε, forming the central stalk. Fo consists of a subunit c-ring and one copy 
each of subunits a, b, d, F6 and the oligomycin sensitivity-conferring protein (OSCP). Subunits b, d, 
F6 and OSCP form the peripheral stalk which lies to one side of the complex. A number of additional 
subunits (e, f, g, and A6L), all spanning the membrane, are associated with Fo. 
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In the scope of this thesis, we investigated an extensive family with mitochondrial 
disease and axonal neuropathy in which the index case presented with a pure motor 
neuropathy in childhood evolving into motor-predominant CMT2 in later life and 
found a pathogenic missense mutation m.9185T>C in ATPase 6, encoding the ATP6 
subunit of the mitochondrial ATP synthase (OXPHOS complex V). This segregated 
with disease in affected members of the pedigree. 
3.1.4 Mutations in ATP synthase  
Mutations in respiratory chain complex V are known to cause Leigh syndrome or 
Neurogenic muscle weakness, Ataxia and Retinitis Pigmentosa (NARP) (Holt et al., 
1990; Rahman et al., 1996; De Coo et al., 1996). In our study, we found two 
mutations in the gene encoding for respiratory chain complex V, located on the 
mitochondrial genome: m.9185T>C, substituting a leucine for a proline and 
m.8993T>C, causing the same AA-substitution. The presence of these mutations 
confirms the link between mitochondrial dysfunction and neurodegeneration and the 
importance of this system in CMT.  
In order to examine the prevalence of this mutation and the importance of other 
variants in the mitochondrial genome, I investigated a large number of patients with 
CMT2, HMN and HSAN for mutations in the ATPase 6 gene and the partially 
overlapping ATPase 8 gene, the only other mitochondrially encoded subunit of 
complex V of the respiratory chain. Since the overall phenotype in the CMT2 patient 
was a severe axonal neuropathy, a number of CMT1 patients was included, to 
examine whether this mutation could influence the severity of the neuropathy.  
3.1.5 Mitochondrial genetics in humans  
Following the endosymbiotic theory, mtDNA is derived from the circular genomes 
of the bacteria that were engulfed by the early ancestors of today's eukaryotic cells. 
This separate evolutionary origin gives rise to some distinct features that distinguish 
nuclear from mitochondrial DNA.  
Each mitochondrion present in human cells will contain several copies of the 
circular, covalently closed, double-stranded mitochondrial DNA. This results in the 
presence of 100-10,000 separate copies of mtDNA per cell. There are no histones or 
any other proteins associated with mitochondrial DNA and the genes contain no 
introns. As a consequence of this lack of protective histones and the highly oxidizing 
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environment there is a much higher rate of mutations than nuclear DNA (Wei et al., 
1998; Sigurgardottir et al., 2000).  
The mitochondrial genome  
The mitochondrial genome encodes for 37 genes and contains around 16,600 base 
pairs. These genes encompass mitochondrial ribosome subunits, transfer RNAs and 
subunits of the ETC. Twenty-eight out of 37 are located on the mitochondrial heavy-
strand (H-strand), so called due to its high content of guanine. The opposing light 
strand (L-strand), mainly consisting of cytosines, encodes the remaining nine genes. 
For replication and transcription, the mitochondrial DNA relies on a set of nuclear 
gene products, after having lost the self-provisional qualities it had as a prokaryote.  
The genetic code is, for the most part, universal, with few exceptions: mitochondrial 
genetics includes some of these. For most organisms the "stop codons" are “UAA”, 
“UAG”, and “UGA”. In vertebrate mitochondria “AGA” and “AGG” are also stop 
codons, but not “UGA”, which codes for tryptophan instead. “AUA” codes for 
isoleucine in most organisms but for methionine in vertebrate mitochondrial mRNA 
(Barrell et al., 1979). 
Inheritance of mitochondrial variants  
In contrast to nuclear DNA, mitochondrial DNA gets passed on to future generations 
by maternal inheritance only. An oocyte will carry around 100,000- 1,000,000,000 
mtDNA copies, whilst a spermatozoid will only carry 100-1000 copies, which will 
be degraded by ubiquitination (Sutovsky et al., 1999).  
 
An important concept in mitochondrial inheritance is the existence of the genetic 
bottleneck. Only a fraction of the mtDNA copies in the germ-cell precursor are 
amplified to generate the approximately 105 mtDNA copies present in the mature 
oocyte. During maturation, this specific subpopulation of genomes will be rapidly 
replicated. Depending on which oocyte will be fertilised, this can result in different 
populations of mtDNA in the offspring. In the presence of mutated mtDNA, a 
different mutant load can be found between family members (Taylor et al., 2005).  
Recent evidence also suggests a higher selectivity against nonsynonymous changes 
in protein-coding genes, resulting in a reduction of mutations in following 
generations. Differences have been found between different sites of mutations, 
resulting in levels that cause no phenotype at a lower level but can cause a disease-
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like phenotype at higher levels (Taylor et al., 2005; Stewart et al., 2008; Samuels et 
al., 2010).   
Mitochondrial diseases  
Several disorders affecting the nervous system, the muscles, or both are caused by 
mutations (acquired or inherited) in mitochondrial DNA or in nuclear genes that 
code for mitochondrial components; these may be collectively called mitochondrial 
diseases. Mitochondrial abnormalities have been found in several neurodegenerative 
disorders, in multiple sclerosis and in an increasing number of axonal inherited 
neuropathies (Chinnery, 2010).  
 
Mitochondrial diseases take on unique characteristics both because of the way the 
diseases are inherited and because mitochondria are so critical to cell function. 
Along with regulation of apoptosis, mitochondria also modulate cell pathogenesis by 
means of energy production, heme synthesis, heat production, reactive oxygen 
species (ROS) generation, and calcium buffering. Patients with mitochondrial 
diseases typically present with multi-system involvement, due to the critical 
importance of ATP for all the organ systems. Primary symptoms can range from 
seizures and liver failure, to cerebellar ataxia and myopathy. In the case of peripheral 
neuropathies, these can either manifest as primary or additional features and NCS 
usually point towards a predominantly axonal sensorimotor polyneuropathy 
(Chinnery, 2010).  
 
Since every cell in the human body has several copies of the mtDNA, mutations 
residing within the mtDNA can exist in a homoplasmic state, where all the mtDNA 
molecules are either wild type or mutated, or in a heteroplasmic state, where varying 
levels of mutated and wild type mtDNA can coexist in one single cell.  
 
The vast majority of mtDNA mutations require high levels of mutated mtDNA 
necessary before a phenotype is observed in cells. The threshold effect is suggested 
to result from a loss of wild type mtDNA molecules, and below a critical level of 
wild type mtDNA, a functional defect within a cell is likely to be obtained (Lax et al, 
2011). As mentioned before, mitochondrial DNA is only transferred by the ovule 
during the impregnation, which means that mitochondrial diseases will show a 
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pattern of maternally inherited syndromes. Since the precursor cells for the ovule 
only replicate a limited amount of mitochondria, which are randomly distributed, 
different ovules encompass a range of mutant mtDNA levels, causing offspring to 
have variable disease severity (Taylor et al., 2005).  
Leigh Syndrome 
The pathogenic mutations found in our group of patients, m.9185T>C and 
m.8993T>C, are known to cause Leigh syndrome and NARP. Leigh syndrome is an 
early-onset progressive neurodegenerative disorder with a characteristic 
neuropathology consisting of focal, bilateral lesions in one or more areas of the 
central nervous system, including the brainstem, thalamus, basal ganglia, cerebellum, 
and spinal cord. The lesions are areas of demyelination, gliosis, necrosis, spongiosis, 
or capillary proliferation. Clinical symptoms depend on which areas of the central 
nervous system are involved, but often include hypotonia, spasticity, movement 
disorders, hypertrophic cardiomyopathy, cerebellar ataxia, and peripheral 
neuropathy. Onset of disease is typically between 3 to 12 months, frequently 
following a viral infection (Dahl, 1998; Thorburn et al., 2003).  
 
Leigh syndrome is a progressive disease, often with poor prognosis. Death occurs 
usually within the first decade of life, frequently due to respiratory failure due to 
brain stem lesions or cardiac failure. No effective treatments have been established 
so far and management of the disease mainly includes education and support for the 
patients and their family, whilst monitoring progression of neurologic, 
ophthalmologic and cardiologic features. Seizures, dystonia, acidosis, 
cardiomyopathy and other complications are treated separately when appropriate 
(Koene et al., 2011).  
 
A high genetic heterogeneity exists between patients with Leigh syndrome and 
transmission can be X-linked recessive, autosomal recessive or mitochondrial 
(DiMauro et al, 1996), though approximately 30% of all Leigh syndrome is mtDNA-
associated (Rahman et al, 1996). Patients with Leigh syndrome caused by a mtDNA 
mutation are often referred to as having “maternally inherited Leigh syndrome” 
(MILS) (Ciafaloni et al., 1993).  
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Apart from mutations in the ATPase6 gene, Leigh syndrome can also be caused by 
mutations in eleven additional mitochondrial encoded genes. Genetic testing is 
usually initially performed in muscle tissue to look for the two most common 
mutations in the ATPase 6 gene (m.8993T>G and m.8993T>C). If negative, whole 
mitochondrial genome screening is performed.  
NARP 
NARP (Neurogenic muscle weakness, Ataxia, and Retinitis Pigmentosa) is 
characterised by proximal neurogenic muscle weakness with sensory neuropathy, 
ataxia, pigmentary retinopathy, seizures, learning difficulties and dementia (Holt at 
al., 1990). Other clinical features include short stature, sensorineural hearing loss, 
progressive external ophthalmoplegia, cardiac conduction defects (heart block) and a 
mild anxiety disorder (Santorelli et al., 1997). Ataxia and learning difficulties often 
present in early childhood and patients can be relatively stable for many years. 
Similar to Leigh syndrome, management consists of treatment for individual 
manifestations (Koene et al., 2011).   
 
The T-to-G transversion (m.8993T>G) is most common in NARP, but a T-to-C 
transition (m.8993T>C) has also been described. Together they account for up to 
50% of NARP patients. Individuals with moderate levels (~70%-90%) of the 
m.8993T>G mutation present with the NARP phenotype, while those with mutant 
loads above 90% have maternally inherited Leigh syndrome (Fig. 3.3). Individuals 
with levels lower than 60% will be asymptomatic. The transition is a less severe 
mutation than the transversion, and virtually all symptomatic individuals have 
mutant loads of more than 90% (Thorburn et al, 2011). Patients with the T>C 
mutation tend to present with milder symptoms but a higher frequency of ataxia 
(Fujii et al., 1998).  
 
For most mtDNA mutations, it is difficult to distinguish a simple correlation between 
genotype and phenotype not only because of the difference in heteroplasmic levels of 
mtDNA. The clinical expression of a mtDNA mutation is also influenced by the 
pathogenicity of the mutation itself, the variation in mutant load among different 
tissues, and the energy requirements of brain and other tissues, which may vary with 
age (Thorburn et al, 2011). 
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Figure 3-3 Genotype-phenotype correlation for the m.8993T>G transversion.  
Since this phenotype-genotype correlation is very important in mitochondrial 
diseases, I performed a quantitation of the mutant load for several individuals in this 
thesis to investigate whether this could have an influence on the severity of the 
neuropathy in our cohort of patients.  
 
In contrast to Leigh syndrome, no additional genes have been reported to cause 
NARP. However, one paper recently stated that mutations in the mitochondrially 
encoded MT-TL2 gene result in an overlapping phenotype of Myoclonic epilepsy 
with ragged red fibres (MERRF) and NARP in one patient (Martin-Jimenez et al., 
2012).  
3.1.6 Structural results of mutations in the ATPase 6 gene   
In humans, the mitochondrially encoded ATPase 6 and 8 genes together with the 
nuclear-encoded ATPase 9 form the F0 membrane-spanning portion of the ATPase 
complex. Membrane topology of Subunit 6, also known as subunit a, suggests the 
presence of six transmembrane domains. The fourth transmembrane helix of subunit 
6 (Atp6p) is juxtaposed with the first transmembrane helix of subunit 9 and serves as 
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a proton pump. The m.8.993T>C mutation replaces the highly conserved leucine 
residue of subunit 6 that resides opposite an essential glutamate residue of subunit 9 
to a proline residue and thus interferes with the energy-driven ATP synthesis. 
Studies in yeast have shown a 40-50% decrease in the rate of ATP synthesis in the 
mitochondria of the mutant yeast strain, due to a less efficient incorporation of the 
Atp6p region, modified by the m.8993T>C mutation (Kucharczyk et al., 2009). The 
m.9.185T>C mutation results in a leucine to proline change in the fifth 
transmembrane helix adjacent to the outer membrane. The leucine residue at position 
220 is a well conserved residue in all animal species (Kaneko et al., 1993) and the 
substitution of a very poor alpha-helix former, proline, for a good alpha-helix- 
former, leucine, may make the fifth transmembrane structure unstable or distorted in 
configuration and thus interfere with the proton pump. This is the third substitution 
of a Leucine to a Proline in the suggested transmembrane helix that is known to 
cause Leigh Syndrome (Castagna et al, 2007).  
 
3.2 Results  
3.2.1 Genetic screening of the ATPase 6 and ATPase 8 genes resulted in a 
mutation frequency of 1.4%   
Standard PCR reaction was performed to amplify the overlapping ATPase 6/8 genes 
in a cohort of 673 patients. Of those patients, the majority (40.6%) was diagnosed 
with CMT2, and HMN and HSAN in respectively 172 (25.6%) and 133 (19.8%) of 
the patients. 93 (13.8%) patients were diagnosed with CMT1 and were primarily 
screened to examine whether mutations in the mitochondrial DNA could be a 
modifying factor for the demyelinating phenotype.  All patients with CMT2 were 
negative for mutations in MFN2. The majority of patients with CMT2 were also 
screened for mutations in MPZ, HSPB1, HSPB8, TRPV4, and GJB1 where 
appropriate. Patients with dHMN were negative for mutations in HSPB1, HSPB8, 
and TRPV4, and selected patients were negative for mutations in BSCL2 and GARS. 
 
Mutations in the ATPase 6 gene that are known to cause Leigh Syndrome were 
detected in five individuals diagnosed with CMT2. As mentioned before, the 
investigation of an extensive family with mitochondrial disease and axonal 
neuropathy in which the index case presented with a pure motor neuropathy in 
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childhood evolving into motor-predominant CMT2 in later life resulted in the 
discovery of a pathogenic missense mutation m.9185T>C in ATPase 6. This 
mutation was detected in three further unrelated probands by our genetic screening. 
Considering 275 CMT2 index cases were analysed, the representing frequency for 
this specific mutation in the ATPase 6 gene results in a percentage of 1.4% amongst 
CMT2 patients.  
 
No pathogenic variants were found in patients with dHMN, HSAN or CMT1, and no 
pathogenic mutations in ATPase 8 were found in either of the groups. The 
m.8993T>C mutation, which substitutes a leucine for proline, was found in one 
patient diagnosed with CMT2. When looking at the chromatographs of the four 
patients with the m.9185T>C mutation, a clear difference can be observed between 
patients with a heteroplasmic mutant load and patients with a homoplasmic (or high 
heteroplasmic) load (Fig. 3.4).  
 
 
 
 
 
 
 
3.2.2 Segregation analysis and the use of heteroplasmy investigation  
Segregation analysis of these mutations all showed the presence of the pathogenic 
mutation in the affected cases. Three of these probands were part of a large family, 
creating the opportunity to compare the percentages of heteroplasmy with the 
severity of the phenotypes and the sequencing results. Different tissue samples were 
used to compare the mutant load in the different organs. This was mainly performed 
to analyse whether blood samples could be representative of muscle samples, to 
reduce the need of muscle biopsy.  
3.2.3 Family A 
The first family consisted of four generations, with three generations of affected 
individuals (Fig. 3.5). Blood samples were available for seven members of the 
A B C 
Figure 3-4 Sequencing results for the m.9.185T>C variant. A: Homoplasmic wild type; B: 
heteroplasmic wild type/mutant; C: homoplasmic mutant. 
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family, while muscle samples were provided for three members. The index case also 
provided a urine sample.  
Clinical details of family A are compatible with a diagnosis of motor-predominant 
CMT2 
The index case (Patient III-5) presented in the first decade with recurrent falls and 
foot drop at age 6 after normal early development. Electrophysiologically, the 
neuropathy was a pure motor neuropathy/neuronopathy, however, sensory signs have 
since developed, making the diagnosis clinically compatible with motor-predominant 
CMT2. Recent clinical examination at age 21 showed distal muscle wasting of the 
legs, pes cavus, and clawing of the toes. Muscle strength was normal in the upper 
limbs with mild proximal lower limb weakness and moderate distal lower limb 
weakness. Ankle jerks were absent. Plantar responses were extensor. Pinprick 
sensation was normal, but vibration detection was reduced to the knees.  
Extra clinical features present in Family A suggesting mitochondrial involvement  
Apart from a pure motor neuropathy in all affected patients and minor sensory 
involvement in patient III-5, several patients also suffered from learning difficulties, 
sensorineural hearing loss and retinal degeneration. Two patients died due to sepsis 
at the ages of 9 (Patient IV-1) and 16 (Patient III-2). This type of rapid 
decompensation is distinctive for Leigh syndrome, suggesting mitochondrial 
involvement. The neuropathy was particularly severe in 2 adults with wheelchair 
dependence in the third decade (patients II-3 and III-1). 
Genetic analysis of family A indicate a homoplasmic m.9.185T>C mutation  
After mitochondrial DNA sequencing the homoplasmic presence of the m.9185T>C 
mutation was revealed, which segregated in the whole family. This causes a 
missense change from leucine to proline at amino acid position 220 of the ATP6 
protein (Leu220Pro). Affected individuals all presented with a mutant load of 100% 
in blood, whereas unaffected family members had lower levels of mutant load. The 
mutation was also quantified in two muscle samples and one urine sample, which 
showed an equivalent mutant load of 100% (Fig. 3.5). 
Blue native gels of Family A show abnormalities in comparison to controls  
Blue native gels for complex V of the respiratory chain were also performed 
elsewhere for three of the patients (Patients III-2, III-3 and IV-2). These both showed 
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reduced activity as well as impaired assembly of the complex in muscle samples 
(results not shown).  
 
 
 
 
 
 
3.2.4 Family B  
Clinical details of Family B show several generations with CMT2 and individuals 
with solely Upper Motor Neuron signs  
The second family has a history of four generations presenting with CMT2 (Fig. 
3.6). Patients presented in their first or second decade with typical features of 
inherited neuropathy, following a gradually progressive clinical course but 
experienced rapid decline in mobility in their fifth and sixth decades with wheelchair 
dependence from unaided walking over a 5-year period. Electrophysiological studies 
in patient III-9 pointed towards a pure motor neuropathy at age 29, but repeated 
studies at a later age showed sensory involvement, characteristic of CMT2. 
Generation III also included two individuals who displayed upper motor neuron 
(UMN) signs without a peripheral neuropathy. 
 Heteroplasmy analysis showed a difference in the mutant load between patients 
with CMT2 and individuals with UMN signs  
Restrictive enzyme analysis suggested a mutant load of 100% in all patients of 
Family B characterised with CMT2, whereas both of the patients with UMN signs 
Figure 3-5 Pedigree of Family A. Black symbols specify patients with CMT2, light grey symbols 
specify patients with unknown clinical status.  Arrow indicates index patient. b = blood; m = muscle; 
u = urine.  
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had a mutant load between 70-80%. The index patient (III-9) also had a skin and 
muscle biopsy, both showing the same level of mutant DNA. 
 
Figure 3-6 Pedigree of family B. Black symbols represent patients with CMT2, dark grey symbols 
represent individuals with upper motor signs. Arrow indicates the index patient. b = blood; f = 
fibroblasts; m = muscle. Asterisks indicate affected individuals that were not examined locally. 
Blue native gel of the index patient of Family B shows abnormalities in 
comparison with controls.  
Blue native gel of patient III-9 suggested a reduced activity of complex V in 
comparison with controls (results not shown).  
3.2.5 Family C.  
Clinical details of Family C are consistent with CMT2 
The third family consisted of three generations of affected individuals (Fig. 3.7). 
Patient III-16 had NCS compatible with a sensorimotor axonal neuropathy, whilst 
studies in patient IV-2 showed a pure motor neuropathy. Patient IV-2 also presented  
with learning difficulties, behavioral problems, and wheelchair dependence by early 
adulthood. Patient III-16 had motor-predominant CMT2 with pyramidal tract signs 
and proximal muscle weakness, which developed in later life.  
 
A history of insulin-dependent diabetes mellitus existed in the family, presenting in 
both generation II and III. This was not seen in patients with CMT2 and appeared to 
come from the father’s side of the family. 
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Heteroplasmy analysis showed different levels of mutant load in the whole family  
Both patients characterised had a mutant load of 100%. Two individuals in the 
family (III-5 and IV-1) had an unknown clinical status and had a mutant load of 
respectively 75% and 45%.  
 
 
Figure 3-7 Pedigree of Family C. Black symbols represent patients with CMT2, light grey symbols 
represent individuals with unknown clinical status, blue symbols represent individuals with Insulin-
dependent diabetes melitus. b = blood. Triangles with numbers indicate multiple individuals with 
unknown gender; small square with slash = still birth; small triangle with slash = miscarriage. 
Asterisks indicate affected individuals that were not examined locally. 
3.2.6 Sporadic case    
Clinical details indicate a sensorimotor axonal neuropathy 
The fourth patient presenting with the m.9185T>C mutation appeared to be a 
sporadic case in the family, suggesting a de-novo mutation (Fig. 3.8). He presented 
in the first decade and was characterised with sensorimotor axonal neuropathy, 
confirmed by NCS. EMG showed proximal and distal lower limb denervation with 
no evidence of myopathy. DNA of the parents was not available for sequencing.  
Heteroplasmy content showed levels lower than 100%  
Chromatographs indicated a heteroplasmic content of mutant DNA. Restrictive 
enzyme digest resulted in a mutant load of 92%. 
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Figure 3-8 Pedigree of the sporadic case. 
Black symbols specify patients with CMT2. 
b = blood.  
3.2.7. Estimating pathogenicity of unknown variations in the mitochondrial 
genome   
Since the mitochondrial genome consists of numerous variations, a list of steps has 
been followed to exclude non-pathogenic variations amongst all the variants found in 
our cohort of patients (See appendix I). Mitochondrial DNA has few regulatory 
sequences; therefore all synonymous or non-coding variations were excluded, 
together with known polymorphisms. Subsequently, variations were entered into 
four separate databases of control individuals, available online or internally. The 
largest database, mitowheel, consists of 3735 human mtDNA sequences 
(Zsurka,Gábor and Csordás, Attila; MitoWheel, visualizing the human mitochondrial 
genome. Available from Nature Precedings, 2009). Variations found in more than 
five control individuals were excluded. Other databases used were: mtDB (Ingman et 
al., 2006), HmtDB (Rubino et al., 2012) and the NHNN database (Internal database). 
Variations found in fewer than five controls, but associated with haplotypes or 
proven to be non-pathogenic were also excluded.  
Mutation # Patients Diagnosis Conservation # Controls  
m.8381A>G: Thr-Ala 1 CMT2 Changed to I in monkey 
and elephant  
2 
m.8516T>C: Trp-Arg 1 CMT2 Conserved in all species  1 
m.8605C>T: Pro-Ser 2 CMT2 Changed to Q in 
Dormouse  
1 
m.8828A>G: Asn-Ser 1 CMT2 Conserved in all species   
m.9025G>A: Gly-Ser 2 CMT2 + HSAN Conserved in all species 1 
Table 3-1 Possible mutations amongst variants found in the ATPase 6/8 genes in the mitochondrial 
genome. Mutation in bold was found in heteroplasmic levels in one patient.  
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Additionally, the conservation of basepairs was analysed by using the mtSNP 
database search (Fuku et al., 2005). Only variations with high conservation 
remained. This elimination led to a list of five possible mutations (Table 3-1). The 
m.8605C>T mutation was found in two CMT2 patients, one with seemingly 
heteroplasmic levels of the mutation.  
 
3.3 Discussion  
We identified five patients with mutations in the ATPase6 gene. In our genetically 
undefined cohort of CMT2 patients, this results in a prevalence of 1.8% harbouring a 
mutation in the ATPase 6 gene. Considering only one out of four patients with 
CMT2 receives a molecular diagnosis, this is a notable result. Several lines of 
evidence support the indication that this mutation is the cause of the phenotype.  
3.3.1 Clinical details  
All patients were seen by experienced clinicians and were considered to have a 
CMT2 phenotype based on clinical and electrophysiological parameters. Each of the 
pedigrees are compatible with a maternal lineage, however patients were never tested 
for mutations in this gene since they had isolated involvement of the peripheral 
nerves. Since there are four different families with the same mutation, the question 
arises if these families are related. While screening the families for mutations, 
polymorphisms were found in two of the four families, indicating these families are 
not related.  
3.3.2 Pattern of disease severity  
Three out of four patients were homoplasmic for the mutant DNA, the remaining 
patient had a mutant load of 92%. The pattern of variable disease severity matching 
with the levels of heteroplasmy is characteristic for diseases caused by mutations in 
the mtDNA. The consistency of mutant load in the different tissue samples implies a 
redundancy for skin or muscle biopsies, since heteroplasmy could be estimated with 
blood samples only. This is only demonstrated in patients with a mutant load of 
100%, so caution is needed when applying this to patients with a less severe 
phenotype. To evaluate whether the presence of extra symptoms relates to the 
heteroplasmic content in other tissues, mutant load characterisation in post mortem 
brain tissue and peripheral tissue would be desirable.  
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Considering all of the CMT2 cases with a mutant load between 92% and 100% had 
predominantly motor axonal neuropathy, it implies that all affected individuals with 
neuropathy present with levels higher than 92% of mutated DNA. Whether all of the 
patients truly have 100% mutated DNA is not guaranteed, as we have to allow for 
the detection level of the method. Reverse restriction enzyme experiments, in which 
wild type DNA was cut rather than mutant DNA could rule out the presence of any 
wild type DNA present.  
 
According to the levels of mutated DNA, patients could be broadly subdivided in 
four clinical groups (Fig. 3.9):  group 1, affected individual with symptoms and signs 
of predominantly motor axonal neuropathy (100-92% mutant load); group 2, affected 
individuals with clinical symptoms and signs of UMN involvement without 
neuropathy (91%−80% mutant load); group 3, asymptomatic individuals with upper 
motor neuron (UMN) signs detectable on examination only (79%−64% mutant 
load); and group 4, unaffected individuals (<64% mutant load). Patient I-2 from the 
first family does not seem to fit in this classification, since she had a mutant load of 
88%, without clinical features. However, this patient has never been examined and 
therefore cannot be excluded as a potentially affected individual.  
 
Figure 3-9 Correlation between heteroplasmic content of  
mutant DNA and severity of the disease. 
 
These cut-off percentages are very characteristic for mitochondrial diseases, 
supporting the pathogenicity of mutations in ATPase6 in CMT2 disease. To correctly 
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estimate the boundaries between the different phenotypes, more patients with 
different loads of mutant DNA need to be characterised, but estimations can be 
made. 
3.3.3 Blue native gels  
The use of an E.coli model for the m.9185T>C mutation in previous studies indicates 
a 70% decrease in ATP synthetic ability (Ogilvie and Capaldi, 1999), and studies in 
fibroblasts have shown a decrease of ATPase activity in patients with Leigh 
syndrome (Castagna et al., 2007). Similarly, in this study, the effects of the 
c.9185T>C mutation on complex V were studied in 4 different patients originating 
from 2 different families. These all showed impairment in the assembly and stability 
of the complex and/or the activity of the enzyme. This data supports the 
pathogenicity of the c.9185T>C mutation and indicates that this mutation is 
important in mitochondrial dysfunction, adding to the role of mitochondria in CMT2 
disease.   
 
The identification of the m.8993T>C mutation in a patient with CMT2 also adds 
supportive evidence for pathogenicity of mutations in the ATPase 6 gene. This 
mutation is not as extensively studied as the more common m.8993T>G mutation, 
which produces a more severe phenotype in mitochondrial diseases. BN-page has 
previously been used to prove the pathogenicity of the c.8993T>G mutation, where 
an impaired assembly and activity of the enzyme indicates the deleterious effects of 
the mutation. The same studies were done for the m.8993T>C mutation in this study, 
which only showed a substantial decrease of ATP synthesis in fresh muscle biopsies 
of patients and not in fibroblasts cell cultures. Unfortunately, no muscle tissue was 
available for this patient. 
3.3.4 Explanation for the phenotypic spectrum is unknown 
Since these mutations are also known to cause Leigh syndrome and NARP, other 
factors influencing the phenotype must be present, although the exact relationship 
between phenotype and genotype still has to be explained. The existence of 
modification factors could explain this broad phenotype spectrum, but this requires 
further research. Considering this is the first mitochondrial gene associated with a 
pure neuropathy, sequencing of the whole mitochondrial genome would be 
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appropriate to investigate whether more mutations in mitochondrial genes can be 
associated with neuropathy.  
3.3.5 Guidelines for mutational analysis in patients with CMT2   
With the emergence of next generation sequencing and whole exome or genome 
sequencing, a decision has to be made whether it is worth screening for mutations in 
the mitochondrial DNA as well. Although most patients presented with a typical 
CMT2/dHMN phenotype, mutations in ATPase6 should be particularly considered in 
the following cases: 1) an evolving clinical phenotype from a pure motor to a motor-
predominant axonal neuropathy in the third and fourth decades; 2) early proximal 
lower limb muscle involvement despite mild distal weakness; 3) multisystem 
involvement in the patient or relatives; 4) UMN signs in affected or asymptomatic 
relatives; 5) rapid clinical decompensation in affected individuals after viral or septic 
illness. 
3.3.6 Cohort study 
After exclusion of non-pathogenic mutations, five possible mutations remained. 
These cannot be excluded with the pre-existing information available. One way to 
determine if these mutations are pathogenic would be to measure the ATPase activity 
in vitro, by the use of blue native gels, but this could not be performed in the time 
available.  
 
Mutation #Patients Diagnosis Conservation #Controls 
m.8605C>T: P-S 1 CMT2 Changed to Q in Dormouse 1 
m.8828A>G: N-S 1 CMT2 Conserved in all species  
m.9025G>A: G-S 2 CMT2 + HSAN Conserved in all species 1 
Table 3-2 Variants of unknown significance found in the ATPase 6 gene in our cohort. 
Since mitochondrial DNA is very prone to variations, it is expected that most of 
these mutations will be polymorphisms. Considering the absence of definitely 
pathogenic mutations in the ATPase 8 gene, we only focused on the variants found in 
the ATPase 6 gene (Table 3.2).  
 
The familial history of the m.8605T>C variant showed a pattern of paternal 
inheritance, which makes it highly unlikely that this is the causative mutation for the 
phenotype, unless two different causes of disease are present in one family. One 
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patient with CMT2 had a novel variant m.8828A>G, causing a missense change 
from asparagine to serine at amino acid position 101 of the ATP6 protein 
(Asn101Ser). Unfortunately, there was no muscle tissue available from the patient 
for BN-PAGE; thus, the potential pathogenic nature of this variant remains 
uncertain. The m.9025G>A variation was also of particular interest, and since 
additional information did not exclude this variation from our list of possible 
mutations, this variation was checked for ATPase activity using blue native gel. 
However, no abnormalities were found.  
 
To conclude, mutations in the ATPase6 gene in patients with CMT2 add to the 
expanding evidence for the involvement of mitochondria in axonal neuropathy and 
suggest the mitochondrial genome should be screened for mutations in patients with 
axonal neuropathy.  
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Chapter 4 
Candidate gene screening 
in patients with CMT2 
4.1 Introduction  
4.1.1 Expanding clinical spectrum of known disease genes  
Due to the phenotypically heterogeneous nature of CMT, a significant amount of 
genetic overlap can be found between subtypes of CMT. As genetic testing becomes 
more widely available, mutations in one single gene have been found to cause 
multiple phenotypes and different modes of inheritance; for example, mutations in 
HSPB1 can cause CMT2 and dHMN in both an autosomal dominant and autosomal 
recessive manner. Genetic advances such as WES and WGS in recent years have 
broadened the phenotype of CMT and related neurodegenerative disorders (Gess et 
al., 2014; Robusto et al., 2014; Liu et al., 2014; Mathis et al., 2014; Schabhutti et al., 
2014; Azzedine et al., 2013). Not only can an entire new phenotype be found for the 
same gene, but broadening the already known phenotype can be beneficial to the 
understanding of disease pathways.  
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FIG4 
CMT4J is a rare subtype of demyelinating CMT, responsible for ∼20% of recessive 
Charcot–Marie–Tooth disease and 0.4% of all Charcot–Marie–Tooth disease. It is 
caused by recessive mutations in the phosphoinositide phosphatase FIG4 gene, and 
characterised by childhood onset with accelerated proximal and distal weakness and 
muscle atrophy in both proximal and distal muscles. Examination may reveal 
decreased response to touch, pin prick, or vibration distally (Zhang et al., 2008). The 
first mutations in the FIG4 gene were found in the ‘pale tremor’ mouse model, 
presenting with a multi-organ disorder with neuronal degeneration in the central 
nervous system, peripheral neuronopathy and diluted pigmentation, caused by an 
insertion in intron 18 of FIG4. The first screen of FIG4 in 95 CMT2 patients 
revealed four unrelated patients with recessive mutations consisting of a combination 
of a missense mutation p.Ile41Thr in exon 2 and a protein truncating mutation. Few 
mutations have been reported in FIG4 so far, and the majority of CMT4J patients 
have the compound heterozygous genotype FIG4I41T/null that was originally 
described in four families and has reached an allele frequency of 0.001 in the 
Northern European population whilst carriers remain clinically unaffected. 
Homozygotes have not been observed, showing that the presence of a null mutation 
on the other allele is required to manifest disease (Nicholson et al., 2011). The 
p.Ile41Thr mutation results in an impaired interaction with VAC14, required for the 
stability of the protein in vivo. As a result, protein levels in mice and patient 
fibroblasts are extremely low.  To date, 18 cases have been described with FIG4 
mutations. 17 of these had the FIG4I41T/null genotype. The remaining patient had a 
FIG4L17P/null genotype (Lenk et al., 2011). A recent paper in 2014 by Menezes et 
al. describes one of these patients as carrying the FIG4I41T/null genotype. However, 
the mother of the index patient seemed to present with a homozygous p.Ile41Thr 
mutation. When looking into more detail, a deletion of exon 2 was established on the 
other allele. This indicates that caution has to be taken in families with two affected 
generations that would usually be regarded as dominantly inherited forms of CMT. 
Other explanations can be possible, such as recessive inheritance due to three 
mutations segregating within the family. 
 
Besides CMT4J, heterozygous mutations in FIG4 have been found in patients with 
ALS (Chow et al., 2009) and homozygous null mutations have been shown to cause 
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Yunis-Varon syndrome, a severe autosomal-recessive congenital disorder affecting 
multiple tissues (Campeau et al., 2013). The clinical phenotype of CMT4J shows a 
significant amount of overlap with patients characterised with CMT4B1 and 
CMT4B2, due to loss-of-function mutations in MTMR2 and MTMR13 respectively. 
These overlapping clinical symptoms of CMT4B with CMT4J might result from 
either less [PI5P] or elevated [PI3P] or misregulation of [PI(3,5)P2]. 
 
No mutations have been found in VAC14 and mutations in PIKfyve result in Fleck 
corneal dystrophy (FCD), a rare autosomal dominant disease characterised by 
numerous tiny, dot-like white flecks scattered in all layers of the corneal stroma. 
Most patients are asymptomatic with normal vision, although photophobia has been 
reported in a small subset (Li et al., 2005).  
 
The FIG4 protein removes the 5-phosphatase from the low-abundance signalling 
phosphoinositide [PI(3,5)P2], which  is localised on the cytoplasmic surface of 
vesicles of the endosome/lysosome pathway. As mentioned in Chapter 1, [PI(3,5)P2] 
is one of the lowest abundant phosphoinositols present, making it difficult to study. 
Concentration of [PI(3,5)P2] is tightly regulated by the PAS complex, containing the 
PIKfyve, Vac14 and FIG4 proteins in mammals, in which PIKfyve functions as a 
kinase. Interestingly, activation of PIKfyve requires catalytic activity of FIG4, 
resulting in a tight coordination between synthesis and turnover of [PI(3,5)P2]. There 
is a significant role for this complex in an amount of pathways, such as the traffic of 
cell surface receptors to lysosomes, ion channel function or exocytosis (McCartney 
et al., 2014). Besides this, [PI(3,5)P2] also serves as a precursor for [PI5P]. This 
requires the presence of proteins with 3-phosphatase activity such has MTRMRs. 
MTMR2, another protein mutated in CMT4B1, acts on the same substrate as FIG4 
but with opposing effects. It is suggested that an imbalance of [PI(3,5)P2] might be 
at the basis of the excessive myelin growth and hypermyelination (Vaccari et al., 
2011). However, there are still alternative hypotheses that indicate generation of 
[PI5P] by PIKfyve (Shisheva, 2012).  
 
In mice, the imbalance of [PI(3,5)P2] leads to accumulation of enlarged vesicles 
derived from the endosome/lysosome pathway in fibroblasts and neurons, similar to 
the vesicle accumulation that can be seen in fibroblasts from a patient with CMT4J 
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(Chow et al., 2007; Zhang et al., 2008; Ferguson et al., 2009). Pale tremor mice also 
exhibit impaired autophagy with accumulation of p62/ubiquitin-positive inclusion 
bodies in astrocytes and neurons (Ferguson et al., 2009). The original mouse model, 
consisting of a homozygous insertion in intron 18 of FIG4 has been shown to 
survive for 4–6 weeks and exhibits extensive spongiform neurodegeneration in brain 
and peripheral ganglia, as well as loss of large diameter-myelinated neurons in 
sciatic nerve (Chow et al., 2007). A severe reduction in protein levels in comparison 
with the transcript level can be observed and is thought to originate from the protein 
instability caused by impaired interaction of the mutant protein with VAC14. This 
result was also confirmed in patient fibroblasts. A transgenic model expressing the 
CMT4J variant FIG4I41T on a FIG4 null background was later developed and 
exhibits dose-dependent rescue of mutant phenotypes, including neurodegeneration 
in the brain and dorsal root ganglia, and myelination of the sciatic nerve (Lenk et al., 
2011).  
 
Disease onset in patients varies widely from early childhood to the sixth decade, but 
so far no correlation with the mutation spectrum has been found. Proximal weakness 
in patients with CMT4J can be used to distinguish from typical CMT that is 
predominantly distal. Most patients show asymmetric weakness and in several cases 
trauma, such as a fall, can trigger the initial symptoms or cause a period of rapid 
progression. There is major reduction of motor nerve conduction velocity affecting 
both upper and lower extremities with frequent progression to severe amyotrophy. 
Sensory findings are uniformly less severe than motor findings but can progress to 
total loss of sharp sensation and reduced joint position sense with sensory nerve 
action potentials being reduced and becoming unobtainable with time. Most patients 
are also areflexic and few have shown signs of cranial nerve involvement. 
Neurophysiologic studies show severe combined axonal and demyelinating 
neuropathy, with major reduction of motor nerve conduction velocities, much slower 
than expected from denervation alone and often showing a decrease in amplitude 
(Chow et al., 2007; Zhang et al., 2008; Nicholson et al., 2011).  
 
EMG shows evidence of active and chronic denervation, including fibrillation 
potentials, positive sharp waves and reduced recruitment patterns. Sites of muscle 
atrophy correspond to the sites of weakness. Sural nerve biopsies show loss of large-
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diameter myelinated fibres, onion bulb formations, and progressive loss of axons in 
most patients. 
 
Chronic inflammatory demyelinating polyradiculopathy (CIDP) typically presents 
acutely, often with a patchy, non-homogeneous, predominantly motor neuropathy 
with associated demyelinating features on nerve conduction studies. Rapid 
progression of weakness in a single limb usually suggests an acquired inflammatory 
neuropathy like CIDP. It is becoming more recognised that patients who were 
previously thought of having an inflammatory neuropathy such as CIDP are being 
diagnosed with CMT (Houlden et al., 2009; Michell et al., 2009); hence we screened 
a cohort of 35 patients in this study with an early onset demyelinating neuropathy 
and distal motor neuropathy/neuronopathy for mutations in the phosphoinositide 
phosphatase FIG4. Cases were selected where the disorder was progressive and 
asymmetrical, as these would normally be interpreted as CIDP in comparison with 
the more symmetrical pattern expected from inherited neuropathies. 
C9orf72 
Two separate studies simultaneously reported the discovery of a GGGGCC repeat 
expansion in the first exon and promotor region of the C9orf72 gene in families with 
genetic linkage to chromosome 9p21 and a phenotype of  FTLD-ALS (DeJesus-
Hernandez et al., 2011; Renton et al., 2011). Amyotrophic lateral sclerosis (ALS) 
and frontotemporal lobar degeneration (FTLD) are two fatal neurodegenerative 
diseases without effective therapies. ALS is the most frequent motor neuron disease 
and is characterised by the degeneration of upper and lower motor neurons, leading 
to muscle weakness, spasticity and atrophy. FTLD is a common cause of early onset 
dementia, resulting from the degeneration of frontal and temporal lobes, and 
encompasses a group of disorders distinguished clinically by abnormalities in 
behaviour, language and personality. Both are part of a spectrum of disorders that 
have overlapping clinical, pathological and genetical features (Verma et al., 2014). 
After screening the appropriate cohorts, it was shown that the GGGGCC repeat is the 
most frequent genetic cause of both conditions. Further research found C9orf72 
expansions in patients with Parkinson’s disease (PD) (Lesage et al., 2013), 
progressive supranuclear palsy (Origone et al., 2013), ataxic syndromes and 
corticobasal degeneration (Lindquist et al., 2013). Most controls possess either 2,5 or 
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8 repeats on each allele, as does the non-expanded allele in patients whilst the 
disease allele has more than 400 repeats, usually up to 2000. The maximum number 
of repeats in controls was estimated at 25-30 repeats, depending on the study. Since 
the expansion repeat exceeded the upper detection limit of the assay in two of the 
studies, a minimum length of 60 repeats was suggested (DeJesus-Hernandez et al., 
2011; Renton et al., 2011; Gijselinck et al., 2011). A classification was suggested 
with repeats under 30 being non-pathogenic, repeats between 30 and 60 possibly 
pathogenic and repeats over 60 definitely pathogenic. More research is being 
performed on the grey zone below 60 repeats, where the number of repeats is not 
clearly pathological, but outside the typical range of healthy control repeat size. In 
rare cases, there have been reports of repeat lengths lower than 30 segregating in 
families (Gomez-Tortosa et al., 2013; Millecamps et al., 2012), even though these 
numbers have also been found in controls in other studies (Ratti et al., 2012; Simon-
Sanchez et al., 2012; Beck et al., 2013). Different disease mechanisms have been 
suggested which include toxicity induced by repeat-containing RNAs forming 
nuclear RNA foci that interact with various RNA-binding proteins causing 
transcriptome defects, RAN-translation of the c9orf72 transcript leading to 
accumulation of RAN proteins in cytoplasmic aggregates in affected brain regions or 
decreased mRNA expression leading to loss of C9orf72 function (Gendron et al., 
2014). Whilst the exact mechanism of pathogenicity is not yet known, studies 
indicate the clue can be found with repeat-containing RNAs. The normal function of 
C9orf72 has only recently begun to be elucidated and co-expression studies suggest 
it might be involved in ubiquitin-dependent protein degradation (Bieniek et al., 
2013), whilst others suggest a role in endosomal trafficking due to colocalisation 
with Rab proteins implicated in autophagy and endocytic transport such as Rab7, 
also implicated in CMT. Since CMT is also a neurodegenerative disorder, it was 
questioned whether the disease mechanism could stretch as far as being the cause for 
peripheral neuropathies.  
4.1.2 Frequency of genetic subtypes  
Dealing with a genetically heterogeneous disease has the consequence that new 
genes will be discovered continuously and the search can seem never-ending. The 
majority of these genes are found in few families with a very specific phenotype and 
estimations of the frequency of the genetic subtypes are difficult to make. These 
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frequencies can also differ significantly depending on the population and can 
demonstrate a founder effect in different ethnic groups. In the event new genes are 
discovered by other research groups, screening appropriate cohorts to estimate the 
frequency of the gene and diagnose some of the patients present in the in-house 
databases is a good opportunity and can provide a useful tool for clinicians to 
determine which genes to screen first.  
 
In a large study by Saporta et al including 787 CMT patients, it was estimated that 
67% of CMT patients receive a genetic diagnosis, and out of these 92% has either 
the PMP22 duplication or mutations in PMP22, MPZ, GJB1 or MFN2 (Saporta et 
al., 2011). The same percentage was established in a study by Murphy et al in 425 
patients with CMT (Murphy et al., 2012). A more recent study by DiVincenzo et al 
estimated the amount to be 94,9% of genetically diagnosed patients (DiVincenzo et 
al., 2014). All other genetic subtypes accounted for less than 1-3% of the total CMT 
patients with a genetic diagnosis, depending on the study (Saporta et al., 2011; 
Murphy et al., 2012). Whilst only 1.8% of patients with CMT1 were left without a 
genetic diagnosis in the study in Detroit, the study in London reported a genetic 
diagnosis in 80% of CMT1 patients. For CMT2, 34.5% of patients in Detroit and 
25,2% of patients in London received a genetic diagnosis, indicating there are still 
multiple genes to be discovered in axonal CMT.  
HINT1 
In 2012, Zimon et al. reported a new gene called Histidine triad nucleotide-binding 
protein 1 (HINT1) in which loss-of-function mutations cause an axonal neuropathy 
with neuromyotonia in 33 families. Neuromyotonia is a rare neuromuscular disorder 
that can either be acquired, paraneoplastic or hereditary. It results from 
hyperexcitability of peripheral motor nerves, characterised by spontaneous muscular 
activity at rest (myokymia), impaired muscle relaxation (pseudomyotonia), and 
contractures of the hands and feet. In hereditary cases it usually has an onset in late 
childhood or early adulthood. The authors stated a frequency of 11% for mutations in 
HINT1 in patients with autosomal recessive or sporadic CMT.  
 
HINT1 is a 126 amino acid protein that is ubiquitously expressed and functions as a 
homodimeric purine phosphoramidase and lysyl-adenylate generated by lysyl-tRNA 
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synthetase (LysRS) (Chou et al. 2007). HINT1 is also a member of the evolutionarily 
conserved family of histidine triad proteins that acts as a haplo-insufficient tumour 
suppressor, participating in several apoptotic pathways (Weiske et al, 2006). Eight 
different mutations were originally described to cause the same phenotype of axonal 
neuropathy with neuromyotonia (Zimon M et al., 2012). The most prevalent 
mutation is the p.Arg37Pro, with a later study in Czech patients showing a presence 
of 95% (Laššuthová et al., 2015). The same study reports a significant under-
recognition of neuromyotonia in patients, with only three out of 19 patients with 
neuromyotonia being characterised before molecular diagnosis. Most patients 
described with mutations in HINT1 come from eastern-European countries, 
suggesting a founder-effect (Zhao et al., 2014; Caetano et al., 2014).  
 
Yeast complementation assays resulted in reduced viability or no growth of the 
transformed strains, due to protein instability. Lymphoblast cultures of patients 
showed negligible expression of the HINT1 protein due to post-translational 
degradation. How this leads to neurodegeneration has not been established yet but 
transcriptional regulation and/or RNA metabolism have been implied (Zimon et al., 
2012). The original study was performed in a cohort with predominantly eastern 
European patients with autosomal recessive or sporadic CMT. To examine the 
frequency of mutations in HINT1 in the UK population, a cohort with predominantly 
recessive CMT2 was selected from the cases available at Queen Square for this 
study.  
SCN9A 
Pain disorders can be severe, debilitating conditions, which affect almost 10% of the 
worldwide population. Currently, treatment of these disorders remains unsatisfactory 
(Lampert et al, 2010). The most essential nociceptive or pain-signalling sensory 
neurons are located in the dorsal root ganglia (DRG) and trigeminal ganglia and 
constitute the peripheral entry point of the pain pathway. When stimulated, these 
neurons produce a series of action potentials, allowing information about the external 
sensory world to be transmitted to the brain. Injury to these neurons causes them to 
become hyperexcitable, thus giving rise to abnormal, unprovoked spontaneous action 
potentials or pathological bursting, which results in chronic pain (Fisher et al, 2010).  
Two distinct phenotypes involving chronic pain are caused by gain-of-function 
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mutations in SCN9A, while loss-of-function mutations have been found in patients 
with a congenital insensitivity to pain (CIP). Despite SCN9A mutations having been 
a long-established cause of pain disorders, we screened a cohort of our patients for 
mutations in the gene. A large number of SCN9A mutations have been reported in 
this highly polymorphic gene, but little estimation has been made about how 
frequently mutations occur in these disorders. For example, a study in 19 patients 
with pain disorders resulted in a positive result in SCN9A in only two of the patients 
(Klein et al., 2013).  
 
Inherited erythromelalgia is characterised by episodic symmetrical red congestion, 
vasodilatation and burning pain of the feet and the lower legs, mostly provoked by 
exercise, long standing or exposure to warmth. Relief could be obtained with cold 
(Michiels et al, 2005). The severity of this disorder can progress with age, and the 
symptoms may extend over a larger bodily area and become constant (Mandell et al, 
1977). In the absence of an underlying cause (such as myeloproliferative diseases or 
as a side effect of medication), it is referred as‘Primary erythromelalgia’, which is 
known to be an autosomal dominant disorder (Fisher et al, 2010).  
 
Paroxysmal extreme pain disorder, also known as familial rectal pain, is 
characterised by paroxysms of rectal, ocular, or submandibular pain with flushing 
(Fertleman et al, 2006). These pain attacks start as early as infancy and are 
accompanied by autonomic manifestations such as skin flushing. The severity of 
pain is worst in the lower part of the body and can be triggered by bowel movements 
or probing of the perianal area. Attacks can also be accompanied by tonic 
nonepileptic seizures, bradycardia, and/or apnea, which appear to be more common 
in infancy and young children. The cause for the seizure-like activity and cardiac 
symptoms is not well understood (Fisher et al, 2010).  
Why IEM patients experience pain in the feet and hands, triggered by warmth, while 
PEPD patients experience pain in the perianal area, triggered by rectal stimuli, 
perimandibular and/or periocular pain, is not currently known (Fisher et al, 2010).  
 
In the case of loss-of-function mutations in SCN9A, which produce truncated, 
nonfunctional proteins (Fisher et al, 2010), the resulting phenotype is congenital 
insensitivity to pain (CIP). Patients display painless burns, fractures, and injuries of 
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the lips and tongue and were reported never to have felt pain in any part of the body 
in response to any injury or noxious stimulus. Other sensory modalities are preserved 
and the remainder of the patients’ central and peripheral nervous systems are intact 
by report. Patients did not appear to exhibit any autonomic or motor abnormalities, 
and reportedly had normal tear formation, sweating ability, reflexes, and intelligence. 
(Fisher et al, 2010).  
 
Voltage-gated sodium channels are important in the generation and conduction of 
action potentials. These are integral membrane proteins and are comprised of a large 
α-subunit, which forms the voltage-sensitive and ion-selective pore, and smaller 
auxiliary β-subunit(s) that can modulate the kinetics and voltage dependence of 
channel gating (Catteral et al, 2000). There are 9 isoforms known of the sodium-
channel α-subunit (Nav1.1–Nav1.9), each with a unique central and peripheral 
nervous system expression profile. These different sodium channels share a common 
structure but are encoded by different genes and manifest distinct voltage-dependent 
and kinetic properties (Catteral et al, 2005). All α-subunits share the same general 
structure of six transmembrane segments (S1 to S6) present in each of four domains 
(DI to DIV), which are connected by intracellular peptide linkers. Voltage-gated 
sodium channels are members of the P-loop channel superfamily, which also 
includes voltage-gated potassium and calcium channels. 
The voltage sensors in these channels are formed by the S1 to S4 transmembrane 
segments in every domain, while the walls of the permeation pathway are formed by 
the S6 helices. S4 is characterised by a series of positive gating charges that are 
crucial for sensing changes in the membrane potential (Lampert et al, 2010).  
 
Nav1.7, Nav1.8, and Nav1.9 are the sodium channels known to be expressed 
neuronally. They are preferentially expressed in DRG and trigeminal ganglia 
neurons, most of which are nociceptive. The Nav 1.7 channel is expressed in almost 
all DRG neurons at various levels while the Nav1.8 and Nav1.9 channels are 
primarily expressed in small DRG neurons that include nociceptors (Fisher et al, 
2010). Although Nav1.3 channels are not expressed above background levels in 
adult DRG neurons, the Nav1.3 channel has been shown to be upregulated in DRG 
neurons following injury. Therefore, along with the Nav1.8 and Nav1.9 channels, 
Nav1.3 has been suggested to play a role in neuropathic pain (Black et al, 1999). The 
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various voltage-dependent sodium channels present in these neurons can not only be 
differentiated by their gating kinetics and voltage dependence, but also by their 
sensitivity to the voltage-gated sodium-channel blocker tetrodotoxin (TTX) (Drenth 
et al, 2007). The Nav1.8 and Nav1.9 channels can be distinguished from the Nav1.7 
channel by their resistance to TTX (Dib-hajj et al, 1999), while the Nav1.7 channel 
produces a rapidly activating and inactivating current that is sensitive to 
submicromolar levels of TTX. Here, we will focus on the first of the α-subunits, 
Nav1.7, because of its critical role in pain sensation. 
 
Nav1.7 is encoded by SCN9A, a 113,5-kb gene comprising 26 exons. The coding 
region accounts for 1977 amino acids, which are organised into the typical structure 
of four domains each with six transmembrane segments. This particular sodium 
channel is predominantly expressed in the dorsal root ganglion neurons and 
sympathetic neurons (Toledo, 1997). The large majority of DRG neurons that 
express this channel are pain sensing (nociceptive), suggesting a role for Nav1.7 in 
the pathogenesis of pain.  
 
Nav1.7 is characterised by slow transition of the channel into an inactive state when 
it is depolarised, even to a minor degree, a property that allows these channels to 
remain available for activation with small or slowly developing depolarisations. 
Thus, Nav1.7 acts as a “threshold channel” that amplifies small, subtle 
depolarisations such as generator potentials, thereby bringing neurons to voltages 
that stimulate Nav1.8, which has a more depolarised activation threshold. Nav1.8 
then produces most of the transmembrane current responsible for the depolarising 
phase of action potentials (Renganathan et al, 2001). In this regard, Nav1.7 is 
proposed as a molecular gatekeeper of pain detection at peripheral nociceptors 
(Waxman, 2007). 
 
A number of SCN9A gene point mutations are associated with human genetic pain 
disorders. Mutations causing a loss of function of Nav1.7 have been found in 
individuals with CIP. Conversely, 22 distinct mutations of Nav1.7 causing a gain of 
function have been found in individuals suffering from the pain syndromes IEM and 
PEPD. All 14 CIP-inducing mutations identified so far introduce a stop codon, 
which leads to premature protein truncation. The majority of patients are 
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homozygous, although some are compound heterozygotes with two different 
mutations, one on each allele. Mutations for IEM and PEPD on the contrary, are all 
missense mutations. The 13 mutations described for IEM were all identified as 
mutations located in highly conserved regions, while the substituted amino acids in 
PEPD lie in channel sections essential for fast inactivation, namely the linker 
between domains III and IV containing the IFM sequence motif that constitutes the 
inactivation particle and the inactivation particle receptor site (Lampert et al, 2010). 
4.1.3 Mouse models as an example to screen new genes  
Apart from accumulating additional knowledge about already known genes, further 
data can also be extracted by comparison with already known genes in animal 
models. The discovery of new animal models which are phenotypically similar to 
existing models or resemble the phenotype in patients invoke the need to screen 
relevant patient groups, to investigate whether these could also result in disease in 
humans.  For most cases, animal models were generated after the discovery of the 
gene, but a handful of mouse models have been described with motor 
neurodegeneration where initially there was no causal gene known. Examples of this 
are the motor neuron degeneration 2 (mnd2) mouse (Jones et al., 1993) or the motor 
neuron disease (mneu) mouse (Miyata, 1983). Over the years, some of these cases 
were solved by finding the causative gene such as for the neuromuscular 
degeneration (nmd) mouse (Cox et al., 1998), the peripheral motoneuronopathy 
(pmn) mouse (Martin et al., 2002) and the legs at odd angles (loa) mouse 
(Hafezparast et al., 2003). In these three examples, patients were found with 
mutations in the same genes, leading to a similar phenotype.  
 
Through collaboration with the MRC functional genomics unit in Oxford, a mutation 
in the ADP-ribosylation factor-like protein 1 (ARL1) gene was found in a mouse 
mutant. This mutation caused a progressive tremor and loss of fibres in the nerves, 
which points towards demyelination. ARL1 is known to be localised on the trans-
golgi and has been proposed to have a function in both exocytosis and in retrograde 
traffic from endosomes (Lowe et al., 1996). In this context, myelin biogenesis and 
maintenance is a complex process involving coordinated exocytosis, endocytosis, 
and cytoskeletal dynamics. Faults in the myelin protein trafficking and/or turnover 
could lead to demyelinating neuropathies in humans (Scherer et al., 2008).   
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In the same pathway, a mutation in the ARL6ip1 gene was found in-house in a family 
with spasticity, neuropathy and mental retardation. This gene has previously  been 
suggested as a HSP candidate gene, as a homozygous frameshift variant was found 
in a large family with the disease (Novarino et al., 2014). ARL6ip1 encodes a 
membrane protein found in the ER, implicated in the formation of ER tubules. A 
zebrafish knockdown resulted in a phenotype of both touch-induced and spontaneous 
locomotion behaviour, as previously reported for other HSP candidate genes (Fassier 
et al., 2010). In combination with the results from the mouse model, the presence of 
mutations in two genes of the same pathway leading to neurodegeneration 
encouraged us to screen different cohorts for mutations in these genes.  
 
4.2 Results  
4.2.1 FIG4 
Primer sequences were obtained from the lab of Prof. Timmerman in Belgium and in 
the selected cohort of 35 patients, one case was found to be a FIG4 compound 
heterozygote carrying the previously reported p.Ile41Thr missense mutation and the 
protein truncation mutation p.Lys278YfsX5 (Fig. 4.1). A further nine variants were 
found in the cohort, six of which were intronic (Table 4.1). All but one were present 
in a high frequency in the EVS server database. One novel variant, c.289+5G>A, 
was predicted to affect the splicing site by spliceport. However, since CMT4J is a 
recessive disease, the presence of an additional mutation is required. Investigation 
showed no extra variants in this patient.  
 
Figure 4-1 Electropherograms of compound heterozygous mutations found in FIG4. 
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Variants dbSNP No Info 
c.67-7T>C rs56378532 Intronic 
c.289+5G>A   Intronic 
c.647-18C>A rs2273752 Intronic 
c.877-54_877-50delTCATT rs57291908 Intronic 
c.1948+3A>G rs10499054 Intronic 
c.1961T>C rs9885672 High frequency 
c.2180+63G>T rs9384723 Intronic 
c.2559G>A rs1127771 Synonymous 
c.*29G>A rs10659 High frequency 
Table 4-1 Variants found in the FIG4 gene. 
Clinical details  
A 26-year old man diagnosed with a congenital hypomyelinating neuropathy 
(CMT1), with early onset progressive weakness in all 4 limbs, was referred to clinic 
with rapid development of a wasted left arm over a period of 2 years. Following 
normal pregnancy and delivery, he had walked late at 26 months of age. He was the 
youngest of four brothers in a non-consanguineous Scottish family with no family 
history of neuromuscular disease. Both parents previously had normal clinical and  
neurophysiological examinations. In early childhood, progressive weakness, starting 
distally and advancing proximally, was observed. At 13 years of age, he started using 
a wheelchair and he became completely wheelchair dependent following a fracture 
of the left femur at 22 years of age. Two years prior to presentation, he developed 
rapidly progressive distal weakness of the left upper limb that progressed proximally. 
The left hand has been left functionally useless, whilst before there was only mild 
symmetric weakness and function was preserved function in both hands. No 
improvement was seen despite a 5-day course of 500 mg methylprednisolone.  
 
On examination, he had a wasted, flaccid clawed left hand with wrist drop. There 
was no movement on finger extension or in the intrinsic muscles of the left hand and 
strength at the elbow, wrist and the intrinsic muscles of the left hand was lower than 
the right hand. There was mild weakness of hip flexion. He was areflexic. Vibration 
sense was normal in the right hand, reduced to the metacarpophalangeal joint in the 
left hand, and to the costal margins bilaterally in the lower limbs. Proprioception was 
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reduced to the right metacarpophalangeal joint, left wrist, and knees bilaterally. 
Sensation for pinprick was reduced to the wrist and ankles bilaterally.  
 
Due to the rapidly progressive distal weakness of the left upper limb and the lack of 
a response to anti-inflammatories, a neoplastic cause was also suspected, particularly 
involving the left brachial plexus. An MRI of both brachial plexuses was normal and 
a T1 weighted MRI of the left upper limb at latest presentation demonstrated fatty 
infiltration of muscles, more marked distally, with sparing of biceps compared with 
triceps (Fig. 4.2).  
 
 
 
 
 
 
 
Figure 4-2 MRI of the patient. At the level of the upper humerus (A) there are 
streaks of fat infiltration in deltoid muscle.  At the level of the lower humerus (B) 
there is extensive fat infiltration of triceps (black arrowhead) with less infiltration in 
biceps (white arrowhead).  In the forearm (C) there is extensive fat infiltration of all 
muscle compartments.  Image orientation is the same for all images. 
Nerve conduction studies were performed at the age of 13 years, 19 years and at the 
latest presentation at age 26 years (Table 4.2). These showed a demyelinating 
neuropathy with dispersed proximal responses and a fall in the conduction velocity 
in the right median nerve from 16 m/s to 4 m/s over 6 years. In the latest studies, 
there was a significant asymmetry in the CMAP, with low amplitudes in the right 
median and ulnar nerves, and absent amplitudes on the left. There was evidence of 
conduction block in the right median nerve. 
 
The most recent EMG showed no spontaneous activity and wide polyphasic units 
firing at high rates in relative isolation, consistent with severe chronic denervation, in 
the right triceps, right first dorsal interosseous (FDIO), left deltoid, left biceps, left 
triceps, and left extensor digitorum communis muscles. EMG of the left FDIO 
126 
 
showed frequent fibrillations and positive sharp waves and no motor units under 
voluntary control. A sural nerve biopsy was performed at 14 years of age and 
showed a severe demyelinating neuropathy with complete absence of large regularly 
myelinated axons in the resin semi-thin section and electron microscopy (Fig. 4.3).  
 
 13 years 19 years 26 years 
Motor conduction    
Median (R)    
  DML                 7.6 ms 12.0 ms 9.2 ms 
  CMAP (Wrist)      2.3 mV 4.4 mV 3.9 mV 
  CMAP (Elbow) 0.5 mV (dispersed) 2.4 mV (dispersed) unobtainable 
  CV                     16 m/s 4 m/s  
Median (L)    
  CMAP (Wrist)   absent 
Ulnar (R)    
    DML                   6.8 ms 7.6 ms 15.6 
    CMAP (Wrist)   1.4 mV 1.3 mV 0.7 mV 
    CMAP (Elbow) unobtainable unobtainable 0.4 mV (dispersed) 
    CV                        4 m/s 
Ulnar (L)    
    CMAP (Wrist)  absent absent 
Posterior Tibial (R)    
    CMAP (Ankle) absent   
Common Peroneal (R)    
    CMAP (Ankle) absent   
Sensory conduction    
Median (Right) absent absent  
Ulnar (Right) absent absent  
Radial (Right)  absent  
Median (Left)   absent 
Ulnar (Left)   absent 
Sural (Right) absent   
Table 4-2 Nerve conduction studies at ages 13,19 and 26. L = Left; R = Right; DML = distal motor 
latency; CMAP = compound muscle action potential; CV = conduction velocity. 
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There were relatively frequent large and medium-sized thinly myelinated fibres 
surrounded by concentric layers of Schwann cell profiles in keeping with onion 
bulbs. Several axons within the onion bulbs were devoid of myelin sheaths. No 
inflammation was present. 
 
Figure 4-3 Sural nerve biopsy at age 14 years. (A and B) Semi-thin resin sections, stained with 
methylene blue azure – basic fuchsin. One single fascicle with absent large normally myelinated 
fibres and frequent large thinly myelinated fibres surrounded by concentric Schwann cell profiles (red 
arrowheads). (C) Electron microscopy showing demyelinating fibres losing their myelin sheath (blue 
arrowheads) (D) Electron microscopy showing frequent onion bulbs consisting of concentric 
multilayers of Schwann cell processes (blue arrowheads). The Schwann cell processes within the 
onion bulbs are separated by densely packed collagen bundles. Scale bar: 200 μm (A), 100 μm (B), 
2.5 μm (C), 5 μm (D).  
4.2.2 C9orf72 
A cohort of 185 dHMN patients was screened for the repeat expansion in C9orf72.  
No patients presented with a pathological repeat expansion that was significantly 
over the threshold. Different amounts of repeats were found in the cohort with the 
longest repeat length consisting of 17 repeats, found in two patients (Fig. 4.4). 
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Whilst the pathogenic cut-off for the repeat expansions remains debatable, repeat 
sizes of 17 are commonly found in controls and are regarded as non-pathogenic.  
 
Figure 4-4 Example of fragment analysis in C9orf72. Upper panel = control. Lower panel = CMT2 
patient. A repeat size of 17 repeats was found, which has been shown to be non-pathogenic. 
4.2.3 HINT1  
We investigated a cohort of 127 patients with predominantly recessive CMT2, but no 
mutations in the HINT1 gene were found (Table 4.3).   
 
Phenotype #Patients  
CMT2 84 
Intermediate CMT 15 
CMT1 2 
Unclassified CMT 4 
CMT2 plus 7 
CMT1 plus 2 
dHMN 11 
HSAN 2 
Table 4-3 Phenotype for the 127 patients 
analysed for mutations in the HINT1 gene. 
In the whole cohort, four variants were found, two of which were intronic and two 
synonymous; all were present in the EVS at a high frequency (Table 4.4). A cohort 
of 33 samples with CMT2 of Spanish origin was investigated by Dr. Alex Horga, a 
fellow PhD student, which also resulted in no pathogenic variants (In press). 
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Variants dbSNP No. Info 
c.57T>C rs4696 Synonymous 
c.111+37T>G rs2278060  Intronic  
c.159G>A rs199716973 Synonymous  
c.216+37T>C rs17165688 Intronic  
Table 4-4 Variants found in the HINT1 gene. 
4.2.4 SCN9A 
Three patients with CIP and twelve patients with IEM were selected for screening of 
SCN9A (Table 4.5).  
 
Cases Sex Diagnosis Clinical features 
1  F CIP AR neuropathy, lack of sensation hands and feet, parents are 
cousins 
2 F CIP CIP, AR neuropathy, very early onset, lack of distal sensation 
mainly to pain. 
3 M IEM Stinking, painful and bright red feet felt to be consistent with 
erythromelalgia. 
4 F CIP Neuropathy, pain loss distally. 
5 F IEM Facial flushing provoked by heat, wheat and spicy food. 
Episodes associated with burning dypaesthenia. Episodic 
bilateral facial aedoma. Onset age 13.  
6 F IEM FH of narcolepsy and pes cavus. Small fibre neuropathy. Painful 
feet with redness.  
Checking for mutations in SPTLC and RAS7.  
7 F IEM Arms and face associated with face pain and headache. 
8 M IEM Painful neuropathy. Redness and discolouration. Negative for 
SPTLC1. 
9 F IEM Painful feet and cold feet. 
10 F IEM Familial neuropathy. Pain and numbness. 
11 M IEM Painful erythromelalgia and redness. 
12 F IEM Episodic pain + redness in feet. 
13 M IEM History of pain & redness - episodic - both feet. Some 
improvement with carbamazepine. 
14 M IEM Painful erythromelalgia and redness. 
15 F IEM Sister also affected. Very painful neuropathy with erythema. 
Table 4-5 Patient cohort for the screening of SCN9A. 
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No known mutations were found in either of the two groups. However, 18 intronic 
and 15 coding variants were found, seven of which were synonymous (Table 4.6). 
No further investigations were made for the intronic variants, since none of them 
were located close to a splice site. Out of seven synonymous variants, only one was 
novel, which was not located anywhere close to a splice site hence no further 
investigations were made. Seven out of eight coding, nonsynonymous variants were 
prevalent in the EVS and ExAc databases. The remaining novel variant was the 
c.4645T>C (p.Trp1549Arg) missense variant in patient no.9, suffering from IEM 
with painful and cold feet (Fig.4.5). This variation is situated in the S2 
transmembranic segment of domain four and changes tryptophan 1549 to arginine. 
So far, no other mutations have been found in any of the S2 segments. Few 
mutations, causing either CIP or PEPD have been found in domain four. Both 
PolyPhen2 as SIFT prediction programs were used, resulting in a contradicting 
outcome. However, prediction programs are often not very accurate, and when 
known SCN9A mutations are entered, they can also be predicted as being benign. 
Tryptophan 1549 is conserved amongst higher species and the change of an aromatic 
aminoacid to a negative would suggest that this might be a pathogenic mutation.  
 
Synonymous changes  Coding nonsynonymous 
c.174G>A  rs6432901 c.684C>G rs71428908 
c.444A>G rs9646771 c.2971G>T rs4369876 
c.1119T>C rs13414203 c.3329G>A rs74401238 
c.1266A>G  rs13402180 c.3448T>C rs6746030 
c.1287T>A rs6747673 c.4612T>C rs202084411 
c.3642C>A rs77144869 c.4645T>C   
c.4812G>T   c.4741+16T>A rs10180721 
  c.5725A>G rs3750904 
Table 4-6 Coding changes found in the SCN9A gene. 
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Figure 4-5 Missense variant  in SCN9A. (A) Electropherogram of the c.4645T>C 
missense variant in patient 9. (B) Conservation of the tryptophan aminoacid at 
position 1549 in SCN9A. 
4.2.5 ARL1 and ARL6ip1 
Screening of ARL1  
A cohort of 35 patients with CMT1 was selected for screening of ARL1, but no 
coding variants were found. Five variants were found outside the coding regions, 
with four of them located deep in the introns of the gene (Table 4.7). The last variant 
was located three base pairs from the stop codon but showed a high prevalence in the 
EVS database.  
Variants dbSNP no  
c.1-82G>C rs76432489 
c.225-58T>G  rs17500203 
c.336+74A>G   
c.337-18A>G rs73159756 
c.*3C>A rs201219157 
Table 4-7 Variants found in the 
ARL1 gene. 
Screening of ARL6ip1 
45 patients with a CMT2 phenotype were selected for screening of ARL6ip1. Results 
showed three intronic variants and one coding, synonymous variant present in the 
EVS database (Table 4.8).  
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Variants RS no 
c.36+104delC rs141868228 
c.170+12A>T rs17663173 
c.204C>T rs138748723 
c.409-18T>C rs71382566 
Table 4-8 Variants found in the 
ARL6ip1 gene.  
4.3 Discussion  
4.3.1 FIG4 
Multiple reports have shown cases of patients with CMT and mutations in GJB1, 
SH3TC2 or SPTLC1 mimicking CIDP by showing asymmetric or proximal weakness 
(Houlden et al., 2006; Houlden et al., 2009; Michell et al., 2009). When combined 
with a progressive course and a poor response to treatment, the possibility of CMT 
might arise. The presence of a proximal and asymmetric weakness and rapid 
deterioration of strength in a single limb in our patient suggested the presentation of 
CIDP with an underlying genetic neuropathy, which would have been expected to 
improve with immunosuppressant medication. However, two compound 
heterozygous mutations in the FIG4 gene were found resulting in the FIG4 
I41T/K278YfsX5 genotype. One patient has been described with the same genotype 
before, and has also been treated with immunosuppressant medication (Nicholson et 
al., 2011). He had been diagnosed with Dejerine-Sottas syndrome at age 5 and 
progressed to wheelchair dependence over a period of 30 years, then developed a 
rapidly progressive weakness of his left arm at age 41. Sural nerve biopsy also 
showed features of onion bulbs and extensive loss of large diameter myelinated 
fibres. Improvement with corticosteroids was not sustained, and there was no 
response to intravenous immunoglobulin.  
 
This leads to the conclusion that compound heterozygous mutations in FIG4 can be a 
rare cause of Charcot-Marie-Tooth disease where initially inflammatory 
demyelinating neuropathy is suspected. Early onset and progressive proximal and 
distal weakness in a single limb with chronic denervation changes on EMG are 
clinical clues that could suggest the diagnosis.  
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4.3.2 C9orf72 
There was an absence of C9orf72 repeat expansions in the dHMN cohort screened, 
which helped to define the spectrum of C9orf72 expansion-associated 
neuropathology. Repeats above 60 are normally considered pathologic; repeat sizes 
between 30-60 remain debatable as intermediate alleles and their significance has not 
been clarified yet. The longest repeat size found in our cohort was 17 repeats, 
regarded as being non-pathogenic. Therefore it could be concluded that repeat 
expansions in C9orf72 are highly unlikely to be responsible for a CMT phenotype.  
4.3.3 HINT1  
The original report by Zimon et al. stated a frequency of mutations in HINT1 of 
11%, which could not be replicated in our study. Only 33 families with a very 
specific phenotype were originally screened in the paper, explaining the high 
frequency. It is remarkable that even in a large cohort of more phenotypically 
heterogeneous CMT2, no mutations were observed. This suggest that mutations in 
HINT1 might not be as frequent as stated in CMT and predominantly occur in 
families presenting with a specific phenotype of axonal neuropathy and 
neuromyotonia. Screening of a Spanish cohort resulted in the same negative results 
and together with the observation that from a total of 73 patients with HINT1-related 
neuropathies reported to date, 59 (81%) are from the Czech Republic, Austria, 
Serbia, Bulgaria and Turkey, the presence of a founder-effect is highly likely. This 
geographical distribution together with mutation distribution and haplotype studies 
suggests the presence of founder effects that may explain the prevalence of the 
disorder in those areas. HINT1-related neuropathies are not widely distributed but 
mostly confined to specific European populations, although additional studies are 
needed to confirm this observation. This conclusion underlines the importance of 
considering the ethnic background of a patient when screening for mutations in 
neuropathy-related genes. 
4.3.4 SCN9A 
Only one potentially pathogenic variant was found in the 15 patients with pain 
disorders. This patient was seen in clinic only once and was diagnosed with a small 
fibre painful neuropathy at late onset in adulthood. She had no family history and is 
now in her seventies. Unfortunately, the patient did not return for further clinical 
investigation and DNA from the family was not available for segregation. Whilst the 
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prediction programs were contradictionary, the absence of the mutation in controls 
and the relatively high conservation indicate the potential pathogenicity of the 
variant. None of the other patients with CIP or IEM showed any possible pathogenic 
variants in the exons of the SCN9A gene and will be investigated further for 
mutations that could explain the phenotype.  
4.3.5 ARL1 and ARL6ip1 
Although no mutations were found in our cohort for the ARL1 or ARL6ip1 genes, 
this does not rule out these genes as causative genes for peripheral neuropathies. The 
presence of a progressive tremor and loss of fibres in the nerves in mutated mice 
indicates demyelination and further studies in undiagnosed families with similar 
phenotypes might reveal mutations in these genes. 
4.3.6 Overall discussion  
Recent advantages in next-generation sequencing have dramatically changed the 
process of Mendelian disease gene identification. Past identification of Mendelian 
disease genes was carried out by Sanger sequencing, with candidate genes being 
selected due to resemblance of genes in similar diseases, predicted protein function 
being relevant or positional mapping pointing to a genomic region. The rise of next 
generation sequencing techniques has resulted in a move from the use of Sanger 
sequencing for a general search of causative genes towards more targeted 
resequencing. There is no longer a need for complex and time-consuming processes 
for gene-identification and in the future, more advanced techniques will become 
faster and more affordable, leading to the disappearance of single gene testing. In the 
meantime, diagnostic guidelines are used to target specific genes in undiagnosed 
families or cohorts.  
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Chapter 5 
Whole exome sequencing 
5.1 Introduction  
5.1.1 Previous ways to identify disease genes 
Historically, before the use of mapping information, the discovery of pathogenic 
mutations in genes started with position-independent methods based on the 
knowledge of the gene product. Approaches ranged from the generation of a cDNA 
expression library out of amino acid information, animal models or detection of 
repeat expansions in the case of anticipation of disorders along generations. When 
techniques such as linkage analysis became available to estimate the approximate 
chromosomal location, positional cloning techniques were used to identify the causal 
gene. Clones were established for the whole of the candidate region and a transcript 
map was used to identify all genes within the candidate region. This list of genes was 
further prioritised by appropriate expression pattern, function, or homology to a 
relevant paralogous or orthologous gene. In rare cases, chromosomal abnormalities 
such as translocations or deletions provided an alternative method of localising a 
disease gene.  Mutation screening, restoration of the normal phenotype in vitro or 
production of a mouse model of the disease were used to demonstrate the likeliness 
of a candidate gene as disease locus.  
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5.1.1 Discovering new genes with the use of whole exome sequencing  
The recent shift from traditional Sanger sequencing and linkage analysis to high-
throughput next-generation sequencing methods has revolutionised gene discovery 
and diagnostics for Mendelian and complex diseases, and exome sequencing has 
already been proven to be a useful tool in the discovery of new Mendelian disease 
genes. In more than 85% of the cases, mutations associated with known Mendelian 
diseases are located in protein-coding exons (Bamshad et al., 2011). Therefore, 
exome sequencing may be an efficient tool for the identification of novel 
mutations/genes in patients with diseases such as CMT2. While there are still some 
challenges to overcome, using this technique is on the whole advantageous. In the 
first two results sections, focus will be on two examples where interesting candidate 
genes were found and pursued with functional experiments. However, in the 
majority of cases, identifying one specific candidate gene has been proven to be 
difficult. Most of the remaining undiagnosed CMT families are small and only few 
ways to narrow down the list of candidate genes are possible. Even in larger families 
this raises a problem. The remaining result sections will go through the challenges of 
finding a new gene with the help of exome sequencing and some of the open 
questions that it results in.     
5.1.2 The usage of linkage analysis in combination with whole exome 
sequencing  
Although exome sequencing is an extremely useful technique, one of the 
disadvantages when performed on two distant relatives such as cousins is that it can 
give up to thousands of shared nonsynonymous variants. Different filters can be used 
to narrow down these lists of variants, but one highly useful technique is linkage 
analysis (Fig. 5.1). Several generations with multiple affected and unaffected 
individuals are necessary to give power to this technique. These affected and 
unaffected family members are used to map the fragments of the genome that are 
shared only by the affected patients and not by the unaffected members of the 
family. Only variants that are present in linkage areas could be causing the disease. 
This could narrow down the list of possible variants significantly, but for diseases 
where there is a high risk of incomplete penetrance, this is not the optimal technique 
to use. In CMT2, there are only few cases that have shown reduced penetrance in 
families with MFN2 or TRPV4 mutations (Nicholson et al., 2008; Berciano et al., 
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2011), meaning we can safely assume no pathogenic variants will be excluded when 
using a model with 90% penetrance.  
5.1.3 Prioritizing variants to find a favourable candidate gene  
Even though linkage analysis can significantly reduce the candidate gene list, 
additional methods are necessary to decide on a specific candidate gene (Fig. 5.1). 
First of all, synonymous variants and variants with a segmental duplication 
coefficient higher than 0.96 will be excluded. Of the remaining variants, those that 
have a minor allele frequency higher than 0.5% in the public databases will also be 
omitted. As few genes in CMT2 show incomplete penetrance, variants that are novel 
and have not been found in any of the publicly available databases will be 
prioritised. Providing there are no mutations in the known CMT2 genes, variants in 
genes that have been implicated in other neurological diseases can be excellent 
candidates. Recent research has shown the expansion of phenotypes associated with 
genes is becoming increasingly more common. In the event that none of the variants 
are located in pathogenic genes, a selection can be made of genes specifically 
expressed in the PNS, or with functions related to known pathogenic mechanisms in 
CMT2. Evidence of genetic or functional interactions with known CMT2 genes can 
also shortlist candidates. This usually results in a reduced list of potential candidates. 
5.1.4 The ubiquitous variants of unknown significance  
For many, if not all, novel missense mutations, there can be little data on which 
pathogenicity can be based. A range of bioinformatics tools are available to predict 
or estimate the influence of a variant by looking at the evolutionary conservation, the 
consequences on structural conformation, and many others.  
 
Whilst these tools can be useful to prioritise the most likely candidate gene, their 
predictive power is highly variable and does not lead to definitive conclusions. Due 
to the genotypically heterogeneous character of CMT, the functions of known 
pathogenic genes are extremely divergent; meaning functional testing of candidate 
genes will rarely have a precursor amongst the known genes. This results in the 
development of individual functional tests to prove the pathogenicity of novel 
variants, a time-consuming and often difficult task.  
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Figure 5-1 Exome sequencing workflow, starting 
from the return of the data to the choice of a 
candidate gene.  
 
Similarly, it can be as challenging to prove a variant is benign as it is to prove it is 
pathogenic. This will result in the presence of variants of unknown significance that 
can only be ruled out over time. As more next-generation sequencing data will 
become available, fewer variants will be considered novel and clinical and molecular 
research will categorise variants as convincingly benign or pathogenic. However, 
caution has to be taken with publicly available data.  The increase in NGS data will 
identify rare variants previously considered as rare to be polymorphisms, but at the 
same time  will  return more novel variants that result from the normal mutation rate. 
It should be anticipated that the existence of novel mutations will persist and will 
remain challenging.   
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5.2 Results  
5.2.1 Success rate of exome sequencing in rare diseases  
In our centre, exome sequencing was performed in 31 probands and 22 relatives with 
CMT. Out of these, 24 cases were familial and 7 were sporadic. In three of the 
probands, mutations were located in known genes. One probable pathogenic genetic 
variant was identified in a novel gene in one pedigree, and two definite pathogenic 
variants were found in two unrelated pedigrees in novel genes. Whilst analysis is still 
in progress, preliminary results suggest a success rate of 6/31 (19%) of exome 
sequencing for the detection of known or novel variants in inherited neuropathies 
(unpublished data). Published data by several groups can range from a success rate 
of 10-71% (Gilissen et al., 2012; Need et al., 2012; Gahl et al., 2012; de Ligt et al., 
2012; Choi et al., 2012). This immense range results from differences in the exome 
sequencing approach. Studies with a high success rate have a higher turnover of 
mutations in known pathogenic CMT genes, resulting from a more diagnostic 
approach. Depending on the phenotype of the family and the centre of research, 
exome sequencing can be a more cost-efficient way to find the genetic diagnosis, 
especially when families are less well-characterised.  
5.2.2 Family D 
The index case (Patient IV-1, Fig. 5.2) was a 24 year-old patient who had normal 
birth and normal milestones. From the age of 2 he had frequent falls, lower limb 
wasting and a tendency to turn over his ankles and high arches. Slowly progressive 
distal wasting and weakness of the lower limbs and sensory loss in the feet followed. 
During examination, he was unable to stand unaided from sitting and had a positive 
Gower’s manoeuvre. He was unable to stand on heels or toes and walked with a 
slightly stiff gait. Tone was increased in the lower limbs, with no clonus. Distal 
wasting was present in both the upper and lower limbs. He was areflexic. Sensory 
examination showed pin prick reduction in the fingers and to the proximal half of the 
calf bilaterally; vibration sense was present at the knees and proprioception was 
normal.  
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Figure 5-2 Pedigree of CMT2 family D. The index 
case is indicated with an arrow. Black symbols 
represent individuals with CMT2.  
NCS revealed an axonal sensorimotor neuropathy affecting the lower limbs only. 
EMG showed a neurogenic pattern with proximal and distal lower limb muscles 
affected equally. Central motor conduction times to the lower limbs were mildly 
prolonged. Lateral vastus muscle biopsy showed angular atrophic fibres, grouping of 
type I and III fibres consistent with denervation and reinnervation. Respiratory chain 
enzyme analysis showed reduction of complex I  0.077 (ratio 0.104 – 0.268), II 
0.032 (ratio 0.040 – 0.204), IV 0.008 (ration 0.014 -0.034). 
 
The father of the index case (Patient III.1; Fig. 5.2) was 56 and has worn shoes with 
ankle support since the age of 15. He complained of occasional cramps and could 
run until the age of 48.  Neurological examination showed minimal wasting of 
intrinsic muscle of the hands and tibialis anterior. He had mild distal weakness in the 
upper and lower limbs. Reflexes were normal except ankle reflexes which were 
absent. Plantars were extensor. Sensory examination showed reduced pinprick to mid 
foot and mid palm bilaterally, reduced vibration sense to ankles, normal 
proprioception. NCS was consistent with an axonal sensory and motor neuropathy. 
EMG showed denervation changes in upper and lower limb muscles again equally 
involving proximal and distal muscles. 
The grandmother (Patient II.1; Fig. 5.2) was an 88 year old woman who had been 
diagnosed with Charcot-Marie-Tooth disease at the age of 49. She recalled being 
unable to stand on her toes in her 20s and walking “flat footed”. She began to use a 
stick at the age of 50 and her walking slowly deteriorated over the years and she 
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became wheelchair-bound in her 70s. In her 50s she developed symptoms in her 
upper limbs with hand fine movements difficulties. She developed hearing loss at the 
age of 78. Neurological examination showed intrinsic hand muscles and proximal 
and distal wasting in the lower limbs. She had moderate distal weakness in the upper 
limbs, mild proximal weakness in the lower limbs and severe distal lower limb 
weakness. She was areflexic. Sensory examination showed reduction of pin prick to 
the knees; vibration sense was absent in the lower limbs. Proprioception was normal. 
NCS showed a severe axonal motor and sensory peripheral neuropathy. EMG 
showed denervation in upper and lower limb muscles again with proximal and distal 
muscles being equally affected. The neurophysiological findings were similar to 
those demonstrated in her son and grandson.  
 
Overall, the phenotype in this family was consistent with an axonal sensor and motor 
neuropathy, however, the index case was much more severe in comparison to the 
father and grandmother.  
The discovery of a candidate gene  
Sequencing of the index patient at a diagnostic level returned negative results for 
PMP22, MPZ, GJB1, MFN2, TRPV4, HSPB1, HSPB8, GDAP and BSCL2.  He was 
also negative for common point mutations and large scale rearrangements of 
mitochondrial DNA in the muscle, and for common mutations in the nuclear 
encoded DNA polymerase gamma (POLG) and PEO1 genes. Full mitochondrial 
genome sequencing of muscle from the index patient identified a homoplasmic 
m.12241delC deletion in tRNA serine 2 (Fig. 5.3). This single base pair deletion was 
heteroplasmic (63%) in the mother’s blood. This variant has not been previously 
described and is located at a highly conserved nucleotide suggesting it may be 
pathogenic. Mitomap shows the presence of this variant in six samples out of 26,851; 
all located within different haplotypes, but no phenotypic data was available. 
Considering the difference in severity between the index case and the father and 
grandmother, the presence of this deletion in both index case and mother questions 
whether this might be an influencing factor on the phenotype of the index patient. 
This deletion is located in the T-stem of the tRNA Ser (AGY), in a short c-stretch, 
containing five G-C base pairs (Fig. 5.3). The m.12241 position is highly conserved 
amongst species, but depending on the nomenclature, this variant can also be 
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referred to as m.12239delC, a location that is much less conserved and is deleted in 
many species (Sprinzl et al., 1998). However, whilst other tRNA genes have shown 
to be more affected by mutations, only six mutations in the MT-TS2 are known to 
cause disease. These were associated with chronic intestinal pseudo-obstruction with 
myopathy and ophtalmoplegia, diabetes mellitus with deafness and retinitis 
pigmentosa with progressive sensorineural hearing loss, MELAS-like phenotype, 
and non-syndromic hearing impairment (Cardaioli et al., 2011).  
 
To find the causative variant, exome sequencing in the index patient, father and 
grandmother revealed novel variants in several genes which could explain the 
phenotype. In collaboration with Professor Zuchner’s lab in Miami, the candidate list 
was narrowed down to 34 possible candidates by a strict filtering approach for 
segregation of nonsynonymous heterozygous variants using the Genomes 
Management Application (GEM.app) software (See appendix II), one of them being 
the trafficking protein, kinesin binding 2 (TRAK2) gene.  
Trafficking protein, kinesin binding 2 
TRAK2, also known as Grif1 or Milton in drosophila, is a member of the molecular 
complex that links mitochondria to kinesin motors and is known to associate with 
MFN2 (Glater et al., 2006; Misko et al., 2010),  making it a suitable candidate to 
explain the phenotype, considering the lower activities of the complexes in the 
electron transport chain. TRAK2 is a 913-amino acid protein that was originally 
identified as a GABAA receptor-trafficking protein called GABAA receptor 
interacting factor-1 (GRIF-1) (Beck et al., 2002). It was renamed TRAK2 in 2006 
after studies showed it is a kinesin adaptor protein, part of the TRAK family of 
kinesin adaptors (Brickley et al., 2005; Smith et al., 2006). This family consists of 
two members, TRAK1 and TRAK2. Both bind to the cargo binding domain of 
kinesin-1 heavy chains to connect the motor protein and the cargo. One well-
established cargo in this context is the mitochondria.  
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Figure 5-3 (A) Electropherograms of the m.12441delC variant in the blood and muscle of the index 
patient and blood of the mother (III.2) in comparison with a control. b = blood; m = muscle (B) 
Localisation of the m.12241delC frameshift variant in tRNA serine 2 (C) Conservation of the basepare 
amongst different species.  
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Both TRAK1 and TRAK2 associate with the outer mitochondrial membrane GTPase 
protein Miro, facilitating mitochondrial transport (MacAskill et al., 2009; Brickley et 
al., 2011). Recent studies show that TRAK2 preferably binds to Dyenin/dynactin and 
is more abundantly expressed in dendrites. These differences in preference follow 
from their distinct conformations; TRAK2 adopts a folded conformation through an 
association between its NH2 and COOH termini, which inhibits the binding to 
kinesin-1 in low concentrations (Van Spronsen et al., 2013).  
The implications of mutations in TRAK2  
The transport of mitochondria is particularly vital in neurons because of their 
extended processes, and the disruption of mitochondrial transport is correlated with 
neurodegenerative diseases (Hollenbeck et al., 2005). So far, neither TRAK1 nor 
TRAK2 have been implicated in disease. Knockdown studies in hippocampal 
neurons show a decreased mitochondrial mobility in the TRAK1 shRNAi transfected 
cells, but no difference was found in TRAK2 shRNAi transfected cells (Brickley at 
al., 2011).  
 
In reference to CMT2, interaction between MFN2 and TRAK1/2 has been shown to 
mediate mitochondrial transport. CMT2A mutants result in an increased pause time 
and slower movement velocities in both anterograde and retrograde directions, 
similar as to what has been seen in the TRAK1 shRNAi transfected cells. Results 
suggest this occurs by affecting the functionality of the molecular adaptor complex 
that links mitochondria to kinesins and not by disrupting the formation, since the 
interaction is still present (Misko et al., 2010). With MFN2 being the most common 
gene in CMT2, TRAK2 presents as an interesting candidate gene to explain the 
phenotype in this family. Exome sequencing in our index patient revealed a novel 
variant in the TRAK2 gene, c.682C>T (p.Arg228Ter), which introduces a stop 
codon. This variant is located at a conserved location, part of a 297 amino acid 
stretch encoding a coiled-coil domain that shows high similarity to the Huntingtin-
associated protein-1 (HAP1). This protein is also a GABAA receptor β subunit 
interacting protein, similarly to TRAK2 (Kittler et al., 2004). HAP1 also functions as 
a kinesin adaptor protein, suggesting that this variant might affect the binding with 
kinesin (Twelvetrees et al., 2010).  
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Genetic screening of patients with CMT2 revealed two unrelated probands with 
variants in TRAK2  
Genomic DNA sequence analysis in a specifically selected cohort of 48 patients with 
CMT2 identified two different novel missense variants in two separate patients that 
were screened for variants in TRAK2: c.416G>A (p.Arg139Gln) in exon 5 and 
c.2099G>T (p.Ser700Ile) in exon 13 (Fig. 5.4). Neither was detected in 5250 
controls. Polyphen2 predicted c.416G>A to be damaging, contrasting the benign 
prediction of SIFT. The latter variant was predicted to be possibly damaging by both 
programs. Whilst the conservation of the c.416G>A variant is conserved over 
species and it is also located in the HAP1 homologous region, this is not the case for 
the c.2099G>T variant. Familial segregation analysis in the first patient revealed that 
the p.Arg139Gln variant was not present in the unaffected mother of the patient. 
DNA for the father was not available. The p.Ser700Ile variant in the second patient 
was found in the father of the patient, who was unaffected. This indicates that this 
variant is a polymorphism and not the cause of disease. Collaborators in Miami later 
on discovered an additional patient that presented with a CMT2 phenotype and a 
nonsense variant in the TRAK2 gene. However, this variant was also present in the 
non-affected father. The presence of a nonsense variant in this gene in a non-affected 
individual strongly suggests the variant found in our index case is not pathogenic and 
a hypothesis of haploinsufficiency would not be valid. Preliminary functional studies 
were already performed before this variant was found and will be discussed below.  
Clinical details of the patient with the c.416G>A missense variant in the TRAK2 
gene  
A 51 year-old male developed lower back pain at the age of 39. Two years later he 
developed numbness in his left leg. At the age of 43 he underwent L5/S1 discectomy 
and at that time he noticed wasting of the left calf. Over the years he had progressive 
wasting, weakness and sensory loss in the left leg and he noticed involvement of the 
right leg. His parents were not consanguineous; the mother was clinically examined 
and was unaffected and the father and one sibling were reportedly unaffected, 
although they were unavailable for examination. On neurological examination he 
walked with a bilateral foot drop and could not stand on toes or heels. He had distal 
wasting of the lower limbs, more pronounced on the left side. He had normal 
strength in the upper limbs and distal weakness in the lower limb.  
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Figure 5-4 Electropherograms and conservation of the novel missense variants found in the CMT2 patient cohort. 
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Triceps and knee reflexes were brisk, ankle jerks were absent and all other reflexes 
were present. Plantars were downgoing. Sensory examination showed decreased pin 
prick up to the distal half of the calf bilaterally. Vibration sense was reduced at the 
knees and proprioception was normal. Nerve conduction studies demonstrated 
length-dependent axonal peripheral neuropathy with predominant sensory 
involvement.  
Nonsense-mediated decay is present in fibroblasts of patients with variants in 
TRAK2  
PCR analysis of the extracted mRNA indicated degradation of the mutated mRNA 
by the nonsense-mediated decay (NMD) pathway rather than the production of 
truncated proteins. Figure 5.5 shows that the mRNA level of the mutated codon was 
found to be significantly lower than the WT codon, indicating NMD. This occurs by 
selectively degrading mRNA transcripts that contain premature termination codons 
(PTCs) from nonsense and frameshift mutations. Two different analysing programs 
were used to analyse the sequence, with different calling thresholds. The seqscape 
program did call the variant, whilst sequencher did not pick up the signal.  
 
Figure 5-5 cDNA analysis of the nonsense variation in TRAK2. The 
variant is not present, indicating NMD. 
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Subcellular localisation of TRAK2 in patient fibroblasts is normal 
In collaboration with the lab in Miami, localisation experiments were performed. 
COS7 cells were transfected with wild type and mutant c.682C>T TRAK2. This 
resulted in aggregation in puncta of the truncated TRAK2 in the nucleus (Fig. 5.6).  
 
Figure 5-6 Localisation experiments of TRAK2 in transfected COS7 cells, experiments performed in 
Miami.  
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To investigate whether the nonsense variant also affected the localisation of the 
endogenous protein, experiments were performed in patient fibroblasts. However, 
immunocytochemistry showed no morphological differences between the cultured 
fibroblasts from patient and controls (Fig. 5.7). The subcellular localisation of the 
TRAK2 protein remained the same in all the different cell lines and no puncta were 
present in the patient cell lines.  
 
 
Figure 5-7 Localisation of TRAK2 in patient fibroblasts in comparison with a MFN2 patient and two 
controls. Scale = 49 μm. Green: TRAK2; Blue: 4',6-diamidino-2-phenylindole (DAPI) staining for the 
nucleus. No difference in clustering of the truncated protein is found between the controls and both 
the TRAK2 and MFN2 mutated cell lines. TRAK2 patient = p.Arg228Ter; MFN2 patient = 
p.Ser249Thr. 
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Basal mitochondrial membrane potential in TRAK2 fibroblasts results in too 
variable results  
The mitochondrial membrane potential (ΔΨm) is an important indicator of 
mitochondrial health. An essential player in the maintenance of this potential is the 
electron transport chain. Since the activities of complex I, II and IV were below 
average in the index patient, abnormalities in the ΔΨm could elucidate the 
pathomechanism of this variant by examining whether it is involved in this pathway. 
Using TMRM as an indicator of ΔΨm, we investigated patient fibroblasts for 
abnormalities in comparison with other CMT2 patients and controls, but no 
significant differences between the cell lines were found (Fig. 5.8-5.9). Due to the 
high variance within the different fibroblasts and between the different controls, even 
after repeated experiments, it was difficult to draw any conclusions out of these 
results.   
 
 
Figure 5-8 Percentage of mitochondrial membrane potential of 
patient fibroblasts and MFN2 positive control in comparison with 
normal control fibroblasts. Results are standardised against control 
1. Statistical significance across groups was analysed using one-
way analysis of variance and Bonferroni's post hoc test to compare 
all data groups, but no significance was found.  
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The mitochondrial membrane potential is maintained by the mitochondrial 
respiratory chain  
In order to examine the mechanism of maintenance of ΔΨm, a series of 
mitochondrial toxins were applied to observe their effects on ΔΨm. Application of 
oligomycin, an inhibitor of the F1F0-ATPase, induced no response or a slight 
hyperpolarisation in all the cell lines as proton entry through the ATP synthase was 
constrained. This implies that the ΔΨm is still maintained by the mitochondrial 
respiratory chain. Application of rotenone, which inhibits complex I, occasionally 
showed depolarisation after addition, but this was observed with the same frequency 
in controls and patients. Complete depolarisation was estimated by addition of the 
mitochondrial uncoupler FCCP. No significant differences between the cell lines 
were observed. These results are in contrast with the initial screening that showed a 
decreased activity of complex I. However, activity levels were only slightly below 
average and repeated experiments showed borderline-low complex I and IV 
activities, within normal limits.  
 
 
Figure 5-9 Confocal images of the mitochondrial membrane potential of patient fibroblasts in 
comparison with a MFN2 positive control and normal control fibroblasts. No significant difference 
was found. Scale = 36 μm. TRAK2 patient = p.Arg228Ter; MFN2 patient = p.Ser249Thr.  
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TRAK2 discussion  
The index patient presented with a nonsense p.Arg228Ter variant in the TRAK2 
gene, which segregated in the family. Since the presence of a nonsense mutation 
could lead to NMD, this was investigated. mRNA analysis showed NMD was 
present, leaning towards a pathogenic mechanism of haploinsufficiency. Functional 
analyses were performed to look at the cellular localisation and the mitochondrial 
membrane potential, but these were too variable to draw any conclusions. It is 
important to remark that a patient with a mutation in MFN2 was used as control in 
these experiments. However, no remarkable changes were observed in this patient, 
which might indicate that using fibroblasts is not optimal for these experiments. 
Whilst this cell type has been used before for the purpose of mitochondrial 
membrane experiments (Bartolome et al., 2013), our results were too variable 
amongst the cell lines, so in future experiments, a different type of cell line might 
have to be used for estimation of the mitochondrial membrane potential in peripheral 
neuropathies. No optimisation to this process was made, due to the discovery of an 
additional patient with a nonsense variant that was also present in the non-affected 
father, clearly undermining the hypothesis of haploinsufficiency. Together with the 
lack of functional data pointing to an effect of the variant in the TRAK2 gene, 
evidence to prove the pathogenicity of this variant is weak.  
The discovery of a new candidate gene  
Several possible pathogenic variants still remained that could be causing this disease. 
In collaboration with Prof. Zuchner’s lab in Miami, experiments were later 
performed to investigate a frameshift in the neurofilament, heavy polypeptide 
(NEFH) gene: c.3010_3011delCA, resulting in a stop loss and the addition of 40 
extra aminoacids at the C-terminal end of the protein: p.Asp1004fs*56. After 
screening exome data of 322 families, one extra family with another heterozygous 
frameshift in NEFH was found. Segregation analysis identified the presence of the 
variant in all four affected siblings whilst the unaffected sibling and the father did 
not have the variant. Further functional experiments are still ongoing in the lab of 
Professor Zuchner regarding the pathogenicity of this gene.  
 
The phenotype of the index patient is more severe than his relatives. In cases like 
this, the presence of a genetic modifier can partially explain the variability observed. 
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The m.12241delC variant, located in the mitochondrial tRNA Serine 2 gene and only 
present in the index patient and not in the father or grandmother, highlights the 
possibility of mitochondrial mutations acting as genetic modifiers for disease, 
especially within families. However, this variant is located in a variable domain, and 
pathogenicity has not been proven.  
5.2.3 Family E   
Despite most of the research being focused on patients with an isolated neuropathy, 
in some cases the axonal neuropathy can be part of a more generalised disorder. 
Knowing the cause of disease in these cases could help us clarify the presence of the 
neuropathy and the mechanism underlying the molecular basis of pathology.  
Clinical details of family E 
For this part of the study, exome sequencing was performed by one of our 
collaborators on a consanguineous family with four affected individuals (Fig. 5.10). 
The patients presented with a spastic diplegic/quadriplegic cerebral palsy, 
intellectual disabilities and axonal neuropathy. The parents of the affected children 
were asymptomatic, with normal intellectual and adaptive functioning, without 
neuromotor findings. One sibling was unaffected (Fig. 5.10, II-4) 
 
 
Figure 5-10 Pedigree of family F 
The discovery of a candidate gene  
Filtering was performed by Michael Kruer’s lab in Sanford. Five interesting 
homozygous candidates were identified within the chromosome 10 autozygous 
regions that were found. Only two of these segregated in the family: Adducin 3 
(ADD3) and ATP-binding cassette, subfamily C, member 2 (ABCC2). 
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Mutations in ABCC2 cause a metabolic disease called Dubin-Johnson syndrome. 
This is a well-characterised autosomal recessive disorder that leads to episodic 
jaundice and conjugated hyperbilirubinemia in times of metabolic stress (Wada et 
al., 1998). Considering this protein is mainly expressed in the canalicular part of the 
hepatocyte and functions in biliary transport and mutations have never been 
associated with a neurological phenotype, the novel variant (p.Ser1342Tyr) 
identified in this gene was not investigated any further. Episodic jaundice was 
observed in affected family members and could be accounted for by the homozygous 
variant in this gene. Most likely, this variant co-segregates with the gene responsible 
for the neurologic phenotype, residing within the same haplotype block.  
The other variant found was in the ADD3 gene c.1100G>A; p.Gly367Asp, and this 
was the variant focused on during research on this family.   
y-adducin  
Adducin is a ubiquitously expressed protein that was first identified as an erythrocyte 
membrane-associated protein with calmodulin binding activity (Gardner at al., 
1986). Further experiments indicated that it is located at the spectrin-actin junctions 
and binds to spectrin-F-actin complexes, promoting binding of spectrin to F-actin. It 
exists as a tetramer, formed out of either α/β or α/γ heterodimers, with ADD3 
encoding for the γ-subunit. The p.Gly367Asp mutation in the γ-subunit is localised 
in the oligomerisation domain, between subunits 335-436, responsible for the 
binding with the α–subunit (Dong et al., 1995; Hughes et al., 1995; Y Matsuoka et 
al., 1999). ADD3 functions as an in vivo substrate for protein kinase A and C 
(PKA/PKC) and phosphorylation by PKA, but not PKC, reducing the affinity of 
spectrin-F-actin binding. Rho-kinase also phosphorylates α-adducin, resulting in an 
enhanced interaction of α-adducin with actin filaments in vitro (Kimura et al., 1998).  
The implications of mutations in y-adducin  
Thus far, inherited forms of spastic quadriplegic cerebral palsy have been known to 
be caused by the Kn motif-and ankyrin repeat domain-containing protein 1 
(KANK1) protein, which contributes to the regulation of actin polymerisation. This 
results from a deletion of approximately 225 kb, encompassing the KANK1 gene. 
Deletions were transmitted from unaffected fathers to affected children in an 
apparently maternally imprinted inheritance pattern. This means that KANK1 is 
expressed in healthy individuals who carry the deletion on the maternal allele and a 
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normal paternal allele, whereas in the affected individuals who are carriers of the 
paternal deletion and a normal maternal allele, expression is repressed (Lerer et al., 
2005). Due to the role of ADD3 in the binding of Spectrin-F-actin and the 
importance of KANK1 in the dynamics of the cytoskeleton, impaired adducin 
function may lead to abnormalities of the dynamic cytoskeleton as a pathogenic 
mechanism contributing to cerebral palsy and therefore makes an interesting 
candidate gene.  
 
Although the p.Gly367Asp variant was predicted to be benign by Polyphen 2, SIFT 
categorised it as pathogenic and conservation of this residue was conserved over all 
species (Fig. 5.11). Considering its location in the oligomerisation domain, it could 
be hypothesised that this variant will affect the function by impairing the binding 
with the α-subunit.  
 
Figure 5-11 Conservation of Glycine 367 in γ-adducin. 
Genetic analysis of the ADD3 gene revealed no mutations in ADD3 in a cohort of 
CMT2 patients   
A cohort of 172 patients with CMT2 was screened for mutations in only exon 9 of 
ADD3, while 96 patients were screened for mutations in the whole of the 16 exon 
gene. No mutations were found in any of the exons of the ADD3 gene in the cohort 
of CMT2 patients. Since the index patient presented with cerebral palsy as the main 
symptom, this is not surprising and indicates mutations in the ADD3 gene are 
unlikely to result in an isolated axonal neuropathy.  
Studies in patient fibroblasts indicate a loss of function mechanism  
As most of this work was done in collaboration with the Kruer lab in Sanford, the 
majority of experiments were performed there. Results showed that fibroblast lysates 
have an impaired actin capping activity in the mutant, comparable to a siRNA 
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knockdown of the ADD3 transcript, suggesting the p.Gly367Asp variant serves as a 
loss-of-function mutation. Co-localisation of the γ-subunit with the α-subunit of 
adducin showed a small decrease in the affected fibroblasts, suggesting an effect on 
the heteromer formation despite adequate protein levels of each isoform. Both 
proliferation and migration of cells were significantly increased in patient cell lines 
compared to controls. Morphologically, mutant fibroblasts demonstrated a lack of 
neurite-like processes as compared to wild type fibroblasts, consistent with the role 
of γ-adducin in controlling process outgrowth (Kruer et al., 2013).  
Endocytosis investigation showed no significant difference between control and 
patient cell lines    
Previous experiments by Torielli et al in 2008 showed that mutations in α-adducin 
result in a reduced overall endocytotic activity in cells transfected with the mutant 
form, associated with a lower internalisation rate of transferrin. Since mutations in 
genes causing CMT2 (e.g. DNM2) also impair clathrin-mediated receptor 
endocytosis (Bitoun et al., 2009), additional experiments were performed by me to 
investigate the effects of this mutation on the endocytotic pathway. 
 
Transferrin labelled with Alexa-Fluor 488 was used to estimate the uptake of 
transferrin in fibroblast cell lines, indicating the overall endocytotic activity. The 
expression of mutated human γ-adducin reduced the average slope of uptake (2.187 
± 0.6063 mean intensity/volume) compared with wild type adducin cells (2.862 ± 
0.5509 mean intensity/volume). However, this was not significant (Fig. 5.12). 
 
High variability in repeated experiments was present amongst the different cell lines, 
especially in patient cell lines (Fig. 5.13). Punctate structures were present in both 
the patient and control cells after 30 minutes, as can be seen in representative images 
for an incubation time of 20 and 30 minutes, shown in Figure 5.14. 
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Figure 5-12 Time course of transferrin internalisation in controls (•) and patients (▪) fibroblast cell 
lines. • = Control fibroblasts (n = 2; 2.862 ± 0.5509 mean intensity/volume)     ▪ = Patient fibroblasts 
(n =3; 2.187 ± 0.6063 mean intensity/volume). Statistical significance across groups was analysed 
using GraphPad Prism version 6.00 but no significance was found.  
 
 
Figure 5-13 Transferrin intensity in the different fibroblast cell 
lines. Results are standardised against control 1. Statistical 
significance across groups was analysed using one-way analysis of 
variance and Bonferroni's post hoc test to compare all data groups, 
but no significance was found.  
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Figure 5-14 Representative confocal images for the uptake of transferrin in human fibroblasts after an 
incubation period of 30 minutes. Scale bar = 49 μm. Green = Transferrin; Blue = DAPI staining for 
the nucleus.  
Basal mitochondrial membrane potential and response to mitochondrial toxins in 
ADD3 patient fibroblasts  
PKC has been suggested to associate with mitochondria and alter the mitochondrial 
membrane potential, especially in the oxidative stress response (Li et al., 1999; 
Majumder et al., 2001).  Considering the presence of a mitochondrial cluster of 
genes mutated in CMT, it was questioned whether this part of the pathway could be 
causing the axonal neuropathy in the patients and mitochondrial membrane potential 
experiments were performed accordingly.  
 
With the use of TMRM dye, the mitochondrial network was investigated in 
fibroblast cell lines of controls and patients. Figure 5.15 shows representative images 
of all the different cell lines, to compare the physiology of the mitochondrial 
network. The network was less outstretched in the diseased cell lines, especially II.1, 
but this was not consistent in all the patient cell lines.  
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Figure 5-15 Physiology of the mitochondrial network in patient and control fibroblasts. No significant 
differences were found. Scale = 36 μm.  
 
Figure 5-16 Mitochondrial membrane potential in the different 
fibroblast cell lines. Results are standardised against control 1. 
Statistical significance across groups was analysed using one-way 
analysis of variance and Bonferroni's post hoc test to compare all 
data groups, but was only found with control 3 in comparison with 
control 2 and E.II.2.  
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As was the case in patients with the TRAK2 variants in subchapter 5.2.1, no 
significant difference was observed between patient and control cell lines with the 
use of the TMRM dye in patients with ADD3 mutations (Fig. 5.16). High variability 
was found between the different cell lines and no conclusions could be drawn.  
 
By adding toxins, depolarisation after addition of oligomycin or complete 
depolarisation after addition of rotenone could occasionally be observed in both 
patient and control cell lines, but these results were not consistent. We could 
hypothesise that the mitochondrial membrane potential is still maintained by the 
mitochondrial respiratory chain, since the depolarisation occurred in both controls 
and patients and there were no significant consistent differences between the 
different cell lines.  
Discussion 
Previous experiments have already shown that abnormalities in the dynamic 
cytoskeleton, process outgrowth or protein trafficking can be linked to hereditary 
forms of cerebral palsy. In this study, a homozygous p.Gly367Asn mutation in 
ADD3 was found in a family with four children with spastic diplegic/quadriplegic 
cerebral palsy and intellectual disability. Experiments performed by the Kruer lab in 
Sanford indicated that this mutation impaired the heterodimer/heterotetramer 
formation, disrupting cellular actin polymer growth. Changes have been observed in 
process extension, cell migration, and proliferation.  
 
As part of this study, statistical analysis were performed to investigate whether there 
was a significant difference in the uptake of transferrin by endocytosis, but no 
differences were found between control and patient cell lines. This indicates that the 
pathomechanism is in all probability not originating from this pathway. However, 
the use of fibroblasts as a cell model has to be questioned, since this is not the main 
tissue of disease. The original study investigating endocytosis made use of 
transfected HEK293 cells, resulting in an overexpression model.  It can be asked 
whether the significance of these results would also be seen at normal physiological 
levels of mutated α-adducin. To answer this, endocytosis experiments would have to 
be repeated in patient related tissues from α-adducin patients.  By clarifying the role 
of adducin in cerebral palsy further, an explanation for the axonal neuropathy in 
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these patients might be uncovered; however, this is not the major focus of this thesis 
and further experiments were not implemented. 
 
Whilst investigation of the mitochondrial membrane potential was also performed in 
these cell lines, as with the use of fibroblasts in the TRAK2 fibroblasts, the results 
were too variable to draw any conclusions, adding to the observation that fibroblasts 
might not be the optimal cell type to use.  
 
In one of the patients, a more condensed network could be observed, but whether this 
is because of a fault in the network or whether the cell size was significantly smaller, 
we cannot conclude from this data. This was not consistently detected in all patients 
and repeated measurements or further experiments to compare the size of the 
mitochondrial network with the cell size were not performed.  
5.2.4 Family F  
Exome sequencing was performed in a family with AD inheritance consisting of 
three generations with eleven affected and one suspected affected family member out 
of 26. DNA was available for six affected, four unaffected and the one suspected 
affected member (Fig. 5.17; Individuals with DNA in bold). Exome sequencing was 
performed on two distant cousins (Fig. 5.17; Patients III-1, III-11) while linkage 
analysis was performed on four affected and three unaffected members (Fig. 5.17; 
Individuals II.2, III.1, III.2, III.4, III.5, III.8, III.11). Exome sequencing alone 
resulted in 7427 nonsynonymous variants shared between the two patients. With a 
cut-off MAF ≤ 0.5% in the public databases, this was reduced to a list of 80 variants.   
 
Linkage analysis was performed twice with a different subset of SNPs and resulted 
in five linkage regions (Fig. 5.18). All of these regions resulted in a maximum lod 
score of 2 and cut-offs were chosen at the zero intersection. Of the remaining 17 
chromosomes, eight had a lod score below -2 over the whole chromosome and could 
be excluded based on the linkage analysis (See appendix III). Using these linkage 
areas, the candidate gene list was reduced to 16 variants. By comparing these 
variants to internal databases, three could be excluded as artefacts from the exome 
sequencing process, whilst two other variants were located in highly polymorphic 
genes. The remaining eleven variants were all investigated by Sanger sequencing for 
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which eight did not segregate in the family, one could not be confirmed with Sanger 
sequencing and the remaining two were present in the EVS database (Table 5.1). The 
MAF ≤ 0.5% cut-off is mainly used to assure no pathogenic variants might be 
missed, and the presence of 22 control individuals with the same variant highly 
suggests the eukaryotic translation initiation factor 2D (EIF2D) gene will not be 
responsible for the phenotype. Similarly, since incomplete penetrance is not expected 
in patients with dHMN, having nine control individuals with the same variant highly 
questions the pathogenicity of the missense variant in the acyl-coa synthetase, 
bubblegum family, member 1 (ACSBG1) gene. During the write-up of this project, 
the ExAc Browser, consisting of exome data of 60,706 unrelated individuals 
sequenced as part of various disease-specific and population genetic studies, was 
also made publicly available and both variants were present in respectively 218 and 
68 individuals, suggesting non-pathogenicity.  
 
However, segregation analysis had already been performed and the latter variant 
segregated in the family, but was not present in the member with suspected disease 
status. This individual was last seen at age 16 and has not been officially diagnosed 
with dHMN. Unless found in other patients with a similar phenotype, follow-up of 
this gene will not be performed. As the implementation of linkage analysis returned 
no pathogenic variants in the linkage areas and lod scores were not higher than 3, the 
list of all nonsynonymous shared heterozygous variants was re-analysed to confirm 
no pathogenic variants were missed. However, none of the variants outside the 
linkage areas that were not present in any of the public databases or in our internal 
database segregated in the family (Table 5.2).  
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Figure 5-17 Pedigree of Family F. Black symbols represent patients with CMT2, grey symbols represent individuals with unknown clinical status.   
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Figure 5-18 Linkage areas of family F located on chromosomes 1,5,7,15 and 19. 
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Gene Exonic Function X1000g -
2012 
SIFT PolyPhen2 Mutation 
Taster 
GERP 
score 
OMIM Signature Status 
PRDM16 nonsynonymous NA D NA D 3.5 605557 1_3342158_G_A Doesn't segregate  
CLSTN1 nonsynonymous NA B B B 4.39 611321 1_9809615_C_T Doesn't segregate  
LCE1F nonframeshift 
substitution 
NA NA NA NA NA 612608;6
12605 
1_152749038_GTGGTGG_GCTGC
TGCAGCTCTGGGGGTGGTGG 
Doesn't segregate  
KIF14 nonsynonymous 0.0023 B D D 2.7 611279 1_200574499_T_C Doesn't segregate  
EIF2D nonsynonymous 5.00E-04 B B B 5.37 151625 1_206772388_T_C Present in 218 genotypes 
in ExAC Browser  
NUP205 nonsynonymous NA NA B B 3.04 NA 7_135290962_C_T Doesn't segregate  
PDIA4 nonsynonymous NA D D D 4.18 NA 7_148718180_C_G Doesn't segregate  
RYR3 nonsynonymous NA NA NA NA NA 180903 15_34030702_G_A Doesn't segregate  
SPTBN5 nonsynonymous NA NA NA NA NA 605916 15_42169056_G_A Doesn't segregate  
ACSBG1 nonsynonymous 0.0014 B D D 5.02 NA 15_78475108_T_A Present in 68 genotypes 
in  ExAC Browser 
ADAMTS7 frameshift 
insertion 
NA NA NA NA NA 605009 15_79058195_-_CCTGGGT Not present in sanger 
sequencing  
Table 5-1 List of eleven candidate genes for Family F within the linkage areas. NA = Not applicable; B = Benign; D = Damaging 
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Gene Exonic 
Function 
X1000g 
2012 
SIFT PolyPhen2 Mutation 
Taster 
GERP 
score 
OMIM signature Status  
ACOT12 Nonsynonymous NA B B B -5.32 NA 5_80626728_T_C Doesn't segregate 
SNRPC nonframeshift 
insertion 
NA NA NA NA NA 603522 6_34725662_-_CTT Doesn't segregate 
TBP nonframeshift 
deletion 
NA NA NA NA NA 608964; 
600075 
6_170871097_GCAGCAGCA
_- 
CAG-stretch 
ASCL1 nonframeshift 
insertion 
NA NA NA NA NA 100790 12_103352208_-_CAG CAG short stretch 
RFX4 Nonsynonymous NA B D D 5.55 603958 12_107109277_A_G Doesn't segregate 
CCDC63 Nonsynonymous NA B B B -7.23 NA 12_111336781_C_A Doesn't segregate 
GPC5 NA NA NA NA NA NA 602446 13_92050913_AGGCGGCG
GCGGCGGCGGCAGTGG_- 
Intronic 
YY1 nonframeshift 
deletion 
NA NA NA NA NA 600013 14_100705803_CCA_- Present in 57 genotypes in 
ExAC Browser 
SPATA22 NA NA NA NA NA NA NA 17_3374975_CA_- Spermatogenesis gene  
MX1 Nonsynonymous NA B B B -1.4 147150 21_42830594_G_A Doesn't segregate 
HLA-H frameshift 
deletion 
NA NA NA NA NA NA 6_29857237_G_- Known pseudogene 
Table 5-2 List of novel variants outside the linkage areas in family F. NA = Not applicable; B = Benign; D = Damaging
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5.2.5 Family G  
Family G was originally seen in Brighton Hospital 13 years ago and was referred to 
our clinic after a couple of years. There were seven affected patients in four 
generations with an AD inheritance pattern. DNA was available for four affected and 
six unaffected family members (Fig. 5.19; Individuals in bold). Exome sequencing 
was performed on four family members at different time points along the project, 
resulting in only three exomes with high quality results (Fig. 5.19; Patients I.2, II.2, 
III.2). As patient II.2 did not add any value to the analysis of shared exomes, only 
data of patients I.2 and III.2 were used. This resulted in 13472 shared variants 
amongst those two individuals, out of which 71 were nonsynonymous heterozygous 
variants with a MAF ≤ 0.5%. Interestingly, when comparing the data of all three 
patients, only 68 shared variants were found. This indicates that even though 
coverage was sufficient, not all variants might have been called with this technique 
and caution is necessary.  
 
 
Figure 5-19 Pedigree of Family G. Black symbols represent patients with CMT2. 
Repeated linkage analysis in all affected and unaffected members resulted in six 
small linkage areas on four different chromosomes that only reached a lod score of 1 
(Fig. 5.20). Out of the 71 variants, only one was present in the linkage area, a 
missense variant in exon 8 of the tryptophanyl-tRNA synthetase (WARS) gene: 
c.818A>T (p.Asp273Val). Considering the involvement of tRNA-synthetases in the 
pathomechanism of CMT, WARS would be an excellent candidate gene. However, 
segregation analysis indicated the presence of this variant in individual II-5, who is 
unaffected, suggesting this is not the causative variant.  
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Figure 5-20 Linkage areas of Family G located on chromosomes 1,13,14 and 17. 
Of 71 original nonsynonymous heterozygous variants with a MAF ≤ 0.5%, there are 
still 34 shared novel variants between the two patients outside the linkage areas that 
could qualify as a candidate gene (Table 5.3). Of these, only one segregated. This 
variant in the WD repeat domain 48 (WDR48) gene is located on one of the 
chromosomes that was originally excluded due to the LOD score being below -2 
(See appendix IV) and results in a c.797C>G variant in exon 9. This will change the 
polar, uncharged proline 266 to a positively charged arginine. In a recent report by 
Novarino et al., a homozygous 3 bp-deletion was identified in this gene in a patient 
with spastic paraplegia (Novarino et al., 2014). This variant (c.1879_1881delAAG) 
resulted in the deletion of a glutamic acid at position 628 (p.Glu628del). 
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Gene Exonic Function X1000g 
2012 
SIFT PolyPhen2 Mutation 
Taster 
GERP 
score 
OMIM signature Status 
KCNA10 nonsynonymous  NA D B B 1.91 602420 1_111061292_G_A Not present in Sanger sequencing  
WDR77 nonsynonymous NA NA P B 2.99 603270; 
611734 
1_111991772_G_A Not present in Sanger: C-stretch  
CTTNBP2NL nonsynonymous NA B P B 5.72 NA 1_112998758_G_A Doesn't segregate 
ITGA10 nonsynonymous  NA B D B 4.5 604042 1_145538779_C_T Doesn't segregate 
CNST nonsynonymous NA B B B 1.8 NA 1_246829025_A_G Doesn't segregate 
DHX57 nonsynonymous NA B D D 5.24 NA 2_39042757_G_A Doesn't segregate 
MTERFD2 nonsynonymous NA D P B -3.35 NA 2_242039227_G_A Doesn't segregate 
WDR48 nonsynonymous NA B B D 5.56 612167 3_39119698_C_G Segregates  
ZNF167 nonsynonymous  NA B B B 3.63 NA 3_44612019_G_A Doesn't segregate 
RPL29 nonframeshift 
insertion 
NA NA NA NA NA 601832 3_52027880_-
_GGGCCT 
Doesn't segregate 
ITIH3 nonsynonymous NA NA NA NA NA 146650 3_52836502_G_T Doesn't segregate 
FLNB nonsynonymous  NA D D D 4.28 603381 3_58083678_C_T Doesn't segregate 
RP1 nonsynonymous  NA D B B -1.78 180100; 
603937 
8_55539000_A_G Doesn't segregate 
SLC10A5 nonsynonymous  NA B D B 5.57 NA 8_82606490_A_C Doesn't segregate 
COL14A1 nonsynonymous  NA B D B 4.17 120324 8_121243810_A_G Doesn't segregate 
NSMCE2 frameshift 
deletion 
NA NA NA NA NA NA 8_126194426_T_- Doesn't segregate 
CSNK2A1 nonsynonymous  NA B B B 4.89 115440 20_467035_C_T Doesn't segregate 
DYRK4 frameshift NA NA NA NA NA 609181 12_4719356_A_- Doesn't segregate 
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deletion 
MLL2 nonsynonymous  NA NA NA NA NA 602113 12_49447305_G_A Doesn't segregate 
LMBR1L nonsynonymous  NA D D D 5.38 610007 12_49491774_A_C Doesn't segregate 
KRT85 nonsynonymous  NA B B B 4.58 602767 12_52761167_A_T Keratin gene  
SRGAP1 nonsynonymous  NA B D B 4.21 606523 12_64472790_G_A Doesn't segregate 
PPTC7 nonframeshift 
deletion 
NA NA NA NA NA 609668 12_111020757_CCG_- Doesn't segregate 
PABPC3 nonsynonymous  NA D B B 0.935 604680 13_25671466_A_G Doesn't segregate 
PABPC3 nonframeshift 
deletion 
NA NA NA NA NA 604680 13_25670424_AAG_- Doesn't segregate 
WARS nonsynonymous  NA D P D 4.5 191050 14_100808907_T_A Doesn't segregate 
PIF1 nonsynonymous  NA D D D 4.99 610953 15_65110540_T_A Doesn't segregate 
C15orf37 nonframeshift 
deletion 
NA NA NA NA NA NA 15_80215177_CAG_- Intronic + present in EVS server  
KRTAP9-1 nonsynonymous  NA NA NA NA NA NA 17_39346629_A_G Keratin gene  
KRT33B stopgain  NA NA NA A 4.18 602762 17_39522769_C_A Keratin gene  
KRT17 frameshift 
insertion 
NA NA NA NA NA 148069 17_39780702_-_C Keratin gene  
RRBP1 nonsynonymous  NA NA NA NA NA 601418 20_17639816_T_G Not present in Sanger sequencing 
- Repetitive stretch  
RRBP1 nonsynonymous  NA NA NA NA NA 601418 20_17639786_T_G Not present in Sanger sequencing 
- Repetitive stretch  
XKRX nonsynonymous  NA B NA B 2.99 300684 X_100183238_A_G Doesn't segregate 
Table 5-3 Shared, novel, nonsynonymous variants in family G. NA = Not applicable; B = Benign; D = Damaging; P = Probably damaging.
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c.1879_1881delAAG was found in one patient who presented with hypertonia, 
nystagmus, increased patellar but absent achilles tendon reflexes, mild learning 
disabilities and peripheral neuropathy, labelled by the authors as spastic paraplegia-
60 (SPG60). Whilst this has been characterised as recessive inheritance, the presence 
of peripheral neuropathy in this patient suggests this might be the causative variant 
in the family. This is supported by the presence of the missense variant in only one 
person out of 60,706 available in the ExAc Browse. The most recent update of 
Polyphen-2 predicts this variant to be possibly damaging, whilst the SIFT prediction 
categorises it as benign. Conservation of this amino acid is preserved over all 
representative species (Fig. 5.21).  
 
Figure 5-21 Conservation of Proline 266 in 
the WDR48 gene.  
WDR48 forms stable complexes with deubiquitinating enzymes in the endosomal 
sorting complexes, is required for enzymatic activity and is linked to lysosomal 
trafficking (Park et al., 2002). Defects in the endosomal-lysosomal pathways have 
been recurrently linked to inherited neuropathies such as CMT, suggesting a possible 
pathogenic role for variants in WDR48. Mice models of the gene resulted in 
embryonic lethality in homozygous mouse; heterozygous mice were smaller and 
showed defects in skeletal development (Park et al., 2013). No functional studies 
were performed due to lack of a second family with potential pathogenic variants in 
this gene, but WDR48 will be treated as a candidate gene in the future.  
5.2.6 Family H  
The following family had a history of AD dHMN in four generations and contained 
nineteen affected family members out of 42. DNA was available for six affected and 
one unaffected members (Fig. 5.22; Individuals in bold).  
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Figure 5-22 Pedigree of Family H. . Black symbols represent patients with CMT2, grey symbols represent individuals with unknown clinical status.
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Exome sequencing was performed on two cousins and all the available DNA 
samples were used for linkage analysis (Fig. 5.22; Patients IV.8, IV.11). After 
analysis of the data, 5792 shared, nonsynonymous, heterozygous variants remained. 
Filtering these variants by examining their presence in the public databases and the 
segment duplication coefficient reduced the list to 196 possible pathogenic variants. 
As this family was already screened for the relevant genes for dHMN, no mutations 
in known pathogenic genes were expected to be found. However, a mutation in the 
HSPB1 gene was discovered (c.544C>G). This is the third mutation affecting the 
same amino acid, with both c.544C>T and c.545C>T having been reported before 
(Kijima et al., 2005, Evgrafov et al., 2004). This gene was originally sequenced in 
these patients and no mutation was present, so sample confusion was suspected. 
Linkage analysis resulted in a linkage area on chromosome 7 that overlapped with 
the HSPB1 gene hence Sanger sequencing was repeated twice, which resulted in the 
presence of the mutation in only one of the runs. This was traced back to a 4-bp 
insertion in intron 2 on the same allele as the missense mutation in exon 3. This was 
captured as part of the exon 3 PCR and occurs in an extremely G/C rich region as an 
insertion of a GGTG within a short repeat sequence. The addition of the extra 4 bp 
into this repeat might cause preferential amplification of the wild type allele and 
provide an explanation for missing the missense mutation in diagnostic sequencing. 
These results were repeated on diagnostic levels to provide the family with a genetic 
diagnosis. 
5.2.7 Family I   
A small family presented with seven individuals characterised with AD CMT2 over 
four generations. DNA was available for four affected and one unaffected member 
(Fig. 5.23; Individuals in bold). Exome sequencing was performed on two cousins 
and the daughter of one of the cousins (Fig. 5.23; Patients III.2, III.4 and IV.1), 
which resulted in 11197 shared variants. After analysis, 30 shared nonsynonymous 
heterozygous variants with a MAF ≤ 0.5% were present. Of those, 19 were novel 
variants. After comparison with the in-house database, a candidate list of 12 genes 
was created (Table 5.4). Of these, three genes segregated in the family, with only the 
nonsense variant present in 15 individuals in the ExAc Browser database. One of the 
missense variants was located in the Repulsive guidance molecule, domain B 
(RGMb) gene – also known as DRAGON (Samad et al., 2004).  
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Figure 5-23 Pedigree of family I. . Black symbols represent patients with CMT2. 
The c.979G>A variant (p.Gly327Ser) is located in a conserved domain (Fig. 5.24), 
with the glycine aminoacid being conserved over multiple species. Both SIFT and 
Polyphen predicted this variant to be pathogenic and no presence in controls was 
found. RGMb is a glycosylphosphatidylinositol-anchored member of the repulsive 
guidance molecule family, which is expressed early in the developing nervous 
system, and has been identified as a factor important for neuronal adhesion in DRG 
neurons by homophilic interactions (Samad et al., 2004). All repulsive guidance 
molecules were characterised as bone morphogenetic protein (BMP) co-receptors 
that enhance BMP signalling (Samad et al., 2005) and it has been suggested RGMb 
is directly involved in the suppression of IL-6 expression through the p38 MAPK 
and Erk1/2 pathways (Xia et al., 2011). This variant segregated in all DNA samples 
of the family but no second family was found when we screened a cohort of 250 
CMT2 patients for mutations. Another missense variant was located in the MORC2 
gene. MORC2 has an ATPase-dependent chromatin remodelling function and has 
been speculated to be involved in DNA transcription (Li et al., 2013). Recent studies 
have implied the involvement of MORC2 in human cancers (Wang et al., 2010; 
Tuupanen et al., 2014) by efficiently integrating growth factor signalling with DNA 
repair processes (Li et al., 2013). The variant found in the family results in the 
change of a highly conserved negative aspartic acid to a neutral aspargine (Fig. 
5.24). Whilst this is located in a conserved area, it is not part of a functional domain. 
Both PolyPhen and SIFT predict this variant to be pathogenic and no presence in 
controls was found. This variant segregated in the family but no further 
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investigations were made and both RGMb and MORC2 will be regarded as a 
candidate gene in future.  Lastly, the deletion of a G in the IDE gene will result in a 
frameshift in the first exon of the gene, leading to a stopcodon instead of Leucine. 
However, this variant is present in 12 alleles in the EVS server and 15 in the ExAc 
Browser, resulting in prioritisation of the two other variants.   
 
 
Figure 5-24 Conservation of the variants in the RGMb 
(upper frame) and MORC2 (lower frame) genes. 
During the write-up of this thesis, one of the family members (III.2) was seen in 
clinic again and mentioned the possible affected status of family member III.6. This 
patient will be brought into clinic to establish the correct clinical status, which might 
result in different candidate genes.  
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Gene Exonic Function X1000g 
2012 
SIFT PolyPhen2 Mutation 
Taster 
GERP 
score 
OMIM signature Status 
NADK nonframeshift 
insertion 
NA NA NA NA NA 611616 1_1684375_-_CTC Not present in sanger sequencing  
RGMB nonsynonymous NA B NA NA NA 612687 5_98128999_G_A Segregates 
DIP2C nonsynonymous NA B D D 5.5 611380 10_428681_C_G Doesn't segregate 
IDE stopgain NA NA NA NA NA 146680 10_94333764_G_- Segregates 
PRSS23 nonsynonymous NA B B B 4.75 NA 11_86519328_G_A Doesn't segregate 
MGA nonsynonymous NA B NA NA NA NA 15_41991118_G_T Doesn't segregate 
EPB42 nonsynonymous NA NA NA NA NA 177070 15_43494077_C_T Doesn't segregate 
PSMD8 nonsynonymous NA B NA NA NA NA 19_38865459_C_T Doesn't segregate 
FAM71E1 nonsynonymous NA D B B -2.67 NA 19_50971037_A_G Doesn't segregate 
ADRA1D nonsynonymous  NA B B D 3.81 104219 20_4228848_C_T Doesn't segregate 
TGM2 nonsynonymous  NA B D B 2.3 190196 20_36789956_C_T Doesn't segregate 
MORC2 nonsynonymous NA B D D 5.37 NA 22_31333672_C_T Segregates 
Table 5-4 Shared, novel, nonsynonymous variants in family I. NA = Not applicable; B = Benign; D = Damaging.
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5.2.8 Family J  
A small family presented with AD HSAN in three generations (Fig. 5.25). DNA was 
available for five family members and exome sequencing was performed on patients 
II.1 and III.3. This resulted in 14313 variants shared between the two patients. After 
exclusion of synonymous variants or those with a frequency over 0.5%, a list of 55 
shared variants was produced. Of these, 30 were novel variants of which six 
segregated in the DNA samples available for the family (Table 5.5).  
 
 
Figure 5-25 Pedigree of Family J. 
 
The variants were located in the following six genes: FAM126A, CNTRL, GOLGA2, 
SSTR5, TBC1D24 and PKMYT1. The missense variant in SSTR5 could be found in 
144 individuals in the ExAc Browser, indicating its polymorphic nature. Whilst the 
missense variant in PKMYT1 was found in six individuals, suggesting non-
pathogenicity, all the other variants were found in three or fewer individuals. 
 
The most interesting variation in the context of HSAN is in the family with sequence 
similarity 126, member a (FAM126A) gene. Recessive mutations in this gene have 
been found in patients with congenital cataract, progressive neurological impairment 
and diffuse myelin deficiency, characterised as HCC (Zara et al., 2006; Ugur et al., 
2008). All patients showed slowly progressive pyramidal and cerebellar dysfunction, 
muscle weakness and wasting predominantly in the lower limbs and most of them 
became wheelchair bound. Clinical features suggested FAM126A as essential for 
proper myelination in both the central and peripheral nervous system.  
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Gene Exonic 
Function 
1000g 
2012 
SIFT PolyPhen2 Mutation 
Taster 
GERP 
score 
OMIM Signature Status 
CDK11A nonframeshift 
insertion 
NA NA NA NA NA 176873; 
116951 
1_1647900_-_TTCTTT Not present in sanger sequencing  
NADK nonframeshift 
insertion 
NA NA NA NA NA 611616 1_1684375_-_CTC Not present in sanger sequencing  
DENND4B nonframeshift 
substitution 
NA NA NA NA NA NA 1_153907278_CCTGC
TGCT… 
Long Q stretch 
RIF1 nonsynonymous  NA B B NA -3.33 608952 2_152322348_T_C Doesn't segregate 
FANCD2 nonsynonymous NA D D D 5.11 227646; 
227650 
3_10107554_C_G Doesn't segregate 
MAGI1 nonframeshift 
substitution 
NA NA NA NA NA 602625 3_65425560_TCTGCT
GCTGCT… 
Long Q stretch 
FAM126A nonsynonymous NA D B B 3.71 610531 7_22985650_G_A Segregates + Present in 1 genoptye 
in the ExAc browser  
AC118759.1 nonsynonymous NA NA NA NA NA NA 7_100549592_T_A Mucin gene 
AC118759.1 nonsynonymous NA NA NA NA NA NA 7_100549787_C_T Mucin gene  
MUC3A nonsynonymous  NA NA NA NA NA NA 7_100552535_G_A Mucus gene  
TRBV5-6 nonsynonymous NA NA NA NA NA NA 7_142131832_C_T Not present in sanger sequencing  
PCSK5 nonsynonymous NA NA NA NA NA 600488 9_78790136_T_C Not present in sanger sequencing  
CNTRL nonsynonymous NA D P B 5.11 605496 9_123912532_T_C Segregates  
GOLGA2 nonsynonymous  NA B B D -3.08 602580 9_131022937_C_T Segregates + Present in 3 genoptyes 
in the ExAc browser 
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MUC6 nonsynonymous NA NA NA NA NA 158374 11_1016890_G_A Mucin gene 
MUC2 nonframeshift 
insertion 
NA NA NA NA NA 158370 11_1092623_-_AAC Mucin gene  
C14orf23 nonframeshift 
insertion 
NA NA NA NA NA NA 14_29261307_-_CAA Doesn't segregate  
DICER1 nonframeshift 
deletion 
NA NA NA NA NA 606241 14_95563003_CTC_- Doesn't segregate  
SSTR5 nonsynonymous NA D P B 4.52 182455 16_1129218_C_T Segregates + Present in 144 
genotypes in the ExAc browser 
TBC1D24 nonsynonymous  NA NA NA B 0.0379 NA 16_2550330_C_T Segregates 
PKMYT1 nonsynonymous  NA B B B 2.37 602474 16_3024281_C_T Segregates + Present in 6 genotypes 
in the ExAc browser 
AC009113.1 nonsynonymous NA NA NA NA NA NA 16_89299807_A_G No gene there  
RRBP1 nonsynonymous  NA NA NA NA NA 601418 20_17639786_T_G Not present in Sanger sequencing - 
Highly repetitive stretch 
OGFR nonsynonymous  NA B NA B -3.64 606459 20_61444633_G_A Doesn't segregate 
IGLV5-45 nonsynonymous NA NA NA NA NA NA 22_22730696_C_T Doesn't segregate 
IGLV5-45 nonsynonymous  NA NA NA NA NA NA 22_22730702_A_G Doesn't segregate 
IGLV5-45 nonsynonymous  NA NA NA NA NA NA 22_22730788_G_A Doesn't segregate 
IGLV5-45 nonsynonymous NA NA NA NA NA NA 22_22730800_A_C Not present in Sanger sequencing 
FAM155B nonframeshift 
deletion 
NA NA NA NA NA NA X_68725197_CTG_- Deletion in CTG stretch, present in 
EVS server on different location  
Table 5-5 Shared, novel, nonsynonymous variants in Family J. NA = Not applicable; B = Benign; D = Damaging; P = Probably damaging.
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To date, six families have been found with mutations in this gene, five of which were 
splice site defects and one was a missense mutation, resulting in lower levels of the 
protein (Zara et al., 2006). The c.C1124T (p.Pro375Leu) missense variant in family J 
resulted in a substitution of proline to a leucine, both nonpolar amino acids. This 
variant has only been found in one allele in the ExAc browser, which does not 
exclude it from being pathogenic. In multiple species, a threonine can be found on 
position 375 instead of a proline, indicating that the amino acid is not conserved 
(Fig. 5.26). Whilst SIFT predicts the substitution to be benign, Polyphen2 is 
contradicting. Considering the prevalence of multiple segregating genes, this has not 
been taken forward.  
 
Figure 5-26 Conservation of the variant in the FAM126A gene. 
5.2.9 Family K 
Once again in collaboration with Professor Zuchner’s lab in Miami, exome 
sequencing was performed on one patient of a complex family to identify mutations 
in known CMT genes (Fig. 5.27). A list of 93 candidates was established by the lab 
in Miami, incorporating several interesting candidate genes (See Appendix V). After 
careful clinical evaluation the phenotype resembled a lower SMA phenotype, which 
is characteristic for mutations in DYNC1H1. This brought up a c.1502G>C 
(p.Arg501Pro) variant in the Bicaudal D homolog 2 (Drosophila) (BICD2) gene as a 
potential cause for the disease. BICD2 is an adaptor protein interacting with the 
dynein-dynactin motor complex, facilitating trafficking of cellular cargos that are 
critical to motor neuron development and maintenance. After confirming the 
segregation of this variant in the family, 39 more cases with a similar phenotype 
were screened for mutations in this gene by me.  
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Figure 5-27 Pedigree of Family K. 
One more patient was found with a mutation in this gene: c.565A>T (p.Ile189Phe) 
(Fig. 5.28). This was a de novo case where the unaffected parents did not carry the 
mutation. Both of the patients presented with autosomal-dominant congenital SMA 
(DCSMA) and upper moto neuron signs (UMN). In collaboration with other centres, 
four more DCSMA (+UMN) or HSP families were found with mutations in this 
gene. Functional studies performed by Dr. Alex Rossor showed a higher affinity of 
the mutated proteins to the dynein-dynactin complex, resulting in altered cellular 
trafficking processes. Simultaneously, two more groups published their studies on 
mutations in BICD2 in patients with DCSMA, adding five separate families to the 
original six (Neveling et al., 2013; Peeters et al., 2013).  
 
Figure 5-28 Electropherograms of mutations in 
BICD2. 
As stated before, BICD2 is an adaptor protein interacting with the dynein-dynactin 
motor complex and the small ATPase RAB6, thereby facilitating the trafficking of 
key cellular cargos such as mRNA, Golgi, and secretory vesicles. Transfected cells 
showed a higher binding affinity between BICD2 and the Dyenin-Dynactin complex 
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when mutated. One study showed accumulation of BICD2 in the perinuclear region 
for one mutation, colocalised with RAB6, potentially decreasing anterograde 
trafficking of secretory vesicles to the plasma membrane (Oates et al., 2013). 
However, opposite results were obtained in the study by Peeters et al., showing 
decreased colocalisation with RAB6A for two other mutations. It is not clear 
whether the alterations in BICD2 lead to gain-of-function or dominant-negative loss-
of function effects, nonetheless it can be concluded BICD2 mutations are linked to 
SMA with dominant inheritance. 
5.2.10 Family L  
In collaboration with Dr. Wilson Marques from Brazil, exome sequencing was 
performed on one index patient from a large family with CMT2 and HMN. This was 
initially performed to examine known pathogenic mutations. When no such 
mutations were found, two additional family members were sequenced. Surprisingly, 
a known pathogenic mutation in the MFN2 gene was found in these two patients: 
c.494A>G. Re-examination of the  raw data files of the index patient revealed this 
area was covered but the mutation was only present in 1 out of 60 reads (Fig. 5.29). 
Sanger sequencing indicated this mutation in all patients, resulting in an explanation 
for the observed phenotype.  
 
Figure 5-29 Coverage of the MFN2 variant in the original exome sequencing. The mutation was only 
present in 1 out of 60 reads.  
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5.3. Discussion  
Exome sequencing was performed in several families resulting in a pathogenic gene 
in five families. Previously pathogenic genes were discovered after performing 
exome sequencing in two undiagnosed families.  
 
In family H, diagnostic guidelines had already indicated the possibility of mutations 
in the HSPB1 gene but Sanger sequencing of the gene showed negative results. 
However, during analysis of the exome data, a c.544C>G variant in this gene was 
found, resulting in a novel mutation of Proline 181 to Alanine. Previous reports have 
stated mutations changing the same exact Proline to both Serine or Leucine in 
patients, indicating the pathogenicity of mutations in this amino acid. Initial Sanger 
sequencing of HSPB1 in the index cases did not call this variant due to a 4-bp 
insertion in intron 2 on the same allele, leading to a preferred amplification of the 
wild type allele and masking the pathogenic variant. This requires caution whilst 
screening for mutations in HSPB1 in undiagnosed families with CMT. Previous 
families screened for mutations in HSPB1 were repeated with new primers to 
investigate whether pathogenic mutations were missed, but no further mutations 
were found.  
 
In family L, a known pathogenic mutation in MFN2 was found. Exome sequencing 
to look for pathogenic mutations in the index case resulted in no positive hits, 
leading to additional exome sequencing in two more family members. This showed a 
c.494A>G variant that has been found in two previous families with axonal 
neuropathy, one of them sporadic and one familial case. This variant was only called 
in 1 out of 60 reads of the exome sequencing of the original index case and 
subsequently was not listed in the variant file. Segregation analysis confirmed the 
presence of the variant in the four generation family, reaffirming the pathogenic 
status of the variant in the family.  
 
In addition to the known pathogenic genes, three novel genes were suggested as 
pathogenic cause for the disease in three separate families. In family D, a nonsense 
variant in the TRAK2 gene was initially pursued and haploinsufficiency was 
suspected to result in an axonal neuropathy. However, the presence of an additional 
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patient with a nonsense variant which also occurred in the unaffected father quickly 
undermined this hypothesis and together with the lack of functional data, evidence 
was low to establish TRAK2 as the causative gene. The focus of investigation was 
shifted to a frameshift variant in the NEFH gene that resulted in a stop-loss and the 
addition of 40 extra aminoacids. Functional experiments are ongoing by our 
collaborators in Miami in cell lines and zebrafish models to investigate the 
pathogenicity of the variant. 
 
In Family E, a homozygous missense mutation in the ADD3 gene was the primary 
candidate to explain the phenotype of spastic diplegic/quadriplegic cerebral palsy, 
intellectual disabilities and axonal neuropathy. Functional investigation of fibroblasts 
performed by the Kruer lab indicated a loss of function mechanism of the mutation 
by impairing heterodimer/heterotetramer formation and disrupting the regulation of 
cellular actin polymer growth. Genetic forms of cerebral palsy are rare and the lack 
of an additional family indicates the rarity of mutations in ADD3. Since no further 
mutations were found in patients with an isolated peripheral neuropathy, chances are 
low that variants in this gene will be causative for isolated inherited neuropathies.  
 
The last novel pathogenic gene was originally found in one family with three 
generations of DCSMA (Family K). Due to the well-characterised phenotype, highly 
resembling patients with mutations in DYNC1H1, an interactor protein, BICD2, was 
pursued as a candidate gene. Five more families were found and functional 
investigations showed altered cellular trafficking processes. Five further  families 
were found at the same time by two other groups, indicating the importance of 
mutations in BICD2 in patients with DCSMA and upper motor signs.  
 
Within the remaining four families, the candidate gene list could not be narrowed 
down to one likely pathogenic gene with the information available. This ensued in a 
shorter list of probable pathogenic genes that will require the presence of an 
additional family or other indications towards pathogenicity before further 
investigations will be performed. Several mutations will only be found in one or two 
families and pathogenicity can still be questioned. This has to be addressed by 
performing functional experiments and extensive studies of the influence of the 
variant. However, functional work cannot be performed on all possible variants due 
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to time limitations, so genetic proof regarding pathogenicity is desirable before 
further steps are undertaken. 
 
Whilst exome sequencing has provided a huge step forward in the discovery of 
pathogenic variants in genes, the enrichment steps involved lead to non-uniform 
coverage, generating both ‘hot spots’ with too much coverage and regions with too little 
coverage and low reading depth. One way to counteract this is the use of whole genome 
sequencing, which does not require an enrichment step, resulting in a more uniform 
coverage of the genome. This will also cover intronic regions and possible deletions that 
might have been missed with the use of whole exome sequencing since the longer reads 
available for whole genome sequencing allow for better determination of copy number 
variations, rearrangements and other structural variations. While previously, exome 
sequencing provided a significantly lower-cost and less time consuming option, whole 
genome sequencing has begun to close in on the price advantage, slowly moving the 
field from exome to genome. It could still be advocated that whole exome sequencing 
requires lower data storage costs and quicker, cheaper and easier data analysis, since the 
reads only focus on ~2% of the genome in comparison to 5% to 98% of the genome. 
There is also a better chance of interpreting variants in a meaningful way due to a better 
characterisation of the coding region of the genome, which promotes whole exome 
sequencing as a first approach. The work in this chapter demonstrates the benefit of 
the use of the whole-exome sequencing in genetic diagnosis; however, the 
limitations of the methodology have also been highlighted. 
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Chapter 6  
Genetic and functional 
analysis of IGHMBP2  
6.1 Introduction  
6.1.1 Spinal Muscular Atrophy with Respiratory distress 1  
In 1974, Mellins et al reported two unrelated cases of spinal muscular atrophy 1 with 
respiratory distress as first manifestation. In cases with SMA1, patients typically 
present with proximal weakness before they suffer from respiratory failure; patients 
with SMARD1 present with diaphragmatic paralysis very early on in disease and 
develop predominantly distal limb involvement (Bertini et al., 1989; Grohmann et 
al., 2001; Grohmann et al., 2003; Kaindl et al., 2008). In 2001, a study by Grohmann 
et al. linked patients with SMARD1 to mutations in IGHMBP2.  
 
Disease onset is normally within the first few weeks after birth and patients rarely 
survive the first decade (Rudnik-Schöneborn et al., 2004; Messina et al., 2012). The 
oldest patient reported to date is a 20 year old man with infantile-onset SMARD1, 
compound heterozygous with the following mutations: c.1082T>C (p.Leu361Pro) 
and c.1144G>A (p.Glu382Lys). He presented with distal weakness and respiratory 
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failure associated with diaphragmatic elevation at 4 months of age and has been 
ventilator-dependent since. Later on, he developed a length-dependent progressive 
sensory-motor neuropathy associated with loss of sensation, muscular denervation 
and atrophy. Cognitive testing was limited but revealed intellectual disability and 
some tongue fasciculations were present; otherwise, his cranial nerves were normal 
(Pierson et al., 2011).  
 
SMARD1 patients with mutations in IGHMBP2 can present with varying clinical 
outcomes. The most dramatic disease progression happens within the first year of 
life, resulting in loss of independent breathing and muscle strength. Whilst prognosis 
is poor, a heterogeneous clinical course with marked differences in the disease 
outcome can be observed in the later years, ranging from not being able to 
communicate to breathing independently in the first decade of life. Clinical scores at 
the age of three months showed a positive correlation with the clinical outcome in 
the later years. When expressed in an in vitro recombinant system, patients with 
more favourable outcomes tend to have mutations that retain residual enzymatic 
activity (Eckart et al., 2012). However, severity does not only depend on the 
mutations and can vary within families. For example, in a family with two siblings 
with an identical compound heterozygous combination of a stop mutation and a 
missense mutation in exon 10 of the IGHMBP2 gene, one presented with a 
phenotype of typical infantile onset with respiratory insufficiency whilst the other 
sibling had motor regression from the age of 19 months with respiratory impairment 
only starting from the age of 7 years (Joseph et al., 2009).  
Nerve conduction studies and electromyography  
NCS are used for the determination of the peripheral nerve function, resulting in 
markedly reduced motor conduction velocities, particularly in the legs, and a very 
marked reduction or loss of the compound muscle action potential. Studies of the 
sensory fibres showed similar results, but much milder. EMG revealed a denervation 
pattern only in distal muscles initially. Abnormal EMG results of the diaphragm, 
showing denervation often with little abnormality in the intercostal muscles, are 
typical in SMARD1. The severity of the initial presentation can be easily obtained by 
the compound muscle action potential of the m. abductor hallucis longus, presenting 
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an easily obtained parameter against which prognosis and progress might be judged 
(Pitt et al., 2003).  
Pathological findings  
Small anterior roots are typically observed in the spinal cord of SMARD1 patients, 
with the remaining motor neurons showing dissolution of the Nissl bodies in the cell 
body. Due to the presence of both atrophy of the anterior roots and primary 
degeneration of the cell bodies, dying-back and dying-forward mechanisms are both 
suggested to be involved. Accumulation of neurofilaments, ubiquitination and 
apoptosis are also frequently observed (Grohmann et al., 1999). Sural and tibial 
nerves of patients showed typical signs of axonal degeneration, the presence of 
tomacula and myelin loops and endoneural fibrosis, but a normal structure 
of unmyelinated axons. A considerable variation of myelin thickness and areas with 
a reduced number of axons is observed, especially the thick myelinated fibres, 
resulting in small myelinated fibres and fascicular areas. Wallerian degeneration and 
marked axonal atrophy with hypo-and hypermyelination were prominent in motor 
and sensory neurons, but no signs of demyelination were present. Signs of active 
axonal degeneration are present but no evidence of regeneration (Pitt et al., 2003; 
Diers et al., 2005). Together these features are suggestive of abnormalities in 
myelination, caused by mutations in IGHMBP2. This could be caused through 
primary Schwann cell dysfunction or as a secondary outcome due to impaired 
interactions between the axons and Schwann cells. In the neuromuscular junctions of 
SMARD1 patients, terminal axons were absent, subsynaptic clefts were reduced and 
no motor end plates could be found in the diaphragm. Skeletal muscle sections 
showed neurogenic atrophy and inactivity without fibre grouping (Diers et al., 2005). 
Ultrastructural analysis of the muscle nuclei showed aberrant heterochromatin 
reorganisation and distorted nuclear-envelope continuity with the formation of 
granular chromatin blebs, abnormalities that were also found in the nuclei of 
Schwann cells and are often seen in laminopathies (Jedrzejowska et al., 2014). These 
suggest an initial anterior horn cell degradation accompanied by myelination 
abnormalities, followed by degeneration of axons and their endings at the endplate.  
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6.1.2 Immunoglobulin mu binding protein 2 protein  
Structure  
Human IGHMBP2 consists of 993 amino acids and contains an RNA/DNA helicase 
domain, an R3H, single-stranded nucleic acid-binding domain and a zinc finger 
domain (Fig. 6.1). The gene encodes a helicase superfamily member that binds a 
specific DNA sequence from the immunoglobulin mu chain switch region and has 
been classified as a member of the Upf1-like group within helicase superfamily 1 
(SF1) (Fukita et al., 1993; Jankowsky, 2011). Also in this group of Upf1-like 
proteins are Upf1 and Senataxin (Bhattacharya et al., 2000; Chen et al., 2006; 
Fairman-Williams et al., 2010). Senataxin encodes a 302.8-kD protein implicated in 
a type of motor neuronopathy called ALS4 and ataxia with neuropathy called ataxia-
oculomotor apraxia type 2 (Chen et al., 2004; Suraweera et al., 2009). The overlap in 
homology suggests that DNA/RNA helicase dysfunction may play an important role 
in the development of different types of neuropathy. The signature of this group of 
proteins is a DEAD box-like helicase/ATPase domain consisting of seven to nine 
canonical motifs, including the Walker A and B motifs, involved in ATP binding and 
hydrolysis (Cordin et al., 2006; Lim et al., 2012).  
 
Residues 638–786, including the R3H domain of IGHMBP2 at the C-terminal end, 
were identified as a segment that specifically binds 5′-phosphorylated, guanine-rich, 
single-stranded DNA (ssDNA) sequences (Fukita et al., 1993). Not only is the R3H 
domain involved in nucleic acid-binding, it also provides a surface area that could be 
involved in yet unknown protein-protein interactions (Liepinsh et al., 2003).  
Function  
The structure of the protein together with the observation that immunoprecipitates of 
IGHMBP2 showed an affinity to single-stranded DNA and an unwinding activity on 
partially double-stranded DNA (Molnar et al., 1997), suggests a potential role of 
IGHMBP2 in replication or transcription of DNA. Research by Guenther et al. in 
2009 identified IGHMBP2 as a 5’-3’ helicase, unwinding DNA and RNA duplices 
with 5’ overhangs in an ATP-dependent manner. IGHMBP2 has an almost exclusive 
localisation within the cytoplasm of the cell, where it co-localises with components 
of the translation machinery as part of ribonucleoprotein complexes by interacting 
with the large and the small ribosomal subunits (Guenther et al., 2009).  
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Figure 6-1 Location of all missense, nonsense and frameshift mutations in the structure of IGHMBP2. 
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Effect of mutations in IGHMBP2  
Mutational analysis of mutations in IGHMBP2 that lead to SMARD1 showed that 
either the unwinding capacity or the ATPase activity of the protein was affected or 
severely reduced steady-state protein levels were detected in vivo. None of the 
mutations affect ribosomal association. Several mutations residing in the helicase 
domain were studied, most of them affecting both the ATPase and the unwinding 
activity of the protein. Three exceptions were found so far: p.His213Arg, 
p.Thr491Ile and p.Asp565Asn. For the latter, only the unwinding activity was 
affected, whilst the other two mutations retained both unwinding and ATPase 
activity. One of these, p.Thr491Ile, was studied in patient lymphoblastoid cell lines 
and showed a lower steady-state protein level.  
 
It has been suggested that a retained residual enzymatic activity correlates with a 
more positive disease outcome and might delay disease progression or manifestation 
age, but this was done in a very small sample size. Since most of these patients are 
compound heterozygotes, the exact contribution of each mutation to the phenotype 
cannot be assessed (Guenther et al., 2009; Eckart et al., 2012). Quantification of the 
steady-state protein levels in five patients with either juvenile or infantile onset and 
different combinations of mutations revealed significantly lower levels in all five 
patients in comparison with controls or heterozygous carriers. Significantly lower 
steady-state protein levels were observed in the infantile patients in comparison with 
the juvenile onset patients. Heterozygous carriers of mutations all showed lower 
steady-state protein levels, ranging between 50-80% of the controls, depending on 
the mutation.  
 
Whilst most mutations in IGHMBP2 are located within the helicase domain, few 
mutations have been found outside of this domain. In most cases, the disease-causing 
mutations outside the helicase domain result in the generation of mRNA with a 
premature stop codon. Only one missense mutation outside the helicase domain has 
been reported so far: c.2922T>G (p.Asp974Glu), in combination with an in-frame 
deletion in exon 12 (Grohmann et al., 2003). So far, 76 mutations have been reported 
to cause SMARD1, 53 of which are missense/nonsense mutations and 15 
deletions/insertions causing a frameshift (Fig. 6.1). Other causes of disease consist of 
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splicing mutations, gross deletions or genomic rearrangements (not depicted in 
figure).   
6.1.3 nmd mouse  
The nmd
2J
 mouse is a spontaneous autosomal recessive mouse mutant caused by loss 
of function of the IGHMBP2 gene due to a splice donor mutation (Cox et al., 1998). 
Nmd mice showed greatly reduced levels of the IGHMBP2 protein and a severe loss 
of spinal cord motor neurons before onset of clinical symptoms. This was followed 
by axonal degeneration in corresponding nerves and loss of axon terminals at motor 
endplates at the final stages of disease. Signs of respiratory distress are only 
developed clinically at the later stages and no significant reduction in axon numbers 
of phrenic nerves was observed in mice of 14 weeks old. Myopathic alterations such 
as large numbers of regenerating muscle fibres and occasional muscle fibre 
necrosis were found in 8-week old mice (Grohmann et al., 2004). Transgenic 
expression of IGHMBP2 cDNA prevented primary motor neuron degeneration, 
while restoring the normal axonal morphology and density in nmd mice. However, 
these mice developed a previously unobserved cardiac and skeletal myopathy, with 
the cardiomyocyte degeneration being much more severe than the myopathy 
observed in the skeletal muscle fibres, suggesting these might have a higher 
requirement for IGHMBP2. Whilst there have been no reports of cardiomyopathy in 
SMARD1 patients, cardiac arrhythmia has been described in several infants (Pitt et 
al., 2003; Grohmann et al., 2003). 
Modifiers of disease  
When first described, it was observed that 25% of the (B6-nmd
2J
 X CAST/EiJ)F2  
nmd
2J
/ nmd
2J
 mice were very mildly affected concerning the neurogenic atrophy and 
paralysis (Cox et al., 1998) This was attributed to a single locus on chromosome 13 
containing the Mnm
C
 gene. Further analysis narrowed the effect down to one single 
BAC rescue clone of 166 kb within the mnm modifier, encompassing the ABT1 and 
Zfp322a genes, six tRNA genes and one noncoding EST. This genetic modifier did 
not restore the splicing defect in nmd mouse, nor did it have an influence on the 
protein levels (de Planell-Saguer et al., 2009). Whether it affects either the 
IGHMBP2 protein directly, or rather contributes to the survival of motor neurons 
independently, remains to be determined. Interestingly, Co-IP experiments have 
shown an interaction between IGHMBP2 and ABT1, a factor in pre-ribosomal RNA 
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processing and maturation of ribosomes (de Planell-Saguer et al., 2009). As 
mentioned before, there is a high intra- and interfamilial heterogeneity in age of 
onset or severity of symptoms in SMARD1 patients, which implies the existence of a 
modifier gene, but none have been identified so far. ES-derived motor neuron 
cultures have been developed from both wild type and mutant mice with or without 
this modifier region, aiming to elucidate the molecular pathway responsible for the 
difference in severity (Van der Pol et al., 2013).  
6.1.4 Treatment and management  
SMARD1 is a severely disabling disorder with a very poor prognosis. All patients 
require ventilation early on in life and few reach the stage of being able to sit 
unsupported. No treatment options are available and focus lies on management of the 
disease. A long-term observational study of patients who survived on permanent 
ventilator support showed that most patients are well-integrated into their 
environments and two thirds are able to attend kindergarten or school (Eckart et al., 
2011). Considering the rarity of these patients, most centres only have few SMARD1 
patients under their care and international collaboration is necessary to establish a 
uniform standard for genotype/phenotype relations and provide updates on relevant 
clinical and research information (Van der Pol et al., 2013).  
6.1.5 Future directions  
Stem cells  
Neuronal stem cell (NSC) and neuronal precursor transplantation in nmd mice have 
shown to result in a longer survival and improvement of the phenotype (Corti et al., 
2006, 2009). Transplantation of human derived iPSC-derived NSCs significantly 
improved the neurological phenotype and the survival of the nmd mice, although not 
sufficiently enough to rescue to nmd phenotype. Molecularly, upregulation of genes 
involved in chromatin organisation, cytoskeletal function, and neurogenesis was 
observed in transplanted mice in comparison to untreated mice as well as 
downregulation of genes involved in excitatory amino acid toxicity and oxidative 
stress (Simone et al., 2014). Co-cultures of NSCs with murine and human motor 
neurons exhibited a neuroprotective effect by producing neurothropic factors that 
inhibit both GSK-3 and HGK kinases. Motor neuron survival improved and an 
increased neurite length and growth cone size was observed in SMARD1 iPSC-
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derived motor neurons (Simone et al., 2014). Not only could iPSC derived from 
affected patients be a more valuable model for testing therapeutic strategies next to 
results from the animal model, the combination of cell transplantation with an 
effective drug therapy might ultimately lead to clinically significant results in 
patients.   
Gene therapy  
Gene therapy in mouse models of SMA has shown positive results, increasing life 
expectancy from 27 to 340 days, preventing motor neuron death, complete correction 
of motor function and rescue of the weight loss phenotype close to normal 
(Dominguez et al., 2011). Recent findings have shown systemic administration of 
AONs to restore SMN2 splicing rescues the phenotype more efficiently than 
intraventricular administration, leading to the targeting of motor neurons by 
intravenous administration with a self-complimentary adeno-associated virus 9 
(scAAV9) vector (Duque et al., 2009; Hua et al., 2011; Van Meerbeke et al., 2011). 
Research for SMA is advancing to the stage of AAV9 vector-based gene therapy 
trials in human patients. This appeals for similar studies in the nmd mouse model 
with scAAV9 vector supported IGHMBP2 gene therapy. 
Insulin-like growth factor 1 (IGF-1)  
IGF1, also known as somatomedin C, plays an important role in the developmental 
process of neurons, promoting peripheral neuron survival and inducing regeneration 
(Gao et al., 1999). Recent studies in the Nmd
2J
 mice identified a systemic IGF1 
deficit in blood serum, which could be compensated by treating mice with 
subcutaneous injections of Polyethylene glycol-coupled IGF1. This resulted in 
improvement of the motor deficits, an 84% reduction of spontaneous activity in the 
gastrocnemius muscle and a slight gain of CMAP amplitude. PEG-IGF1 treatment 
markedly ameliorated or even prevented the myopathic pattern of pathology seen in 
the gastrocnemius and diaphragm muscles but did not rescue motor neuron and 
motor axon loss (Krieger et al., 2014). Studies in the pmn mouse showed positive 
effects on spinal motor neuron survival when a 3-fold higher dose of PEG-IGF1 was 
applied but these could not be replicated in the Nmd
2J 
mice due to fatality of the 
higher dose (Jablonka et al., 2011). Molecular studies suggest that the beneficial 
effect of PEG-IGF1 in striated muscle is mediated through the Akt/p70
S6K
 signalling 
pathway, adjusting muscle differentiation and protein biosynthesis via the PI3 
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kinase/p70
S6K
/mTOR pathway. Recombinant human insulin-like growth factor 1 
(rhIGF1) (Mecasermin) is already a Food and Drug Administration-approved drug 
for the long-term treatment of growth failure in children with severe primary IGF-I 
deficiency (Backeljauw et al., 2012) and was recently used in a phase 1 trial for rett 
syndrome (RTT), a severe X-linked neurodevelopmental disorder associated with 
mutations in MECP2, to evaluate the safety, tolerability and pharmacokinetic 
profiles of IGF-1 in 12 patients (Khwaja et al., 2014). This ameliorated certain 
breathing and behavioural abnormalities and was well tolerated; suggesting PEG-
IGF1 could be a reasonable candidate as a therapeutic compound in SMARD1 
patients. 
 
6.2 Results  
6.2.1 Clinical details of two siblings with CMT2  
In line with the previous chapter, exome sequencing was performed in a recessive 
family with two siblings in their 40’s, affected with axonal neuropathy (Family M). 
Clinical and neurophysiological examination of both parents was normal and family 
history was otherwise unremarkable. Both sisters presented at age 3 and 6 years with 
toe walking and slowly progressive distal lower limb wasting and weakness. Hand 
involvement subsequently developed. There were no sensory symptoms. Disease 
course was similar in both siblings until early in the third decade of life. At that time, 
the oldest sibling developed right shoulder pain radiating down her right arm 
followed by anisocoria and cranial neuropathies of the right XI and XII nerves, but 
no significant abnormalities were observed on brain MRI, PET scan and ENT 
examinations. Neurological examination at the age of 25 disclosed asymmetrical 
pupils reacting normally to light and accommodation with no ptosis, right-sided 
atrophy and weakness of the tongue, and mild weakness of the right trapezius and 
sternocleidomastoid muscles. Electromyography of the right tongue, trapezius, and 
sternocleidomastoid muscles showed chronic neurogenic changes. There was no 
suggestion of myopathy. Sensory examination was normal, but NCS showed absent 
sensory responses in upper and lower limbs, and absent motor responses from the 
median, common peroneal and posterior tibial nerves. Overall, the 
neurophysiological pattern was consistent with a motor and sensory axonal 
polyneuropathy and XI and XII right cranial neuropathies.  
196 
 
During the last examination of the siblings at 42 and 38 years of age, both of them 
worked for the government, were still active, able to drive, and used a stick to walk 
with silicon ankle foot orthosis. Examination of the index case at age 42 revealed 
bilateral foot drop, distal weakness and wasting in the upper and lower limbs, with 
mild proximal lower limb weakness. Reflexes were absent and there was sensory 
loss in the feet and hands. Cranial nerves were normal apart from a wasted tongue. 
There were no respiratory problems. Chest X-ray and sleep study was normal, nerve 
conduction studies indicated an axonal neuropathy and a nerve biopsy showed an 
axonal neuropathy. Her sister had almost identical but milder clinical features, and 
examination findings at the age of 38 years revealed bilateral foot drop, severe distal 
weakness and wasting in the upper and lower limbs, with mild proximal lower limb 
weakness, areflexia and minor sensory deficits. There were no respiratory problems 
and an axonal neuropathy was seen on nerve conduction studies.  
6.2.2 Exome sequencing revealed a mutation in the IGHMBP2 gene  
17p11.2 chromosome region rearrangements were not detected and sequence 
analysis of MPZ, PMP22, GJB1, MFN2 and GDAP1 showed no pathogenic variants. 
Exome sequencing was performed and analysis of the results detected two 
compound heterozygous mutations in the immunoglobulin helicase μ-binding protein 
2 (IGHMBP2) gene. Mutations in this gene have been previously described to cause 
Spinal Muscular Atrophy with Respiratory Distress 1 (SMARD1) (Grohmann et al., 
2001). Exome sequencing revealed a nonsense 5’ mutation (c.138T>A, p.Cys46Ter) 
and a 3’ frameshift mutation in the last exon of the gene (c.2911_2912delAG, 
p.Arg971Glufs*4). The mother and father were heterozygous for the c.138T>A and 
c.2911_2912delAG mutations, respectively. The nonsense mutation has been found 
before in a patient with SMARD1, in combination with a frameshift insertion in 
exon 12: c.1649insC (Grohmann et al., 2003). At the time of discovery, the deletion 
was regarded as a novel mutation, not present in the 1000 genomes database, the 
exome variant server (EVS) of 6500 individuals, or our in-house exome database of 
480 clinically and neuropathologically normal controls. More recent updates show 
the presence of this variation in the online servers. Considering the recessive nature 
of the disorder, the presence of carriers in the population has to be taken into 
account. Verifying the pathogenicity of the deletion is a vital step to take this gene 
forward in the context of CMT2. Seeing there is a substantial difference in the 
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severity of the diseases, an explanation as to why this occurs in CMT2 would lead to 
a better understanding of the pathways in which IGHMBP2 is involved and how 
difference in genotype can establish a difference in phenotype.    
6.2.3 Genetic screening  
As an initial approach, Sanger sequencing was performed in 260 CMT2 patients with 
suggestive or possible recessive inheritance. Five extra patients from four families 
were found with compound heterozygous mutations in the IGHMBP2 gene (Table 
6.1, Families N-Q). Segregation analysis in families N-P revealed the consistent 
presence of one variant in each parent (Fig. 6.2). Further analysis of collaborator data 
revealed three families with compound heterozygous mutations and one with a 
homozygous mutation (Table 6.1, Families R-U). In two extra families, only one 
heterozygous mutation could be identified (Table 6.1, Families V, W). For these two 
families, MLPA for IGHMBP2 did not show any deletions. This brings the total to 
fifteen CMT2 patients with mutations in IGHMBP2 (Table 6.1). Both of the 
mutations initially seen in the index patients were independently found in other 
patients (Table 6.1, Families O and S).   
6.2.4 Clinical details  
All families with CMT2 and IGHMBP2 mutations showed an autosomal recessive 
pattern of inheritance (Table 6.2). All fifteen patients presented in their first decade 
with difficulty walking and distal weakness of predominantly the lower limbs. Upper 
limb involvement developed soon after. The phenotype consists of slow progression 
involving lower limbs more than upper limbs and predominantly motor involvement. 
Sensory involvement was mild glove and stocking and electrophysiology indicated a 
sensory and motor axonal neuropathy in all cases. At the latest examination, all had 
moderate to severe weakness in both upper and lower limbs, pinprick and vibration 
sense was normal for most patients or reduced below wrist/ankle and reflexes were 
absent. Neurological examination showed proximal weakness in the older cases but 
after 40 years of disease. None of the cases had respiratory compromise, recurrent 
chest infections or previous ventilator assistance or sleep apnea. Results of the forced 
vital capacity test in four patients ranged from 25-95% of normal. Out of fifteen 
patients, six are currently wheelchair-bound and one further case had wasting of the 
tongue, comparable to the index patients. Extensive clinical details were available 
for two patients, who were seen locally.  
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Family Ethnicity Sex Diagnosis Age at onset Current age Protein change Nucleotide change 
M English Female CMT2 7 years 42 years p.Cys46Ter + p.Arg971Glufs*4 c.138T>A + c.2911_2912delAG 
M English Female CMT2 6 years 38 years p.Cys46Ter + p.Arg971Glufs*4 c.138T>A + c.2911_2912delAG 
N English Male CMT2 5 years 23 years p.Cys46Ter + p.Arg971Glufs*4 c.138T>A + c.2911_2912delAG 
O Serbian Male CMT2 2 years 14 years p.Cys46Ter + p.Phe202Val c.138T>A + c.604T>G 
O Serbian Female CMT2 2 years 15 years p.Cys46Ter + p.Phe202Val c.138T>A + c.604T>G 
P Pakistani Female CMT2 + 
Trisomy 21 
7 years 20 years p.Pro531Thr + p.Val580Ile c.1591C>A + c.1738G>A 
Q English Male CMT2 4 years 15 years p.Ser80Gly + p.Cys496Ter c.238A>G + c.1488C>A 
R Vietnamese Female CMT2 3 years 39 years p.Arg605Ter + p.His924YTyr c.1813C>T + c.2770C>T 
S USA Female CMT2 6 years 10 years p.Trp386Arg + p.Arg971Glufs*4 c.1156T>C + c.2911_2912delAG 
T Polish Female CMT2 4 years 28 years p.990_994del (Hom) c.2968_2980del (Hom) 
U Italian Female CMT2 1 years 12 years p.Val373Gly + p.Ala528Thr c.1118T>G + c.1582G>A 
U Italian Male CMT2 1 years 6 years p.Val373Gly + p.Ala528Thr c.1118T>G + c. 1582G>A 
V Korean Male CMT2 5 years 41 years p.Asn245Ser (Het) c.734A>G (Het) 
W English Male CMT2 7 years 20 years p.Arg605Ter (Het) c.1813C>T (Het) 
W English Female CMT2 10 years 18 years p.Arg605Ter (Het) c.1813C>T (Het) 
Table 6-1 List of all patients with CMT2 and mutations in IGHMBP2. 
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Figure 6-2 Electropherograms of the segregation analysis in families A-D. 
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Individual 1 2 3 4 5 6 7 8 9 10 12 13 11 14 15 
Family no. M M N O O P Q R S T U U V W W 
Sex/age (y) F/43 F/40 M/23 M/14 F/15 F/19 M/15 F/39 F/10 F/28 F/12 M/6 M/41 M/20 F/18 
Ethnicity English English English Serbian Serbian Pakistani English Vietname
se 
USA Polish Italian Italian Korean English English 
Mutation p.Cys46T
er + 
p.Arg971
Glufs*4 
p.Cys46T
er + 
p.Arg971
Glufs*4 
p.Cys46T
er + 
p.Arg971
Glufs*4 
p.Cys46Te
r + 
p.Phe202
Val 
p.Cys46T
er + 
p.Phe202
Val 
p.Pro531T
hr + 
p.Val580Il
e 
p.Ser80G
ly + 
p.Cys496
Ter 
p.Arg605
Ter + 
p.His924
Tyr 
p.Trp386A
rg + 
p.Arg971
Glufs*4 
p.990_99
4Fs 
(Hom) 
p.Val373
Gly + 
p.Ala528
Thr 
p.Val373
Gly + 
p.Ala528
Thr 
p.Asn245
Ser (Het) 
p.Arg605
Ter (Het) 
p.Arg605
Ter (Het) 
Age at first 
symptoms 
7 y 6 y <5 y <2 y <2 y <10 y 4 y < 3y 6 y 4 y 1y 1y 5 y 7y 10y 
First 
symptom/s 
Toe 
walking, 
high 
stepping 
gait 
Toe 
walking, 
hand and 
leg 
weakness 
Difficulty 
walking, 
foot drop 
Delayed 
milestone, 
hypotonia 
Delayed 
walking 
Hypotonia, 
foot drop 
Foot 
drop 
Delayed 
motor 
milestone
s 
Foot drop, 
high 
stepping 
gait 
Hand 
weakness 
difficulty 
walking 
hand 
fingers 
flexion 
foot 
weakness  
bilateral 
equino-
varus foot 
Gait 
difficulty 
Foot drop, 
clumsiness 
Feet 
deformity 
Weaknessa                               
    UL +++ +++ ++ +++ +++ +++ ++ +++ N ++ +++ + + ++ + 
    LL +++ +++ ++ +++ +++ +++ ++ +++ ++ +++ +++ ++ ++ ++ + 
Pinprickb                               
    UL N N + N N n/a n/a N N + + n/a + N N 
    LL + N + N N n/a n/a N N n/a + n/a + N N 
Vibrationc                               
    UL N N N N N n/a n/a N N n/a n/a n/a ++ N N 
    LL + N + N N n/a n/a N N n/a n/a n/a ++ N N 
Reflexes                               
    UL Abs Abs Abs Abs Abs Abs n/a Abs + +/- Abs abs abs N N 
    LL Abs Abs Abs Abs Abs Abs n/a Abs Abs (AJ) Abs Abs abs abs AJ +/- 
Bulbar 
involvemen
t 
No 
(rhomboi
d-shaped 
tongue) 
Wasted 
tongue 
No No No                                                                                     Wasted
tongue 
n/a No No No No No No No No 
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Individual 1 2 3 4 5 6 7 8 9 10 12 13 11 14 15 
Family no. M M N O O P Q R S T U U V W W 
Respiratory 
problems/ 
Respiratory 
support 
No No No No No No No No No No No No No No No 
Musculo-
skeletal 
deformities 
Equinus 
foot 
deformity 
Equinus 
foot 
deformity 
Feet 
deformity 
(surgery) 
Lumbar 
hyper-
lordosis, 
scoliosis 
Lumbar 
hyper-
lordosis 
Lumbar 
hyper-
lordosis,  
No Varus 
feet hip 
problems 
Achilles 
tendon 
contractur
e 
Scoliosis Achilles 
tendon 
contractur
es, 
scoliosis  
Achilles 
tendon 
contractur
es 
Thenar 
muscle 
atrophy 
(right>lef
t), Pes 
cavus  
Equinus 
foot 
deformity 
(surgery) 
Equinus 
foot 
deformity 
(surgery) 
Overall 
maximal 
function 
Independ
ent 
ambulatio
n 
Independ
ent 
ambulatio
n 
Independ
ent 
ambulatio
n 
n/a n/a Independe
nt 
ambulation 
n/a n/a n/a n/a Independe
nt 
ambulatio
n  
Walking 
with 
support 
FDS(3), 
CMTNS(
19), 9 
hole peg 
test (23.3 
sec) 
Independe
nt 
ambulatio
n 
Independ
ent 
ambulatio
n 
Walking 
aids 
AFO AFO 
(past) 
n/a WC WC WC AFO WC since 
16 
AFO WC WC since 
age 5 
years 
Bilateral 
support 
AFO AFO+Crut
ches 
No 
Other 
features 
n/a Wasted 
right 
shoulder 
and lower 
cranial 
nerves  
n/a n/a Without 
other 
features 
Trisomy 
21 
mosaicism 
Small 
focus of 
increased 
signal in 
right 
cerebella
r 
hemisphe
re (brain 
MRI) 
n/a McCune 
Albright 
syndrome 
(unconfir
med) 
Obese Marked 
worsening 
during 
febrile 
illness 
No Sensory 
ataxia 
Without 
other 
features 
Without 
other 
features 
Table 6-2 Clinical features of all patients with CMT2 and IGHMBP2 mutations. AFO = ankle foot orthosis; n/a = not available; LL= lower limbs; UL = upper limbs; WC = 
wheelchair. a Weakness: N normal; +4> distal muscles; ++ proximal weakness (knee flexion and extension, elbow flexion and extension or above). b Pinprick and vibration 
sensation: N normal; + reduced below wrist/ankle;  ++ reduced below knee/elbow; +++ reduced at or above elbow/knee. c Reflexes: N normal/present; ++ brisk; +++ brisk 
with extensor plantars; +/- = present with reinforcement; abs = absent; abs (AJ) = absent ankle jerks only 
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Family N  
A 16-year-old male presented with a longstanding history of upper and lower limbs 
weakness. Early during development he was noted to drag his feet when walking and 
underwent several operations to his feet since the age of 5 years. He then gradually 
developed slowly progressive weakness of his lower legs and subsequently of his 
hands. Examination at the age of 17 years showed significant distal upper and lower 
limb muscle wasting, weakness of first dorsal interosseus and abductor pollicis 
brevis muscles, no movement below the ankles, absent reflexes and abnormal 
sensation in his fingers and lower legs. Nerve conduction studies at age 16 years 
revealed absent sensory responses in upper and lower limbs, and absent motor 
responses from the median, common peroneal and posterior tibial nerves. Right ulnar 
nerve distal CMAP amplitude was 5.7 mV with conduction velocity of 45 m/s. 
Electromyography of proximal limb muscles showed no significant abnormalities. 
The neurophysiological pattern was consistent with a motor and sensory axonal 
polyneuropathy.  
Family P 
An 18-year-old female was born to non-consanguineous parents in Pakistan. She 
presented with seizures secondary to hypocalcaemia at the age of 3. She was noted to 
be hypotonic and dysmorphic and diagnosed with trisomy 21 mosaicism. During 
childhood, she exhibited developmental delay, bilateral foot drop and limb 
contractures. On examination at the age of 11 years, she had lumbar hyperlordosis, 
severe walking difficulty and was able to stand only for one minute without support. 
There was distal muscle wasting and weakness in her lower limbs and to a lesser 
degree in her hands. Reflexes were absent and the remainder of the examination was 
unremarkable. Forced vital capacity was 1.35 L (57% of predicted) but she had 
difficulty in performing the test. At the age of 18 years, she used a manual 
wheelchair for outdoor mobility. Sensation was difficult to assess. Neurophysiology 
at the age of 14 years was consistent with an axonal neuropathy with no recordable 
motor units from tibialis anterior and extensor digitorum brevis muscles. There were 
denervation changes in extensor digitorum communis and tongue. Neurophysiology 
at the age of 20 years confirmed both motor and sensory involvement. 
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6.2.5 Mutation spectrum 
Three families (five patients) carried the c.138T>A nonsense mutation in 
combination with either a c.2911_2912delAG deletion, causing a p.Arg971Glufs*4 
frameshift in the last exon (Family M and N), or a novel c.604T>G (p.Phe202Val) 
variant (Family O).  The remaining eight families either had two missense mutations 
(Families P,U), a missense mutation in combination with a truncating mutation 
(Families Q-S) – one of which had the same c.2911_2912delAG deletion as the 
index family (Family S) – a homozygous truncating mutation (Family T) or one 
heterozygous missense mutation (Families V,W). Most of these mutations were 
located in the helicase domain of the protein, apart from the c.2911_2912delAG and 
c.2968_2980delGAGAGGGGGACGT truncating mutations in the last exon of the 
gene and the c.2770C>T missense mutation in the zinc finger domain (Fig. 6.3). This 
is consistent with the observation that in SMARD1, the majority of disease-causing 
mutations are found within the helicase domain and those that are found outside this 
domain often result in the generation of mRNAs with premature stop codons. Of all 
mutations in this cohort, five have been found before in SMARD1 patients. Nine are 
novel variants, seven of which are missense mutations. Looking at a selected subset 
of 9 species, representing the 100 species available at the UCSC browser, 
conservation of these variants is highly preserved. The only exception is the 
p.Pro531Thr variant, found in family P (Fig. 6.4). This variant is only preserved in 
the rhesus monkey and the dog. In the other species, proline has changed to 
Glutamine or Lysine. This results in a respectively polar or positively charged amino 
acid instead of a non-polar one. When looking into more detail, the proline is 
preserved over most primates, with gorilla and bushbaby being the exception (Fig. 
6.5). Both of these result from a mutation in the second aminocacid of the codon, 
whilst the variant found in the patient results from changing the first aminoacid of 
the codon. The conservation score of this particular aminoacid has been determined 
at 2.61818 by using the PhyloP program, an incorporated function of the genome 
browser, indicating the conservation and acceleration of this amino acid is more 
preserved than the average.  
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Figure 6-3 Localisation of the newly found mutations in IGHMBP2 in CMT2 patients in comparison with the already known pathogenic mutations in SMARD1 patients. 
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Figure 6-4 Conservation of the novel variants found in IGHMBP2. All variants are well conserved over species apart from the p.Pro531Thr variant. 
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Figure 6-5 Conservation of Proline 531 of 
IGHMBP2 in primates. 
6.2.6 Localisation of the missense mutations within the structural domains 
of IGHMBP2  
Whilst nonsense and frameshift mutations will likely result in the loss of functional 
protein due to nonsense-mediated decay or truncated proteins, the mechanism of 
disease for missense mutations in IGHMBP2 is less clear. Depending on the 
localisation in the structure, missense mutations could interfere with the function of 
the protein or result in accumulation of aberrant proteins. Misfolded or mislocalised 
proteins can interact inappropriately with other cellular factors to cause toxicity. In 
Family O, the novel p.Phe202Val variant is part of an α-helix in domain 1A, but not 
central to the protein structure (Fig 6.6 E). In family P, the known severe pathogenic 
variant p. Val580Ile lies near a β-strand in the core of domain 2A and interacts with 
Ser539 on a neighbouring strand to stabilise the RecA-like fold. Mutating a valine to 
a isoleucine, which has a longer side chain, likely disrupts the formation of the β-
sheet and hence destabilises domain 2A. The other variant in this family, the novel 
p.Pro531Thr, lies in a loop region and is exposed to the solvent region on the protein 
surface. The side chain of the residue does not interact with neighbouring residues 
and will likely have a milder phenotype (Fig. 6.6 A). Similarly, the novel p.Ser80Gly 
variant in family Q lies in a loop region of domain 1B but its side chain does not 
interacts with any neighbouring residues (Fig. 6.6 E).  
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Figure 6-6 Mapping of the missense mutations of families O, P, Q, U, V and W on to the IGHMBP2 
structure. All the missense mutations are mapped onto the structure of hIghmbp2-RNA (PDB code: 
4B3G) with the Cα atoms of the mutated residues shown as red spheres. AMPPNP (in grey) is 
modelled by superposition of the structure of hIghmbp2-RNA with that of human Upf1ΔCH-
AMPPNP (PDB code:2GJK). The bound ssRNA is shown as yellow tube. (A)  Missense mutations in 
Family P (B and C) Missense mutation in Family U. (D) Missense mutations in Families V and W.(E) 
Mutations in family O,P and Q.  
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In family S, a known pathogenic missense variant (p.Trp386Arg) replaces a 
hydrophobic residue to a positively charged residue, resulting in protein instability 
due to the loss of some favourable van der Waals contacts with neighbouring 
hydrophobic residues. The other missense mutations p.Val373Gly and p.Ala528Thr 
in family U are also predicted to cause protein instability, resulting in loss of 
functional protein (Fig. 6.6 B and C). Lastly, the only heterozygous mutation in 
families V, p.Asn245Ser, targets a conserved residue in motif Ia that forms important 
interactions with the phosphate backbone of RNA. Mutating it to a serine residue 
could affect the interaction with RNA since the serine side chain is shorter and lacks 
the amide group (Fig. 6.6 D).  
6.2.7 Haplotyping  
To investigate the relationship of the three CMT2 families with the p.Cys46Ter 
mutation (Families M, N and O), five highly polymorphic microsatellite markers 
closest with respect to the IGHMBP2 gene were genotyped, the distance between the 
outer markers measuring 5.5 cM (Table 6.3). Haplotype analysis was performed on 
the five affected patients and their respective unaffected family members to 
investigate a common founder.  A shared haplotype, spanning 1.2cM (only 2/5 
markers) and containing the p.Cys46Ter nonsense mutation, was found in all three 
families, suggesting families are not closely related.  In families M and N, only one 
marker was shared on the allele with the AG deletion in the last exon. This is the 
closest marker, located 0.1 cM from the gene.  
 
Microsatellite marker name  Chromosome location Distance from IGHMBP2  
D11S1889 11:67313143-67313325 1.51 cM (1,357,985 bp) 
D11S4178 11:68189108-68189359 1.12 cM (481,951 bp) 
IGHMBP2  11: 68671310-68708067 0 cM  
D11S4113 11:68765634-68765859 0.1 cM (57,567 bp) 
D11S4095 11:69268159-69268361 1.09 cM (560,092 bp) 
D11S4139 11:70504269-70504461 3.97 cM (1,796,202 bp) 
Table 6-3 Polymorphic microsatellite markers used for the haplotyping of the nonsense and 
frameshift mutations in IGHMBP2 in families M, N and O. cM = centimorgan  
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Figure 6-7 Haplotyping results for families M, N and O. (A) Pedigree of family M (B) Pedigree of Family N (C) Pedigree of family O (D) 
Markers that were shared between the three families for the c.138T>A mutations or the two families for the c.2911_2912delAG.  
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6.2.8 mRNA analysis of IGHMBP2 nonsense mutations  
The presence of a nonsense-mutation is highly suggestive of nonsense-mediated 
decay. This was investigated by isolation of the mRNA of patient fibroblast and 
lymphoblastoid cell lines. Patient and carrier cell lines of families M and N were 
used to determine whether the p.Cys46Ter nonsense mutation, caused by the 
transversion of a thymine to an adenine at position 138 of the coding DNA, was still 
present. Both in fibroblasts and lymphoblastoid cell lines of carriers and patients, the 
nonsense mutation was still present at the mRNA level, suggesting NMD had not 
been activated. Since the p.Arg971Glufs*4 frameshift is located in the last exon of 
the gene, we would not expect nonsense-mediated decay to occur.  
To determine whether this lack of NMD is specific for the p.Cys46Ter nonsense 
mutation, two fibroblasts lines from SMARD1 patients with heterozygous or 
homozygous frameshift mutations were also investigated. Both the homozygous 
deletion at position 292 and the heterozygous deletion at position 1632 were still 
present in the mRNA, suggesting that IGHMBP2 is somehow protected from NMD, 
leading to truncated proteins. In collaboration with Professor Horvath at the 
University of Newcastle, cDNA analysis was also performed to investigate the 
presence of the nonsense mutation in family W. This showed the stop mutation as 
hemizygous, suggesting a deletion on the other allele (Fig. 6.8).   
 
 
Figure 6-8 Sequence electropherograms of the c.138T>A mutation in the mRNA of lymphoblasts 
and fibroblasts of CMT2 individuals and carriers, the c.1813C>T mutation in fibroblasts of CMT2 
individuals, and frameshift mutations in fibroblasts of SMARD1 individuals. The nonsense 
mutations are still present in the mRNA of both affected individuals and carriers in comparison 
with mRNA from a non-mutation control, indicating NMD is not present. The same is observed 
for the frameshift mutations in the SMARD1 fibroblasts in comparison with mRNA from a non-
mutation control, indicating there is no NMD.  
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6.2.9 Subcellular localisation of IGHMBP2 in patient fibroblasts  
Considering nonsense-mediated decay is not activated, nonsense mutations such as 
p.Cys46Ter will result in shorter, truncated proteins. It was hypothesised these might 
lead to mislocalisation of the protein or the formation of aggregates. However, 
immunocytochemistry experiments in selected fibroblasts of a CMT2 patient, carrier 
and SMARD1 patient showed no significant difference with those from controls (Fig 
6.9). In all cell lines the protein is mainly present in the cytoplasm and spread 
throughout. Actin staining was also performed to look at the overall structure of the 
cell. The intensity of the fluorescence was not measured, since levels of the protein 
were established via western blot in the next section (6.2.10).  
6.2.10 Protein levels of IGHMBP2 in patient fibroblasts  
A previous paper by Guenther et al. in 2008 investigated the levels of the steady-
state IGHMBP2 protein in the lymphoblastoid cell lines of three patients with an 
infantile onset and two patients with juvenile onset at 3.5 or 4.3 years. These were 
compared with three of their parents, carriers for one heterozygous mutation, and 3 
controls. It was observed that infantile onset patients had lower residual levels of the 
protein than juvenile onset patients and all were significantly lower than controls. 
Whilst lymphoblastoid cell lines have been shown to reflect the changes of the 
protein levels in the spinal cord of mice, making it a valuable cell model to study the 
effects on the protein level in patients, immortalisation can be quite costly and time 
consuming. As an alternative, patient-derived fibroblast cell lines were initially used 
to investigate the protein levels in CMT2 and SMARD1 patients in comparison with 
carriers and controls, to evaluate whether this would be a valid cell type to use.  
Fibroblasts were available for families M, N and patients of families O and P. These 
were compared with three controls, one SMA control with a mutation in SMN and 
three SMARD1 patients (Table 6.4). Due to the generosity of Professor Utz Fisher, 
the original 481 antibody used in the paper was obtained. However, using different 
buffers and different running conditions, a working protocol could not be established 
in the fibroblast cell lines and only resulted in background bands without the 
observation of a band at the right weight (Fig. 6.10 A). Different cell lines such as 
lymphosblastoid cell lines were used, since the original experiments were performed 
in that specific cell type, but no usable results could be acquired (Fig. 6.10 B).  
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Figure 6-9 Localisation of the IGHMBP2 protein in fibroblasts. Scale bar = 58.00 μm. Green: 
IGHMBP2; Blue: 4',6-diamidino-2-phenylindole (DAPI) staining for the nucleus. Green last column: 
Actin;  No difference in clustering of the truncated protein is found between the control and both the 
affected individuals and the carrier. A negligible background can be observed with the staining with 
the secondary antibody only. The overall structure of the cells is similar, as indicated by actin. 
SMARD1= p.Gly98Fs; CMT2 = p.Cys46Ter + p.Arg971Glufs*4; Carrier = p.Arg971Glufs*4.  
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This urged the use of a commercial available antibody, IGHMBP2, clone mAb11-24 
(Millipore), which was tested in different cell lines. This resulted in a much higher 
quality blot and was used throughout all further western blot experiments (Fig. 6.10 
C). Initially only HEK and SY5Y cell lysates showed a clearly distinguishable band, 
indicating the overall protein content loaded for fibroblast cell lines needed to be 
heightened, due to low expression in this tissue. Initial experiments were performed 
in triplicate with nine different fibroblast cell lines and showed a consistent lower 
steady-state protein level in the SMARD1 patients (0-12%) in comparison with the 
Patient Family 
no. 
Sex/Age Fibroblasts LCL  Phenotype Mutation 
1 M F/41 M. II.1  CMT2 p.Cys46Ter + 
p.Arg971Glufs*4 
2 M F/38 M. II.2 M. II.2 CMT2 p.Cys46Ter + 
p.Arg971Glufs*4 
3 N M/23 N. II.1 N. II.1 CMT2 p.Cys46Ter + 
p.Arg971Glufs*4 
4 O M/14 O. II.1  Severe 
CMT2 
p.Cys46Ter + 
p.Phe202Val 
5 O F/15 O. II.2  Severe 
CMT2 
p.Cys46Ter + 
p.Phe202Val 
6 P F/19 P. II.1  CMT2 p.Pro531Thr + 
p.Val580Ile 
Carrier 1 M M/72 M. I.1 M. I.1 Unaffected 
carrier 
p.Arg971Glufs*4 
Carrier 2 N M/57 N. I.1 N. I.1 Unaffected 
carrier 
p.Cys46Ter 
Carrier 3 N M/21 N. II.2 N. II.2 Unaffected 
carrier 
p.Cys46Ter 
Unaffected  
Sibling 
N M/19 N. II.3 N. II.3 Unaffected   
Carrier 4   N F/54 N. I.2 N. I.2 Unaffected 
carrier 
p.Arg971Glufs*4 
SMARD1 
1  
 <1y S1  SMARD1 p.Gly98Fs 
SMARD1 
2  
 <1y S2  SMARD1 p.Gln544Fs +  
p. Arg637Cys 
SMARD1 
3 
  S3 S3 SMARD1 p.His213Arg 
SMARD1 
4 
   S4 SMARD1 c.2611+1G>T 
Control 1  F/54 C1  Unaffected  
Control 2  M/9 C2  Unaffected  
Control 3  F/39 C3  Unaffected   
Control 4  Unknown C4  SMN1  
Table 6-4 List of all the available fibroblast and lymphoblast cell lines in the IGHMBP2 project. 
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CMT2 patients (15-20%) when standardised against 2 controls. This hypothesis was 
not followed by the SMARD1 fibroblast cell line S3, which was obtained from Dr. 
Katja Von Au in Germany. However, lymphoblasts of S3 were also available and are 
studied in a further section, showing negligible amounts of protein. One carrier cell 
line was available and showed 42% of steady-state protein levels in comparison with 
controls (Fig. 6.10 D and E). Multiple more fibroblast cell lines were obtained from 
patients, carriers and controls, leading to a total of 17 fibroblast cell lines. Multiple 
rounds of optimisation were required before establishing a protocol returning 
qualitative results.  
 
Figure 6-10 Comparison of the different antibodies for IGHMBP2 in different cell types. (A) 481 
antibody in fibroblasts (B) 481 antibody in different cell lines (C) mAb11-24 antibody in different cell 
lines (D) Representative western blot for the triplicate staining of mAb11-24 in fibroblasts (E) 
Percentages of steady-state protein level in fibroblast cell lines standardised against two controls.  
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Whilst performing these experiments, a major bacterial infection issue arose in the 
tissue culture facilities being used. This instigated a severe delay of experiments and 
untrustworthy results. Cell lysates from infected cell lines were still being used and 
exhibited similar behaviour as healthy cell lines, with results indicating the same 
trend as previous experiments. However, results were not used before cell lines were 
completely eradicated from bacterial infections. Interestingly, when performing 
western blot on infected cell lines, a different protein pattern could be observed with 
the Ponceau staining, suggesting this might influence the protein levels of multiple 
proteins (Fig. 6.11). 
 
Figure 6-11 Ponceau staining of different 
fibroblast cell lines during a period of bacterial 
infections in the tissue culture labs. 
Bacterial analysis showed a contamination with the Achromobacter bacteria, which 
had been identified before as a cell culture contaminant (Gray et al., 2010). Even 
though blast searches excluded the presence of an identical protein sequence that 
would be recognised by the IGHMBP2 antibody, shorter sequences with an 82% 
identity can be found in Achromobacter bacteria. Together with the uncertainty of 
the influence of the infection on different pathways in fibroblast cultures, results 
from potentially affected cell lines were not used for analysis. After taking the 
appropriate measures against future infections, experiments were repeated in 
triplicate in cell lines clear from infections. High variability could be observed 
within the different carriers, and it is noteworthy that those were the main cell lines 
affected by the bacterial infection (N. I.1; N.I.2; N.II.2; N.II.3). However, a trend 
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could be observed for lower steady-state protein levels in carriers than controls, but 
higher than in patients (Fig. 6.12). An example of the variability between different 
blots can be seen in figure 6.13, where two blots with the same samples, harvested 
and processed on different days, are depicted. Especially samples C3, C4 and P.II.1 
vary on these blots, even though the same amount of whole cell protein content was 
loaded.  
 
In the three individuals with the combination of the p.Cys4Ter and p.Arg971Glufs*4 
variants, an extra band was detected between 70–80 kDa. This band was not detected 
in any other affected individuals, carriers or controls (Fig. 6.14). With the help of 
online tools, the molecular weight of the truncated protein resulting from the 
p.Cys46Ter variant was estimated at 52 kDa, whereas the p.Arg971-Glufs*4 
frameshift results in a protein of 109 kDa. In previous experiments by Guenther et al, 
physicochemical properties of the wild type protein were investigated in comparison 
with the p.Thr493Ile variant, known to cause SMARD1. Western blot showed a 
degradation band at 75 kDa that was primarily present in the p.Thr493Ile transfected 
cells and comprises the N-terminal amino acid residues 1–674. Similar to this 
variant, the p.Cys46Ter variant or the p.Arg971Glufs*4 frameshift in these 
individuals could alter the physicochemical properties of the protein and results in a 
degradation product at 75 kDa. Because neither of the carriers with either the 
p.Cys46Ter and p.Arg971Glufs*4 variant show a band at this molecular weight, it 
could be hypothesised that the lower levels of functioning protein in the compound 
heterozygous individuals activate a feedback mechanism that preserved any residual 
truncated protein. 
 
During optimisation of the protocol, an incident occurred where two cell lines, kept 
in a different incubator, were stressed for a period of 48h due to a failure of the 
incubator that resulted in low CO2 pressure. Only one of the cell lines survived and 
protein lysate was run with the same protocol. Results showed a band ~20 kDa 
higher than the original protein, indicating the stress-response might have had an 
influence on IGHMBP2 (Fig. 6.15). This was not comparable to the phosphorylation 
or ubiquitination pattern normally observed in cell lines, where a smear of multiple 
bands are visible. Unfortunately, further inquiries could not be made due to lack of 
time after bacterial infections.   
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Figure 6-12 Steady-state protein levels of IGHMBP2 in fibroblast cell lines. (A) IGHMBP2 levels in 
all 17 cell lines. (B) IGHMBP2 levels grouped according to disease status. (C) IGHMBP2 levels 
compared for the two patient groups against the controls. Statistical significance across groups was 
analysed using one-way analysis of variance and Bonferroni's post hoc test to compare all data groups. 
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Figure 6-13 Western blot results for 2 sets of identical samples, harvested and 
processed on different days. Variability in protein levels can be observed in various 
samples, such as Controls 3 and 4.  
 
Figure 6-14 Existence of a degradation band around 
70–80 kDa in individuals with CMT2 and a 
combination of the p.Cys46Ter and p.Arg971Glufs*4 
mutations. 
 
 
 
 
 
 
 
 
Figure 6-15 Western blot showed 
the presence of an extra band at 
~130 kDa in fibroblasts under 
stressful conditions. 
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6.2.11 Protein levels of IGHMBP2 in lymphoblastoid cell lines  
Matching experiments were replicated in nine available lymphoblastoid cell lines, 
encompassing two CMT2 patients, four carriers, one control and two SMARD1 
patients (Table 6.4). Whilst the levels in the carriers were variable, the difference 
between CMT2 and SMARD1 patients was highly significant, with levels of the 
SMARD1 patients not being detectable with the technique used, even when higher 
protein content was loaded (Fig. 6.16). Levels were standardised against one control, 
resulting in a percentage between 25-50% for CMT2 patients.  
6.2.12 IGHMBP2 expression studies   
Expression of IGHMBP2 was estimated by reverse transcriptase polymerase chain 
reaction using gene-specific primers against cDNA generated from tissue-specific 
RNA as compared to the housekeeping gene GAPDH in eighteen different body 
tissues, with moderate expression in fibroblasts and lymphoblastoid cell lines in 
comparison with the brain and other high-expression level tissues (Fig. 6.17). Within 
the brain, IGHMBP2 expression was assessed in 10 regions of the normal human 
brain, using data from human post-mortem brain tissue from the UK Human Brain 
Expression Consortium (Trabzuni et al., 2011). The highest expression levels were 
detected in the cerebellum, followed by the cortex. According to data from the 
Human Brain Transcriptome (HBT) project, mRNA expression of the IGHMBP2 
gene shows an increase in the cerebellar cortex after birth, whilst other brain regions 
show a small decrease (Fig. 6.18). However, IGHMBP2 gene expression levels seem 
to be constant throughout life in the six brain regions that were assessed in humans 
during development. 
6.2.13 mRNA levels of IGHMBP2 in fibroblasts  
Initial experiments in the paper by Guenther et al. showed slightly elevated levels of 
IGHMBP2 mRNA in both infantile and juvenile patients. To investigate whether 
there were any significant differences between CMT2 patients and carriers/controls, 
mRNA levels were estimated with the SYBR green method in the original 9 
fibroblast cell lines. Both GAPDH and HPRT1 were used as reference genes.   
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Figure 6-16 Steady-state protein levels in lymphoblastoid cell lines. (A) IGHMBP2 levels in all 9 cell 
lines. (B) IGHMBP2 levels grouped according to disease status. (C) IGHMBP2 levels compared for 
the two patient groups against the controls. Statistical significance across groups was analysed using 
one-way analysis of variance and Bonferroni's post hoc test to compare all data groups. * = Affected 
individuals with CMT2.  
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Figure 6-17 Expression of IGHMBP2 (top row) in various human tissues as compared to the 
housekeeping gene GAPDH (bottom row). Expression of IGHMBP2 is ubiquitous, with a moderate 
expression in fibroblasts (18) and lymphoblastoid cell lines (19), used in experiments, 1 = ladder;  2  
= Thrachea; 3 = Thyroid; 4 = Prostate; 5 = Skeletal muscle; 6 = Spleen; 7 = Small intestine; 8 = 
Thymus; 9 = Lung; 10 = Placenta; 11 = Kidney; 12 = Adipose tissue; 13 = Brain; 14 = Oesophagus; 
15 = Colon; 16 = Heart; 17 = Liver; 18 = Fibroblasts; 19 = Lymphoblastoid cell lines; 20 = no cDNA 
control. Expression was determined using gene-specific primers against cDNA generated from tissue-
specific RNA in the FirstChoice Human Total RNA Survey Panel (Life Technologies, Carlsbad, 
USA). 
 
Figure 6-18 mRNA expression levels in different tissues at different stages of life.  Left: Data from 
the Human Brain Transcriptome (HBT) project (http://hbatlas.org/), CBC: the cerebellar cortex, MD: 
mediodorsal nucleus of the thalamus, STR: striatum, AMY: amygdala, HIP: hippocampus, NCX: 11 
areas of the neocortex. Right: Data from the UK Brain Expression Consortium 
(http://caprica.genetics.kcl.ac.uk:51519/BRAINEAC/). Regional brain distribution of IGHMBP2 
mRNA expression in the normal human brain was determined using microarray analysis of human 
post-mortem brain tissue from the UK Human Brain Expression Consortium (Trabzuni et al, 2011).  
CRBL: cerebellum,  FCTX: frontal cortex, HIPP: hippocampus, MEDU: medulla, OCTX: occipital 
cortex, PUTM: putamen, SNIG: substantia nigra, TCTX: temporal cortex, THAL: thalamus, WHMT: 
white matter. 
Since the expression levels of IGHMBP2 are constant throughout life, results from 
all fibroblast cell lines were compared regardless of age. The ΔΔCt method was used 
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to normalise the target amount in the sample against either HPRT1 or GAPDH to 
make a relative quantification, using the average of the unaffected sibling control 
fibroblasts as a calibrator in the following formula: 
 
ΔΔCt = (Cttarget – Ctreference)calibrator – (Cttarget – Ctreference)sample 
 
One pilot study with a limited amount of cell lines was originally performed, to 
investigate whether viable results could be obtained for larger scale experiments. 
Unfortunately, bacterial infection delayed the cultivation of the required fibroblasts 
so significantly that the experiments could not be performed again in triplicate. 
Results were variable when comparing the two reference genes but a trend could be 
seen towards a higher level of mRNA expression in the SMARD1 in comparison 
with the CMT2 patient fibroblasts. Apart from patient M.II.1, all patients had 
elevated levels of mRNA in comparison with controls, as previously indicated in the 
paper by Guenther et al (Fig. 6.19).  
 
 
Figure 6-19 mRNA expression levels of IGHMBP2 in fibroblast cell lines. The ΔΔCt method was 
used to normalise the target amount in the sample against either HPRT1 or GAPDH. Apart from 
patient M.II.1, all patients had elevated levels of mRNA in comparison with controls. 
 
 
 
-2
-1.5
-1
-0.5
0
0.5
1
1.5
2
2.5
3
Controls M.II.1 M.I.1 N.II.1 P.II.1 S1 S2 S3
2
-Δ
Δ
C
t 
Fibroblast cell line 
GAPDH
HPRT1
223 
 
6.2.14 mRNA levels of IGHMBP2 in lymphoblasts  
Matching experiments were performed in all available lymphoblastoid cell lines and 
repeated three times for both HPRT1 and GAPDH. Experiments were originally 
performed on a Corbett Rotor-gene machine, but had to be completed on the 
Stratagene/Agilent MX3000P due to problems with the sealing function of the 
machine. High variation was found in between the repeated runs, as shown by the 
error bars, and no significant difference was found between controls, carriers, CMT2 
or SMARD1 patients (Fig. 6.20). No further investigations were made, due to lack of 
time.  
 
 
Figure 6-20 mRNA expression levels of IGHMBP2 in lymphoblastoid cell lines. The ΔΔCt method 
was used to normalise the target amount in the sample against either HPRT1 or GAPDH. No 
significant difference was found between controls, carriers, CMT2 or SMARD1 patients 
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6.2.15 Co-immunoprecipitation of IGHMBP2 with proteins implicated in 
Amyotrophic lateral sclerosis 
Since SMARD1 and SMA1 have similar phenotypes, research had already been 
performed to investigate whether IGHMBP2 interacts with SMN or other 
components of the SMN complex (de Planell-Saquer et al., 2009). However, none of 
these proteins co-immunoprecipitated with IGHMBP2, suggesting it does not 
associate with the SMN complex. Given the clinical relevance between patients with 
motor neuron diseases such as SMARD1 and Amyotrophic Lateral Sclerosis (ALS), 
co-immunoprecipitation was performed to investigate interactions between 
IGHMBP2 and proteins mutated in ALS, such as Tar DNA-Binding protein, 43-KDa 
(TDP-43), Superoxide dismutase 1 (SOD1) or Fused in Sarcoma (FUS). No 
interaction was found for either SOD1 or FUS (Fig. 6.21), but co-
immunoprecipitation results showed an interaction between IGHMBP2 and TDP-43, 
repeated in triplicate (Fig. 6.22). This is a novel, RNA-independent interaction. To 
examine whether the interaction of TDP-43 with IGHMBP2 might be involved in the 
pathomechanism of disease, constructs were made for the following missense 
mutations: p.Ser80Gly, p.Phe202Val, p.Pro531Thr and p.Val580Ile. All of these are 
novel, except for p.Val580Ile, which has been found as a pathogenic mutation in 
SMARD1 patients.  
 
Figure 6-21 Co-immunoprecipitation experiments carried out 
in HEK293-T cells transfected with wild type construct of 
IGHMBP2 show no interaction between IGHMBP2 and FUS 
or SOD1. IP = Immunoprecipitation.  
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Figure 6-22 Co-immunoprecipitation experiments carried out in HEK293-T cells transfected with 
wild type or mutated construct of IGHMBP2 show that TDP43 interacts with IGHMBP2. (A) Wild 
type and empty vector Co-IP shows an RNA-independent interaction with TDP43, (B-C) A 
significant stronger interaction can be observed in HEK293T cells transfected with the S80G mutant. 
Other mutants show a trend towards higher interaction, which was not significant. n = 3, ** p < 0.01, 
IP = Immunoprecipitation. Statistical analysis was performed with the unpaired t-test.  
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Whilst the results for the latter were variable, potentially due to the sensitivity of the 
technique, a trend was shown towards a greater interaction in all mutant constructs as 
compared to wild type. This reached significance level for the S80G mutation, with a 
p-value below 0.01 with the unpaired t-test. This implicates TDP-43 in the 
pathogenesis of IGHMBP2 mutations, but a larger number of mutations are required 
to be investigated. This could not be explored in further depth due to lack of time 
resulting from the ongoing bacterial infections.  
6.2.16 Subcellular localisation of TDP43  
It is well known that cytoplasmic inclusions containing hyperphosphorylated and 
ubiquitinated TDP-43 are a pathological hallmark of ALS. This has both been shown 
in spinal cord and motor neurons of patients, the primary tissues of disease in 
SMARD1. Spinal cord tissue was available for one SMARD1 patient and TDP43 
staining was performed, but no abnormalities could be seen on the anterior horn cells 
of the spinal cord (Fig. 6.23). Further investigation regarding the localisation of 
TDP-43 in fibroblasts of patients with CMT2 and SMARD1 was implemented, 
however, no differences could be observed between CMT2 or SMARD1 patients in 
comparison with carriers or controls (Fig. 6.24).  
 
Figure 6-23 Immunostaining of TDP43 in the anterior horn cells of the 
spinal cord of a SMARD1 patient with mutations in IGHMBP2. No 
abnormalities could be seen. Scale = 10 µm. 
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Figure 6-24 Localisation of TDP43 and colocalisation of IGHMBP2 and TDP43 in human fibroblasts. 
No significant difference in localisation or clustering is found between the control and both the 
affected individuals and the carrier for TDP43. Green: IGHMBP2; Red: TDP43; Blue: 4',6-
diamidino-2-phenylindole (DAPI) staining for the nucleus. SMARD1= p.Gly98Fs; CMT2 = 
p.Cys46Ter + p.Arg971Glufs*4; Carrier = p.Arg971Glufs*4. 
6.2.17 Colocalisation of IGHMBP2 with TDP43  
To estimate the colocalisation of IGHMBP2 and TDP43, the global Pearson’s 
correlation coefficient was calculated with the Volocity program for the different 
fibroblast cell lines. Whilst the difference is significant between SMARD1 and the 
controls, no significant difference could be found between the CMT2 and SMARD1 
fibroblasts (Fig. 6.24-25).  
228 
 
C o n tro l C a r r ie r C M T 2 S M A R D 1  
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
C o lo c a lis a t io n
P
C
C
**
 
Figure 6-25 Pierson’s correlation coefficient for the colocalisation 
of IGHMBP2 and TDP43 in different human fibroblast cell lines. 
Difference is significant between SMARD1 and controls, but not 
significant between the CMT2 and SMARD1 fibroblasts  
6.2.18 Co-immunoprecipitation of IGHMBP2 with proteins implicated in 
CMT   
Considering the novelty of IGHMBP2 in the pathogenesis of CMT, co-
immunoprecipitation experiments were performed to investigate whether a link 
could be established with one of the already known genes in CMT. The genetic 
background plays an important role in the classification of the disease and is crucial 
to find common pathways to explain the characteristic features seen in most patients.  
Recently, a new gene called LAS1-like (LAS1L) was discovered to cause a 
phenotype of congenital motor neuron disease with early demise due to respiratory 
insufficiency, showing clinical overlap with SMARD1 (Butterfield et al., 2014). 
LAS1L has been implied in ribosome biogenesis, similar to IGHMBP2. Equally, due 
to the predominantly distal involvement in the CMT2 and SMARD1 patients, 
interaction with HSP27 was considered.  
 
Lastly, since HINT1 has been shown to interact with the helicases reptin and pontin, 
which form a complex with IGHMBP2, it was investigated whether a direct 
interaction was also present. However, none of these proteins co-immunoprecipitated 
with the IGHMBP2 protein and so far, no direct interactions between IGHMBP2 and 
any other CMT2 proteins have been reported (Fig. 6.26).  
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Figure 6-26 Co-immunoprecipitation experiments carried out 
in HEK293-T cells transfected with wild type construct of 
IGHMBP2 show no interaction between IGHMBP2 and 
selected proteins involved in CMT2. IP = 
Immunoprecipitation.  
6.2.19 Visualisation of IGHMBP2 in the CMT2 protein network  
With the use of the GeneMANIA prediction server 21 (Warde-Farley et al., 2010), 
the presence of a network of interacting proteins known in CMT2 with IGHMBP2 
can be observed (Fig. 6.27). No direct interactions or other sorts of associations are 
known with any CMT2 proteins so far, but further research might elucidate 
additional pathways linking IGHMBP2 to one of the already known CMT2 proteins.  
6.2.20 ATPase activity of the IGHMBP2 protein in transfected HEK cells  
Not only has it been shown that mutations in IGHMBP2 can result in severely 
reduced steady-state protein levels in SMARD1 patients, pathogenic mutants of 
IGHMBP2 have also been tested for their enzymatic activities, such as ATPase 
activity and the unwinding activity. All mutations residing in or close to conserved 
motifs within the helicase domain resulted in an impaired enzymatic activity  
(Guenther et al., 2009). 
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Figure 6-27 Protein network of CMT2 proteins and IGHMBP2. Different colours of lines indicate the 
nature of the interaction. Purple: Co-expression; Orange: Predicted; Red: Physical interactions; Green: 
Genetic interaction; Grey: Shared protein domains. Abbreviations for proteins can be found in 
Chapter 1.  
One mutation, p.Thr493Ile, was not located within these domains and showed 
unaltered enzymatic activity. This mutation was studied previously and showed 
lower steady-state levels in both infantile and juvenile onset patients (Guenther et al., 
2008). It was concluded that loss of enzymatic activity contributes to the 
pathological basis of SMARD1 and patients with a more favourable outcome 
retained residual catalytic activity (Eckart et al., 2011). This observation could be an 
explanation for the less severe phenotype of CMT2 patients with IGHMBP2 
mutations. Multiple constructs were available, but a pilot study was implemented 
with the wild type construct and the construct with a p.Val580Ile mutation, which 
has been shown to affect the activity of the protein and acted as a positive control. 
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Purification of the protein was accomplished by immunoprecipitation with Anti-
FLAG beads. A negative untransfected control was used and coomassie blue staining 
and western blot were performed on IP samples to confirm purification. Different 
elution protocols were used to optimise the protocol. On the first attempt, only one 
15 cm
2
 dish was used and IPs were washed with a combination of 5 different 
washing buffers (20 mM Tris, 500-150 mM NaCl, 1-0.02% Triton X-100), 
decreasing in NaCl and Triton X-100 concentration. 3x Flag peptide (Sigma-
Aldrich) was used to elute bound protein. However, this resulted in a complete loss 
of protein, most likely due to the amount of washes. Further experiments were 
performed with different combinations of NP40
+
 Lysis buffer without EDTA and 
washing buffers (Table 6.5). 3x Flag peptide (Sigma-Aldrich) was used to elute 
bound protein. Samples of both the eluate and the used beads were separated on a gel 
and stained with Coomassie blue, using different exposure settings to scan the results 
(Fig. 6.28). Due to the presence of background bands in condition 3 + 4, it was 
decided to use condition 2 for further experiments and to scale up to 3x 15 cm
2
 
dishes. These showed an enhanced purification of IGHMBP2 for the wild type 
construct (Fig. 6.29). 
 
Condition Lysis buffer Washing buffer 
1 NP40
+
 w/o EDTA 5 washing buffers (20 mM Tris, 500-150 mM NaCl, 1-
0.02% Triton X-100) 
2 NP40
+
 w/o EDTA 6 washes with 25 mM Tris pH 7.5, 400 mM NaCl, 1% 
Triton X-100  
3 NP40
+
 w/o EDTA 6 washes with NP40
+
 w/o EDTA 
4 NP40
+
 6 washes with NP40
+
 w/o EDTA 
Table 6-5 Different buffers used for the optimisation of IGHMBP2 purification. 
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Figure 6-28 Coomassie blue staining of the different conditions for the optimisation of IGHMBP2 
purification. Due to the presence of background bands in condition 3 + 4, it was decided to use 
condition 2 for further experiments and to scale up to 3x 15 cm
2
 dishes. 
 
 
Figure 6-29 Purification of wild type-
IGHMBP2 with condition 2 and 3x 15 cm
2
 
dishes. E = Eluate; B = Beads. 
 
The same protocol was used for both the wild type, empty vector and the construct 
with the p.Val580Ile mutation for the ATPase assay. However, no difference could 
be observed between the wild type and the mutant transfected cells. The coomassie 
blue staining showed one extra band in all cell lines (even the empty vector), 
suggesting the protein was not optimally purified and other proteins are still present 
in the eluate. A new combination of 3 different washing buffers (20 mM Tris, 1000-
200 mM NaCl, 1% triton X-100) was tried to improve the purification of the eluate 
in different orders, showing optimal results for condition 7 (Table 6.6 – Fig 6.30).   
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Figure 6-30 Coomassie Blue staining for the different conditions used for further IGHMBP2 
purification with conditions 5,6 and 7. Condition 7 was used for further experiments. WT = Wild 
type; UTF = Untransfected; MT = Mutant  
Coomassie blue staining showed a protein band at the expected 110 kDa in both wild 
type and positive control. However, when performing the ATPase assay, no 
hydrolysis could be observed in none of the three samples (Fig. 6.31). An extra band 
was still observed in all three lysates, but as this band is not present on the western 
blot staining for IGHMBP2, it is unlikely to be the targeted protein and is probable 
background. Elimination of this band with the use of various eluting conditions was 
not successful. Whilst purification is necessary to isolate the ATPase activity of 
IGHMBP2, background can be tolerated if no enzymes with ATPase activity are 
present. Additional to these three lysates, calf intestine alkaline phosphatase (CIP) 
enzyme was used as a positive control for buffer conditions of the assay. CIP was 
used in duplicate, once in the buffer accompanying the enzyme, once in the buffer 
used for the IGHMBP2 lysates. In both conditions, CIP hydrolyses ATP to ADP. 
Condition  Buffer order  
5 1-3-1-3-1-3 
6 2-3-2-3-2-3 
7 1-1-2-2-3-3 
Buffer 1 1000 mM Nacl 
Buffer 2 400 mM NaCl 
Buffer 3 200 mM  NaCl 
Table 6-6 Order of different 
buffers used for further 
optimisation of IGHMBP2 
purification. 
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However, with the same conditions, no ATPase activity could be seen in the 
IGHMBP2 lysates (Fig 6.32).  
 
 
Figure 6-31 ATPase assay for different construct of IGHMBP2. No hydrolysis could be observed in 
any of the samples. WT= Wild type; UTF = Untransfected; MT = Mutant. 
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Figure 6-32 ATPase assay for different construct of IGHMBP2 with a positive CIP control. 
Hydrolysis could be observed in the samples incubated with the CIP positive control, but not in the 
samples incubated with the different IGHMBP2 constructs. WT= Wild type; UTF = Untransfected; 
MT = Mutant  
  
6.3 Discussion  
Autosomal recessive mutations in IGHMBP2 were already implied in the 
pathogenesis of SMARD1. Results discussed in this chapter indicate that mutations 
in this gene can also be causative for CMT2. In total, eleven families were found 
with slowly progressive weakness, wasting and sensory loss, and an axonal 
neuropathy typical of CMT2, but no significant respiratory compromise. Nine 
families had compound heterozygous or homozygous mutations in IGHMBP2 and 
two families presented with only one heterozygous variant. The 5’ promoter region 
and the exome BAM files for sequencing coverage did not show any additional 
variants in these two families but IGHMBP2 cDNA sequencing in the two affected 
individuals from family W disclosed the stop mutation as hemizygous, suggesting a 
deletion on the other allele. MLPA was performed, but no large deletions were found 
in the family. mRNA analysis of frameshift and nonsense mutations in SMARD1 
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and CMT2 patients revealed that IGHMBP2 is not subjected to NMD, resulting in 
the presence of truncated proteins.   
Functional investigation in 17 fibroblast and 9 lymphoblastoid cell lines failed to 
show any changes in the subcellular localisation or clustering of the protein; 
however, protein levels in CMT2 patients were significantly lower in comparison 
with controls and carriers, but higher than SMARD1 patient levels. This suggests 
that defective or truncated proteins undergo posttranslational degradation. Clinical 
phenotype differences are related to the IGHMBP2 protein levels, but the small 
numbers require caution about whether this always correlates with the onset of 
disease and phenotype. Higher mRNA levels were observed in individuals with 
SMARD1 in previous reports but despite our best efforts only a trend towards higher 
mRNA levels in patients could be detected. This suggests the presence of a feedback 
mechanism to maintain protein homeostasis.  
 
To elucidate the pathomechanism leading to the difference in severity between the 
two phenotypes, co-immunoprecipitation experiments were performed, showing 
interaction with TDP-43. A trend towards higher interaction with TDP-43 was 
observed in the mutant constructs, and the Pearson’s correlation coefficient was 
significantly higher in SMARD1 fibroblasts in comparison with controls. Whilst no 
significant difference could be observed between CMT2 and SMARD1 patients, 
these results point towards involvement of TDP-43 in the pathogenesis of mutations 
in IGHMBP2. It should be noted that cell lines were only transfected with one 
missense mutation as compared to the compound heterozygous mutations present in 
patients. The effects of the numerous nonsense and frameshift mutations in the CMT 
cohort have not been established yet in transfected cell lines. 
 
In addition to that, experiments were performed in fibroblasts and lymphoblastoid 
cell lines, which are not tissues primarily affected in CMT2, thus caution has to be 
applied when interpreting the results. Considering IGHMBP2 mRNA is widely 
expressed throughout the body, it is likely that these tissues will reflect the 
consequences of mutations.   
 
Unfortunately, results from the helicase assay could not be obtained, but it is highly 
likely that most mutations in IGHMBP2 may lead to the dysfunction of the helicase 
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activity of this protein. The reduced protein levels or the abnormal IGHMBP2 
protein in SMARD1 and CMT2 may impair the capacity of neurons to produce 
error-free mature mRNA, thus leading to neuronal degeneration. Further 
investigation in both CMT2 and SMARD1 patients will reveal the process 
responsible for the differences in severity and the lack of respiratory involvement in 
CMT2 patients. 
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Chapter 7  
General conclusions 
Diverse genetic and functional techniques were used in this thesis to investigate 
different types of inherited neuropathies. The main focus was applied to Charcot-
Marie-Tooth disease, a genetically and phenotypically variable disease. After the 
discovery of the first CMT locus in 1982, the next 30 years of research have led to 
the unearthing of more than 80 disease-causing genes. Initially, these genes were 
identified by using genetic linkage studies, positional cloning, or candidate gene 
approaches. This was accelerated by the development of high-throughput techniques 
such as whole genome/exome sequencing and the publication of the human genome 
in 2001. To complicate things, mutations in the same gene can cause different CMT 
phenotypes at the same time as mutations in different genes may result in the same 
phenotype. Several genes can be grouped into pathogenic pathways involved in 
CMT, such as myelin biogenesis, axonal transport, mitochondrial dynamics and 
others discussed in the introduction. The availability of the human genome has led to 
the identification of mutations in genes that were not the primary functional 
candidates for CMT neuropathies and the discovery of novel pathways involved in 
CMT that did not have such evident involvement. My research has focused on the 
detection and subsequent investigation of new genes implicated in CMT and the 
expansion of the phenotypes associated with known pathogenic genes.  
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Mendelian inheritance patterns occurring in CMT include dominant, recessive, and 
X-linked and mutations in isolated patients can arise as de novo. In chapter 3, we 
discuss four CMT families with a mitochondrial inheritance pattern, caused by 
mutations in the ATPase6 gene. This is the first gene in the mitochondrial genome 
implicated in CMT. Previously, mutations in this gene have been shown to cause 
Leigh Syndrome or NARP, both progressive neurodegenerative disorders. Two 
known pathogenic mutations were found in our cohort, leading to an overall 
presence of 1.1% in patients with CMT2 or dHMN. This is a moderately high 
percentage, considering only 25% of patients with CMT2 receive a genetic 
diagnosis.  
 
So far, this is the only gene in the mitochondrial genome responsible for a CMT 
phenotype. In the future, ATPase 6 sequencing should be performed in patients with 
an appropriate phenotype. Next-generation sequencing does not include the 
mitochondrial genome, meaning mutations in ATPase 6 will be missed when 
performing exome sequencing in CMT families. This necessitates a highly specific 
characterisation of the family phenotype to prompt the screening for mutations in 
ATPase 6, discussed in chapter 3.    
 
To elucidate the mechanism responsible for the differences in phenotype due to 
mutations in ATPase 6, additional functional experiments were undertaken. Since the 
mutations are identical, patient material was used to investigate the differences 
observed in patients. Available muscle biopsies of patients showed reduced activity 
and assembly of complex V, similar to previously performed experiments in patients 
with the NARP m.8993T>G mutation. This suggests the presence of a poorly 
assembled and unstable complex V holoenzyme. Some variability could be observed 
in both activity and assembly on BN-PAGE for patients with identical mutation 
loads which may be attributable to holoenzyme disassembly occurring during sample 
preparation. Whilst this proves the pathogenicity of the mutation in patients with an 
isolated neuropathy, it does not provide an explanation for why some patients 
harbouring homoplasmic levels of m.9185T>C develop a tissue-specific peripheral 
neuropathic phenotype, whereas others with similar mutant loads develop a 
multisystem neurologic syndrome such as Leigh syndrome. Additional factors might 
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increase the susceptibility of certain patients to neuropathy or protect them from a 
more generalised disorder, but this will require further functional studies.  
In chapter 4, the focus was the nuclear genome and traditional methods were used to 
find causative genes for CMT. Compound heterozygous FIG4 mutations were found 
in a suspected case of inflammatory demyelinating neuropathy, with a two year 
history of rapidly progressive weakness in a single limb. FIG4 mutations are 
normally associated with progressive proximal and distal weakness but some 
patients may show asymmetrical rapid deterioration of strength in a single limb, 
mimicking inflammatory demyelinating neuropathy. This expands the already 
known phenotype and should alert clinicians to the possibility of FIG4 mutations 
especially if there is an early onset, chronic progressive course followed by a more 
rapid deterioration in one limb. 
 
Chapter 4 also reports the screening of appropriate cohorts of CMT patients for 
mutations in C9orf72, HINT1, SCN9A, ARL1 and ARL6ip1, but found no definite 
pathogenic mutations. Cohorts consisted of a relatively small number of patients, 
therefore not excluding the potential presence of pathogenic variants. The frequency 
of mutations may be so low as to be missed in a preliminary screen. In future, 
traditional Sanger sequencing will gradually be replaced by next-generation 
sequencing which may reveal variants in the genes mentioned. Interestingly, the 
frequency of mutations in HINT1 was estimated at 11% in the original paper by 
Zimon et al, which could not be replicated. This high frequency is likely due to a 
founder effect in central Europe patients with neuropathy and neuromyotonia.  
 
In the following chapter, next-generation sequencing techniques (whole exome 
sequencing) were used instead of the more traditional methods to find new causative 
genes. Nine families were investigated and resulted in the detection of a pathogenic 
variant in five families out of nine. As well as two previously known pathogenic 
variants in HSPB1 and MFN2, three probably new pathogenic genes were 
discovered: NEFH (still being investigated), ADD3 and BICD2.  
 
A frameshift variant near the 3’ end of the NEFH gene was found in a family with 
axonal neuropathy. This led to the loss of the stopcodon and an extension of 40 
additional amino acids. This potentially adds NF-H to the list of proteins interfering 
241 
 
with the cytoskeleton and further research is required to elucidate the exact 
pathomechanism.  
 
In one family with four children with spastic diplegic/quadriplegic cerebral palsy and 
intellectual disability, a homozygous p.Gly367Asn mutation in ADD3 was found. 
Studies in fibroblast cell lines showed an impaired actin capping activity in the 
mutant cell lines, implicating the involvement of the cytoskeleton in the 
pathomechanism of disease. Mutations in αII spectrin, a cytoskeletal protein that 
lines the intracellular side of the plasma membrane in eukaryotic cells, have 
previously been identified as a cause of epilepsy, intellectual disability and spastic 
quadriparesis. So have mutations in KANK1, which have also been implicated in 
hereditary cerebral palsy and play an important role in the cytoskeleton. This links 
hereditary forms of cerebral palsy to abnormalities of components of the dynamic 
cytoskeleton, as seen before in isolated inherited neuropathies.  
 
Mutations in BICD2 were found by three groups simultaneously in a total of eleven 
families with DCSMA with a pattern of muscle involvement highly similar to that 
seen in patients with DYNC1H1 mutations. BICD2 mutations resulted in an 
increased binding affinity between BICD2 and the dynein-dynactin complex, 
therefore altering BICD2-mediated cellular trafficking processes. As mentioned in 
the introduction, several proteins involved in transporting cargo from the periphery 
to the cell body, such as DCTN1 and DYNH1C1, have been implicated in CMT. The 
addition of BICD2 to the list of pathogenic genes confirms the importance of this 
pathway and the impairment of BICD2-mediated trafficking likely leads to 
compromised development and maintenance of a key subset of anterior horn cells 
and UMNs. 
 
For the remaining four families, shorter lists of probable pathogenic genes have been 
established. Whilst in most cases, candidate genes could be prioritised due to their 
function and segregation analysis in the family, these still require additional families 
or other indications towards pathogenicity before investing in functional experiments 
to prove pathogenicity.  
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Chapter 6 provides an example of functional experiments taken forward to elucidate 
the pathomechanism of a variant. In total, eleven CMT2 families were found with 
recessive compound heterozygous mutations in IGHMBP2, normally causing 
SMARD1. Western blots in fibroblast and lymphoblastoid cell lines showed lower 
protein levels in SMARD1 patients in comparison with CMT2 patients, suggesting 
the severity of the phenotype may depend on the residual levels of the protein. Co-
immunoprecipitation experiments showed interaction with TDP-43, and a trend 
towards higher interaction in the mutant constructs was observed. The mutation 
spectrum in CMT2 patients showed segregating mutations as a combination of a 
nonsense or frameshift and fewer missense mutations, where one or both were in the 
last exon, escaping nonsense mediated decay and leading to a truncated and likely 
still active protein. Several families also presented with a combination of missense 
mutations. Whilst there were no CMT2 patients presenting with the same 
combination of mutations as SMARD1 patients, five mutations found in the CMT2 
cohort were known to be pathogenic in SMARD1 cases. This suggests an extra 
factor influencing the severity of the phenotype. In the nmd mouse model, this factor 
is contained within the BAC-27k3 transgene, with the syntenic genomic area in 
humans comprising four tRNATyr genes and the activator of basal transcription 1 
(ABT1) gene, but no variations were found in these genes in the exomes of the index 
patients. For future experiments, international collaboration will be essential, since 
most clinical centres only have few SMARD/DSMA1 patients under their care and 
tissue is very hard to obtain from these patients. To investigate potential biomarkers 
for disease severity and outcomes such as clinical scales, CMAP amplitudes and 
IGHMBP2 enzymatic activity; large studies with both SMARD1 and CMT2 patients 
will have to be performed. Clarifying the difference in severity will be helpful to 
target potential therapeutic strategies.  
 
This thesis demonstrates the progress of genetic to functional techniques involved in 
the discovery of new pathogenic genes. In the first chapters, more traditional 
methods such as Sanger sequencing were used to identify genetic variants causing 
CMT and genes were chosen due to their function, involvement in similar 
phenotypes or the presence in mouse models. In the later chapters, more advanced 
next generation sequencing techniques were used to explore the whole exome of one 
or multiple patients. In the event of novel variant discovery, further functional tests 
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to prove pathogenicity of the variant were required. In situ methods such as 
Polyphen and SIFT were used to estimate the influence of variants on traits such as 
the folding and functionality of the protein. Whilst being indicative, these are not 
decisive for the pathogenic status of a variant. Known pathogenic variants have 
previously been categorised as non-pathogenic and vice versa. This highlights the 
necessity of in vitro studies.  
 
For the purpose of this thesis, two different types of in vitro models were used. Due 
to excellent transfectability, HEK293 cell lines were used as a model system for 
transfection experiments and DNA was condensed into positively charged particles, 
binding to anionic cell surface residues and brought into the cell via endocytosis. 
This resulted in an overexpression system with the presence of either wild type or 
mutated protein, helping the purification process. However, there are a few 
disadvantages in using overexpression models. Overexpression may influence 
balanced gene dosage, affecting protein folding, localisation, complex assembly and 
downstream regulation.  
 
Additionally, patient-derived cell lines were used as cellular models in multiple 
projects to study disease-related cellular phenotypes. Due to the ease of isolation, 
fibroblasts are a popular cellular model to use. Fibroblast cultures can be derived 
from a 4-mm human skin biopsy and have a very high success rate which is 
important when dealing with patient-derived tissue samples. They are easy to 
cultivate and use, but have relatively low protein content. Whilst these are 
characteristic for the individual patient, the primary affected tissue consists of 
nerves, and results might not always be representative. As shown in chapter 4, 
variability in the mitochondrial membrane potential is too high in fibroblasts to draw 
any results. Depending on the experiment, fibroblasts can prove to be a valuable 
model. This also applies to the lymphoblast cell lines that were used. Human 
peripheral blood mononuclear cells (PBMC's) can be easily isolated from whole 
blood and subsequently immortalised by transformation with the Epstein Barr Virus, 
although the latter can be rather costly and time consuming. However, in comparison 
with fibroblasts, higher protein content is present and as the cells are in suspension it 
makes it easier to cultivate. Since the primarily affected tissue (nerve) could not be 
obtained, these are good alternatives for in vitro experiments. The nature of 
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experiments will depend on the gene of interest and, as mentioned before, the 
heterogeneity in genes with mutations associated with CMT results in a variety of 
functional tests being developed to prove pathogenicity of a variant.  
 
Whilst chapter 4 used a more traditional approach of gene discovery, chapter 5 
incorporated next-generation sequencing techniques that were less commonly used at 
the start of this thesis but during the three years of research became increasingly 
high-throughput. Initially, quality was variable and coverage was not homogeneous 
throughout the genome or showed very low depth. Variants could be missed and 
individual patients required very detailed analysis to avoid missing pathogenic 
variants, preventing it from being used for routine testing. Further optimisation is 
gradually leading to a revolution in gene discovery and diagnostics for Mendelian 
and complex diseases and it is predicted that exome sequencing will become a 
commonly used diagnostic screening tool within the next few years. Smaller families 
and isolated individuals previously omitted from searches based on the traditional 
methods will be able to be investigated, whilst only needing a minimal amount of 
DNA. As a highly heterogeneous phenotypic and genetic disease, CMT is an 
example where NGS is particularly time and cost-efficient. In a diagnostic setting, 
patients with a well characterised phenotype can be screened for the 17p duplication 
-found in two-third of patients with CMT1- and then PMP22, GJB1, MPZ, or MFN2 
when appropriate. However, conventional Sanger sequencing for the remaining 
CMT genes can be time consuming, cumbersome, expensive and unrewarding. 
Instead of consecutive sequencing of multiple genes, NGS can uncover mutations in 
all known genes simultaneously, even rare genes for which until now testing was not 
often available.  
 
Even though NGS is an optimal technique for the discovery of novel genes, the 
heterogeneous functions and ubiquitous expression of several CMT genes and small 
families can make it challenging to identify the one pathogenic variant amongst a 
long list of variants leading to a peripheral nerve phenotype. From the ~20,000 
variants typically found in a European American sample, more than 95% are already 
known as polymorphisms. Additionally, various filtering techniques can be used to 
hone in to the possible culprit gene, such as the mode of inheritance or the pedigree. 
Although increasingly more gene discovery research is focused on exome 
245 
 
sequencing, many families for which exome sequencing is performed remain without 
a genetic diagnosis. Only success stories will be published and whilst exome 
sequencing benefits from traits such as low cost, rapidity, low DNA requirements 
and screening of close to all coding-regions, exome sequencing in singletons and 
very small families still remains extremely challenging, as evidenced in Chapter 5. 
 
Exome sequencing is more cost-efficient and less data-intensive than whole-genome 
sequencing and requires only 2% of the sequencing needed for an entire human 
genome; however, variants outside the coding region will not be covered and large 
indels, duplications and translocations will not be discovered. As the cost of 
sequencing continues to fall, a gradual movement from exome to whole-genome 
sequencing is occurring. Nevertheless, many pitfalls still remain. Finding the one 
pathogenic variant in whole-exome data can be cumbersome and this will prove to 
be even more difficult for whole-genome data, trying to incorporate the effect of 
non-coding variants. Even though challenging, the aim is a future where the genetic 
basis of all Mendelian traits is known, and this knowledge can be used to understand 
the underlying molecular basis of pathology, shifting the emphasis towards 
understanding disease mechanisms and genotype–phenotype relationships, providing 
diagnostic insight and information to patients and their families and developing 
improved therapeutics and improvement of human health.  
 
In addressing to the aims of this thesis, the following conclusions can be made:  
 
 Chapter 3: Detection of mutations in ATPase6 in five families with CMT2 
leads to an overall presence of the mutation in 1.1% in undiagnosed patients 
with a CMT2 or dHMN phenotype. ATPase6 is the first mitochondrial gene 
responsible for an isolated peripheral neuropathy phenotype.  
 Chapter 4: The CMT4J phenotype of FIG4 mutations includes asymmetrical 
rapid deterioration of strength in a single limb, mimicking inflammatory 
demyelinating neuropathy.  
 Chapter 4: There is a likely founder effect for mutations in HINT1 in central 
Europe, due to the absence of mutations in UK/Spanish cohorts.  
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 Chapter 4: C9orf72, ARL1 and ARL6ip1 have been excluded as common 
causes for CMT.  
 Chapter 5: We have identified three novel pathogenic genes (NEFH (to be 
confirmed), ADD3 and BICD2), involved in the pathogenesis of CMT, 
spastic diplegic/quadriplegic cerebral palsy or DCSMA respectively, together 
with several further potential pathogenic genes involved in the pathogenesis 
of CMT, including: ACSBG1, WDR48, RGMb, MORC2, FAM126A, CNTRL, 
GOLGA2, SSTR5, TBC1D24 and PKMYT1. 
 Chapter 6: We have shown mutations in IGHMBP2 to be a cause of axonal 
neuropathy, with significantly lower protein levels in fibroblast and 
lymphoblastoid cell lines of SMARD1 patients in comparison to CMT2 
patients.   
 Chapter 6: We have discovered a novel RNase-independent interaction 
between IGHMBP2 and TDP-43, with a trend of a higher interaction for 
selected mutations implicated in CMT2.  
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Appendix I 
 
Synonymous changes Nonsynonymous changes non-coding region 
8248A>G: M-M: Hom (2) 8381A>G: T-A: Hom (1) 8291G>A: Hom (1) 
8347A>G: L-L: Hom (1) 8388T>C: V-A: Hom (2) 8302A>G: Hom (1) 
8485G>A: L-L: Het (1) 8396A>G: T-A: Het (1) 8311T>C: Hom (2) 
8503T>C: N-N: Hom (4) 8461C>A: N-K: Hom (1) 8349C>T: Hom (2) 
8533G>A: T-T: Hom (1) 8471C>T: P-S: Hom (1)  
8538T>C: N-N: Hom (A6) (1) 8477T>G: S-A: Hom (2)  
8545G>A: S-S: Hom (A8) (1) 8489A>C: M-L: Hom (2)  
8566A>G: Q-Q: Hom (1) 8490T>C: M-T: Hom (2)  
8572G>A: X-X: Hom (A8) (4) 8502A>G: N-S: Hom (1)  
8598T>C: I-I: Hom (2) 8516T>C: W-R: Hom (1)  
8679A>G: L-L : Hom (1) 8519G>A: E-L: Hom (4)  
8740C>T: L-L: Hom (1) 8531A>G: T-A: Hom (1)  
8754C>T: I-I: Hom (1) 8538T>C: I-T: Hom (A8) (1)  
8769A>G: T-T: Hom (2) 8545G>A: A-T: Hom (A6) (1)  
8772T>C: T-T: Hom (1) 8572G>A: G-S: Hom (A6) (4)  
8805A>G: T-T: Hom (1) 8578C>T: P-S: Hom (2)  
8820A>G: L-L: Hom (4) 8605C>T: P-S: Hom (2)  
8889T>C: I-I: Hom (1) 8619C>A: I-M: Hom (1)  
8925A>G:T-T: Hom (2) 8620C>T: P-S: Hom (1)  
8940C>T: I-I: Hom (2) 8633A>G: Y-C: Hom (1)  
8955T>C: I-I: Hom (2) 8698A>G: M-V: Het (1)  
8958C>T: I-I: Hom (1) 8699T>C: M-T: Hom (2)  
9006A>G: L-L: Hom (6) 8704A>G: M-V: Hom (4)  
9015C>T: N-N: Hom (1) 8725A>G: T-A: Hom (1)  
9042C>T: H-H: Hom (3) 8765C>T: A-V: Hom  (2)  
9048T>C: I-I: Hom (1) 8794C>T: H-Y: Hom (1)  
9060C>A: T-T: Het (2) 8828A>G: N-S: Hom (1)  
9060C>T: T-T: Hom (1) 8836A>G: M-V: Hom (4)  
9061C>T: L-L: Hom  (1) 8839G>A: A-T: Hom (3)  
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9075C>T: T-T: Het (1) 8864T>C: V-A: Hom (1)  
9078T>C: I-I: Hom (1) 8875T>C: F-L: Hom (2)  
9117T>C: I-I: Hom (4) 8887A>G: I-V: Hom (2)  
9120A>G: L-L: Hom (2) 8932C>T: P-S: Hom (1)  
9126T>C: T-T: Hom (1) 8950G>A: V-M: Hom (2)  
9168C>T: F-F: Het (1) 8974C>T: L-F: Hom (1)  
9224T>C: H-H: Hom  (1) 8993T>C: L-P: Hom (1)  
9254A>G: W-W: Hom (7) 9025G>A: G-S: Hom (2)  
9266G>A: G-G: Hom (4) 9055G>A: A-T: Hom (5)  
9269C>T: A-A: Hom (1) 9067A>G: M-V: Hom (1)  
9350A>G: L-L: Hom (1) 9070T>G: S-A: Hom (2)  
9374A>G: Q-Q: Hom (1) 9101T>C: I-T: Hom (2)  
9530T>C: P-P: Hom (1) 9139G>A: A-T: Hom (1)  
9653T>C: H-H: Hom (2) 9185T>C: L-P: Hom (4)  
9664A>G: G-G: Hom (3) 9210A>G: T-A: Hom (1)  
9707T>C: I-I: Hom (1) 9243C>A: P-T: Hom (1)  
 9288A>G: T-A: Hom (2)  
 9300G>A: A-T: Hom (6)  
 9325T>C: M-T: Hom (6)  
 9366A>T: M-L: Hom (2)  
 9438G>A: G-S: Hom (3)  
 9580A>G: N-S: Hom (2)  
 9664A>G: G-E: Hom (3)  
 9682T>C: M-T: Hom (1)  
Appendix I: List of all variants found in the ATPase 6/8 genes in our cohort. Hom = homoplasmic; 
Het = Heteroplasmic; A8 = ATPase8 reading frame; A6 = ATPase6 reading frame; Number between 
brackets = number of individuals with this variant. 
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Appendix II 
gene OMIM Exonic 
Function 
Var 
count 
Gene 
count 
Poly 
Phen2 
Grantham 
Score 
PhastCons 
score 
GERP 
Score 
Rs No. MAF Signature 
ARHGAP11A  missense 1 4 D 81 1 5.04 rs140472511 0.004409 15_32921855_G_S 
ATP10B  missense 3 8 D 94 0.949 -0.718 rs61734665 0.012739 5_160042903_G_K 
TTC18  missense 1 2 D 68 1 5.29   10_75051751_T_K 
MFF   missense 1 5 D 29 1 4.83     2_228197228_G_R 
CEP110  missense 1 14 D 101 0.797 3.38 rs34344401 0.001297 9_123931891_C_Y 
DENND5B  missense 1 5  10 0.988 -4.63 rs34129725 0.003106 12_31600503_T_Y 
DNAH10  missense 1 16 D 81 1 5.47 rs147774367 0.002417 12_124270348_T_Y 
DNAH17  missense 1 40  145 0.975 4.77   17_76440872_G_R 
KIAA0232  missense 1 3 D 110 1 5.58 rs111811307 0.5 4_6826228_C_S 
LIPG  missense 2 4 P 46 1 4.31 rs77960347 0.008597 18_47109955_A_R 
MACF1  missense 1 20 D 99 1 5.68 rs144760259 0.002208 1_39853641_G_K 
CAB39L  missense 1 2 D 180 1 4.62   13_49906202_G_R 
OAS3,LOC100287897  nonsense 2 5  NA 0.854 1.88 rs61942233 0.010317 12_113403675_C_Y 
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gene OMIM Exonic 
Function 
Var 
count 
Gene 
count 
Poly 
Phen2 
Grantham 
Score 
PhastCons 
score 
GERP 
Score 
Rs No. MAF Signature 
ZFYVE9  missense 1 4 D 15 1 4.45   1_52759319_C_M 
QRICH2  missense 2 24 P 56 1 4.59 rs61759535 0.005275 17_74276788_T_Y 
SKIV2L2  missense 1 1 D 112 1 5.48 rs142958762 0.004468 5_54645455_C_S 
SPAG5  missense 1 2 D 56 0.995 4.24   17_26905701_C_Y 
SVEP1  missense 4 30  45 0.911 -2.4 rs41296069 0.055389 9_113244732_G_K 
SYNE1 642 missense 1 38 D 101 0.989 3.53 rs34028822 0.004839 6_152757224_G_R 
PLK1S1  missense 1 5  76 0.344 4.22   20_21143521_A_M 
TNS4  missense 1 5 D 43 1 5.05 rs143122913 0.00022 17_38641181_C_Y 
TEK 811 missense 1 7 P 180 1 4.07   9_27158131_C_Y 
TRAK2   nonsense 1 7 NA NA 1 3.25     2_202262876_G_R 
TTN 250 missense 3 142  43 1 4.92 rs72648998 0.036691 2_179575511_C_Y 
USP41  missense 2 4  21 0.425 99 rs75178771 0.018254 22_20723832_T_Y 
C6orf186  missense 1 3 D 22 1 2.84   6_110644001_G_K 
ZNF642  missense 1 2 D 121 0.999 0.975 rs144613252 0.001763 1_40961133_A_W 
Appendix II: List of 34 possible pathogenic variants found in family D.
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Appendix III: Linkage analysis results for Pedigree F. 
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Appendix IV: Linkage analysis results for pedigree G.  
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Appendix V 
 
Gene Exonic  
Function 
Transcript ID 
(NCBI) 
AD AR 
Hom 
XLD XLR # SNVs 
in gene 
# INDEL 
in gene 
Signature 
B3GALT6 missense NM_080605.3 y n n n 46  1_1168046_G_R 
SLC45A1 missense NM_001080397.1 y n n n 27  1_8403940_C_Y 
MYOM3 missense NM_152372.3 y n n n 89  1_24433663_C_Y 
SPTA1 missense NM_003126.2 y n n n 87  1_158612230_C_Y 
SLAMF8 missense NM_020125.2 y n n n 1  1_159805006_G_R 
RCSD1 missense NM_052862.3 y n n n 13  1_167666340_G_R 
CRB1 missense NM_001193640.1 y n n n 15  1_197326120_G_R 
NID1 missense NM_002508.2 y n n n 67  1_236144975_G_R 
C2orf42 missense NM_017880.1 y n n n 13  2_70408453_A_M 
MERTK missense NM_006343.2 y n n n 31 1 2_112705097_G_R 
NEB missense NM_001164507.1 y n n n 224 4 2_152541401_T_K 
DOCK10 missense NM_014689.2 y n n n 60  2_225729789_C_Y 
TOP2B missense NM_001068.2 y n n n 44  3_25665208_A_R 
RNF123 missense NM_022064.2 y n n n 47  3_49753586_C_Y 
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CACNA2D3,LRTM1 missense NM_020678.2 y n n n 7 1 3_54958871_G_R 
SLMAP missense NM_007159.2 y n n n 11 1 3_57835521_T_W 
BBX missense NM_001142568.1 y n n n 13 2 3_107435587_G_R 
STIM2 missense NM_001169118.1 y n n n 21  4_27024391_A_R 
ANKRD37 missense NM_181726.2 y n n n 2  4_186318347_A_R 
SLC38A9 missense NM_173514.2 y n n n 14  5_54948489_T_Y 
KIF2A missense NM_001098511.2 y n n n 11  5_61602334_G_R 
RGNEF missense NM_001080479.2 y n n n 94  5_73190296_T_K 
SLC22A7 missense NM_006672.3 y n n n 17  6_43267379_G_R 
DOPEY1 missense NM_001199942.1 y n n n 29 2 6_83863904_G_R 
NOD1 missense NM_006092.2 y n n n 30  7_30491667_C_Y 
C7orf69,PKD1L1 missense NM_138295.3 y n n n 30  7_47851554_G_S 
RELN missense NM_005045.3 y n n n 65 6 7_103234193_T_W 
KIAA1549 missense NM_001164665.1 y n n n 91  7_138537006_C_Y 
KIAA1549 missense NM_001164665.1 y n n n 91  7_138556013_G_R 
LRRC61,C7orf29 missense NM_138434.2 y n n n 13 1 7_150028187_C_M 
DNAJC5B missense NM_033105.4 y n n n 5  8_66963813_C_Y 
SNTB1 missense NM_021021.3 y n n n 29  8_121561121_C_S 
ACO1 missense NM_002197.2 y n n n 19  9_32449055_A_W 
UNC13B missense NM_006377.3 y n n n 36  9_35398953_C_Y 
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BICD2 missense NM_001003800.1 y n n n 51 1 9_95481425_C_S 
C9orf152 missense NM_001012993.2 y n n n 12 1 9_112969840_G_R 
CRAT missense NM_000755.3 y n n n 30 1 9_131862217_C_Y 
NOTCH1 missense NM_017617.3 y n n n 303 1 9_139391968_C_Y 
CALML3 missense NM_005185.2 y n n n 8  10_5567319_C_Y 
WAC missense NM_016628.4 y n n n 8  10_28872390_C_Y 
NRG3 missense NM_001010848.3 y n n n 41 1 10_83635671_C_Y 
C11orf46 missense NM_152316.1 y n n n 3  11_30354488_G_K 
C11orf46 missense NM_152316.1 y n n n 3  11_30354491_A_R 
RIN1 missense NM_004292.2 y n n n 115 1 11_66103561_G_R 
P2RY2 missense NM_002564.2 y n n n 24  11_72946144_G_S 
C11orf70 missense-
near-
splice 
NM_032930.2 y n n n 2  11_101951947_G_K 
NUAK1 missense NM_014840.2 y n n n 77  12_106480516_T_Y 
FGF9 missense NM_002010.2 y n n n 4  13_22255252_G_R 
MIPEP stop-
gained 
NM_005932.3 y n n n 18 1 13_24413808_G_R 
GSX1 missense NM_145657.1 y n n n 42 1 13_28367973_G_R 
AP1G2 missense- NM_003917.2 y n n n 14 1 14_24032794_G_R 
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near-
splice 
ATG2B missense NM_018036.5 y n n n 42 2 14_96792216_G_R 
MGA missense NM_001080541.2 y n n n 62  15_41991063_A_W 
NOXO1 missense NM_144603.2 y n n n 58 1 16_2029312_A_M 
NOXO1 missense NM_144603.2 y n n n 58 1 16_2029313_G_S 
DNAJA3 missense NM_001135110.2 y n n n 28  16_4491530_C_S 
PHKG2,C16orf93 stop-
gained 
NM_001014979.2 y n n n 7 1 16_30770393_G_R 
ATMIN missense NM_015251.2 y n n n 38  16_81069612_G_K 
ZBTB4 missense NM_001128833.1 y n n n 70 3 17_7366934_G_R 
HAP1 missense NM_001079870.1 y n n n 50 2 17_39888972_T_Y 
SPAG9 missense NM_001130528.2 y n n n 20  17_49072561_A_M 
BAHCC1 missense NM_001080519.2 y n n n 338 1 17_79425291_G_K 
GREB1L missense NM_001142966.1 y n n n 35 1 18_19075668_G_R 
KLHL14 missense NM_020805.1 y n n n 21  18_30349890_C_Y 
MYO5B missense NM_001080467.2 y n n n 75 2 18_47390707_A_M 
TCF3 splice-5 NM_001136139.2 y n n n 101 1 19_1621835_A_W 
PLIN4 missense NM_001080400.1 y n n n 485 2 19_4512974_G_R 
PLIN4 missense NM_001080400.1 y n n n 485 2 19_4513172_G_R 
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NCAN missense NM_004386.2 y n n n 35  19_19359535_G_R 
GGN missense NM_152657.3 y n n n 68 2 19_38876865_C_Y 
GGN missense NM_152657.3 y n n n 68 2 19_38877423_G_K 
ATP1A3 missense NM_152296.3 y n n n 22  19_42492254_C_Y 
ZNF160 missense NM_001102603.1 y n n n 24 1 19_53578346_C_Y 
SIRPA missense NM_001040022.1 y n n n 61 4 20_1876113_C_Y 
PYGB missense NM_002862.3 y n n n 32  20_25261702_G_S 
SDC4 missense NM_002999.3 y n n n 7 1 20_43961667_G_R 
ZNF335 missense NM_022095.3 y n n n 47 2 20_44592228_G_R 
TRAPPC10 missense NM_003274.4 y n n n 28  21_45502843_T_Y 
MRPL40 missense NM_003776.2 y n n n 12  22_19423268_C_S 
SOX10 missense NM_006941.3 y n n n 31  22_38369872_G_R 
SBF1 missense NM_002972.2 y n n n 137  22_50904250_T_K 
PHC2 coding NM_198040.2 y n n n 46 1 1_33820748_GGCTGCTGCT
GTTGTGGCTGT_CGGCTGC
TGCTGTTGTGGCTGT/C 
MAPKAPK2 coding NM_004759.4 y n n n 37 1 1_206858675_A-G_A/AGCC 
PCDHGB4,PCDHGA8
,PCDHGB7,PCDHGB
6,PCDHGB5, 
coding NM_018914.2 y n n n 52 3 5_140802723_GTG_CGTG/C 
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SLC16A10 coding NM_018593.4 y n n n 18 2 6_111494006_TGG_TTGG/T 
CCDC114 coding NM_144577.3 y n n n 51 1 19_48814908_C-A_C/CACG 
LAMA5 coding NM_005560.3 y n n n 481 1 20_60942086_CCGCGCGCC_
GCCGCGCGCC/G 
C1orf141 frameshift NM_001013674.1 y n n n 16 1 1_67558869_TCATT_CTCAT
T/C 
TDRD5 frameshift NM_001199085.1 y n n n 26 1 1_179660076_T-G_T/TGAGG 
CYBRD1 frameshift NM_024843.3 y n n n 8 1 2_172411298_TT_CTT/C 
CACNA2D3,LRTM1 frameshift NM_020678.2 y n n n 7 1 3_54952509_CT_GCT/G 
SLC16A10 frameshift NM_018593.4 y n n n 18 2 6_111494010_TTTGTTGGGC
TCATGT_ATTTGTTGGGCT
CATGT/A 
MED23 frameshift NM_004830.2 y n n n 18 1 6_131939578_A-
A_A/AAACG 
Appendix V: List of 93 candidate variants found in family K. y = yes; n = no.
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